{
  "OPTISAGE": {
    "TITLE": "phase iii study compare graft versus host disease prophylaxis anti thymoglobulin thymoglobulin antithymocyte lymphocyte globulingrafalon elderly patient acute myeloid leukemia myelodysplatic syndrome receive allogeneic hematopoietic stem cell transplantation human leukocyte antigen match unrelated donor follow reduced intensity condition regimen fludarabinetreosulfan",
    "JUSTIFICATION": "allogeneic hematopoietic stem cell transplantation allo hsct remain curative therapy acute myeloid leukemia aml myelodysplastic syndrome mds patient require allohematopoietic stem cell transplantation year age transplant reduced intensity conditioning ric regimen optimal ric graft versus host disease prophylaxis regimen allow good control disease prevent graft versus host disease remain determine elderly patient phase iii trial compare conventional ric fludarabinebusulfan day fludarabinetreosulfan demonstrate advantage flutreosulfan arm term event free survival efs therefore consider new standard ric regimen acute myeloid leukemia mds graft versus host disease prevention crucial role posttransplant outcome potentially interfere graftversusleukemia gvl effect immune reconstitution antithymocyte globulin atg recommend reduce risk acute chronic graft versus host disease transplant perform match unrelated donor however optimal type anti thymoglobulin approve brand atg thymoglobulin antithymocyte lymphocyte globulingrafalon display distinct characteristic optimal dose anti thymoglobulin still unknown retrospective study patient transplant mainly ric match related unrelated donor haematological malignancy observe antithymocyte lymphocyte globulin associate reduction grade iiintravenous infusion acute graft versus host disease comparison anti thymoglobulin without increase incidence relapse phase iii randomize study propose compare graft versus host disease prevention anti thymoglobulin versus antithymocyte lymphocyte globulin acute myeloid leukemia mds patient year age transplant match unrelated donor follow fludarabinetreosulfan ric hypothesis antithymocyte lymphocyte globulin would better control graft versus host disease population patient thus limit risk morbidity mortality procedure",
    "OBJECTIVE": "main objective compare incidence grade iiintravenous infusion acute graft versus host disease anti thrombin day posttransplantation mds acute myeloid leukemia patient transplant match unrelated donor mud follow reduced intensity conditioning fludarabinetreosulfan patient receive graft versus host disease prophylaxis anti thymoglobulinthymoglobulin versus antithymocyte lymphocyte globulingrafalon primary endpoint incidence grade iiintravenous infusion acute graft versus host disease accord magic classification appendix section anti thrombin day posttransplantation secondary objective evaluate effect graft versus host disease prophylaxis engraftment graft failure evaluate effect graft versus host disease prophylaxis incidence grade acute graft versus host disease chronic graft versus host disease evaluate effect graft versus host disease prophylaxis incidence infection evaluate effect graft versus host disease prophylaxis progression free survival evaluate effect graft versus host disease prophylaxis relapse incidence evaluate effect graft versus host disease prophylaxis nonrelapse mortality evaluate effect graft versus host disease prophylaxis overall survival evaluate effect graft versus host disease prophylaxis graft versus host disease relapse free survival grfs evaluate effect graft versus host disease prophylaxis healthrelated quality life fact bmt evaluate effect graft versus host disease prophylaxis chimerism evaluate effect graft versus host disease prophylaxis immune reconstitution nk regulatory cell level peripheral blood evaluate effect graft versus host disease prophylaxis day hospitalisation first month posttransplantation evaluate effect graft versus host disease prophylaxis incidence severity vod identify prognostic factor associate primary endpoint prophylaxis arm search treatmentbycovariate interaction primary endpoint evaluate effect graft versus host disease prophylaxis incidence late acute graft versus host disease day overlap syndrome chronic graft versus host disease secondary endpoint hematopoietic recovery anti thrombin least day neutrophils giga liter platelet giga liter immune reconstitution analyze nk regulatory cell gammaglobulin level peripheral blood anti thrombin month month month month posttransplantation chimerism anti thrombin month month month grade acute graft versus host disease incidence appendix section acute graft versus host disease treatment first line treatment response steroid treatment course refractory acute graft versus host disease chronic graft versus host disease incidence date grading anti thrombin month month nih classification appendix section relapse incidence anti thrombin month month relapse define reappearance leukemic cell mds feature allohematopoietic stem cell transplantation bonne marrow cytology cytogenetic analysis bone marrow aspiration extramedullary site prove biopsy progression free survival anti thrombin month month severe infection ctae grade anti thrombin month fully describe incidences cmv ebv reactivations anti thrombin month month nonrelapse mortality anti thrombin month month month overall survival anti thrombin month month graft versus host disease relapse free survival grfs define alive without disease relapse without develop acute grade iiiintravenous infusion severe chronic graft versus host disease healthrelated quality life assess use questionnaire anti thrombin inclusion anti thrombin month month posttransplantation number day hospitalization transplant hospitalization transplantation relate complication month incidence severity vod anti thrombin lymphocyte count standard blood count conditioning day late acute graft versus host disease overlap syndrome chronic graft versus host disease",
    "DESIGN": "phase iii multicenter randomize control openlabel trial compare gvdh prophylaxis anti thymoglobulin versus antithymocyte lymphocyte globulin patient acute myeloid leukemia mds transplant match unrelated donor follow fludarabinetreosulfan ric bio collection peripheral blood mononuclear cell plasma dry pellet total blood cell perform day base line day month month patient per arm future biological study would perform find complementary funding collection organize via cryostem order good understand modulation immune response two anti thymoglobulin brand plasma collection anti thymoglobulin pharmacokinetic analysis antithymocyte lymphocyte globulin arm sample collect administration antithymocyte lymphocyte globulin anti thrombin day month month frozen center data analyze accord preconditioning lymphocyte count correlate posttransplant outcome gvhd relapse nrm able determine formula optimize antithymocyte lymphocyte globulin dose lymphocyte count future study plasma collection start include patient find complementary funding",
    "INCLUSION CRITERIA": "patients year age present acute myeloid leukemia mds indication allogeneic stem cell transplantation age year patient year unfit myeloblative conditioning acute myeloid leukemia require allogeneic stem cell transplantation intermediate highrisk aml complete cytologic response mds require allogeneic stem cell transplantation ipss international prognostic score systemr international prognostic score systemr risk feature rapide blast increase lifethreatening neutropenia thrombopenia high transfusion need month month without human leukocyte antigen match related donor identify matched human leukocyte antigen unrelated donor usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group performans status severe uncontrolled infection cardiac leave ventricular ejection fraction lung diffuse capacity lung carbon monoxide adequate organ function aspartate amino transferase alanineaminotransferase total bilirubin creatinine clearance ml min except abnormality link hematological disease health insurance coverage sign write informed consent contraception method must prescribe acute lymphoblastic leukemia duration research nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "carcinomas last year except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity human immunodeficiency virus active hepatitis yellow fever vaccine acute lymphoblastic leukemia others live virus vaccine within month transplantation heart failure accord new york heart association ii left ventricular ejection fraction lung diffuse capacity lung carbon monoxide preexisting acute hemorrhagic cystitis renal failure creatinine clearance min pregnancy hcg positive breastfeeding patients debilitate medical psychiatric illness would preclude realization stem cell transplantation understanding protocol patient state medical aid patient legal protection protection court curatorship guardianship grafalon contraindication mention smpc grafalon thymoglobulin hypersensitivity rabbit protein excipients participation clinical trial medicinal product human use exclusion period anti thrombin end previous study contraindication mention smpc acute lymphoblastic leukemia auxiliary medicinal product plan use trial cyclosporine mycophenolate mofetil fludarabine treosulfan",
    "TREATMENT": "phase iii grafalon milligrams kilograms day intravenous infusion consecutive day day transplantation thymoglobuline milligrams kilograms intravenous infusion day transplantation conditionning regimen acute lymphoblastic leukemia patient receive conditioning regimen fludarabine milligrams month day intravenous infusion day day treosulfan month day intravenous infusion day day day donor stem cell source human leukocyte antigen match unrelated donor gcsfmobilized peripheral blood stem cell accept target dose kilograms body weight graft versus host disease prophylaxis prophylaxis graft versus host disease depend randomization arm antithymocyte lymphocyte globulingrafalon milligrams kilograms day intravenous infusion consecutive day day atlggrafalon anti thymoglobulinthymoglobuline atgthymo two schedule administration antithymocyte globulin atg accept milligrams kilograms day intravenous infusion consecutive day milligrams kilograms intravenous infusion day follow milligrams kilograms intravenous infusion day milligrams kilograms day addition patient receive cyclosporine csa milligrams kilograms day mycophenolate mofetil mmf milligrams kilograms day follow cyclosporine month progressive withdrawal start month post stem cell transplantation agvhd accord practice center mycophenolate mofetil day day arm randomisation ratio anti thymoglobulin antithymocyte lymphocyte globulin graft versus host disease prophylaxis healthrelated quality factbmt life anti thrombin month month biological study biocollection pharmacokinetic antithymocyte lymphocyte globulin frozen plasma ml tube edta day day day day day accordance decree february biocollection blood pbmcs plasma dry pellet ml tube ml edta anti thrombin point base line month month via cryostem anti thrombin day day day month ml tube ml edta accordance decree february",
    "STATISTICAL": "hypothesis base reduction incidence day posthematopoietic stem cell transplantation grade iiintravenous infusion acute graft versus host disease atg arm atlg arm assume risk randomised patient world health organization would reach transplant incidence compete risk death without gvhd arm account compete risk twosided logrank test overall sample size subject control group treatment group achieve power anti thrombin significance level detect hazard ratio followup time day total patient include interim analysis schedule perform"
  },
  "CAALLF01": {
    "TITLE": "french protocol treatment acute lymphoblastic leukemia child adolescent",
    "JUSTIFICATION": "acute lymphoblastic leukemia curable disease child adolescent nevertheless numerous problem remain good result obtain intensive prolonged treatment include risk toxic death sequela secondary malignancy results still insufficient highrisk form particularly exhibit early resistance chemotherapy early bone marrow relapse less month diagnosis still dismal prognosis render prevention mandatory acute lymphoblastic leukemia extremely heterogeneous disease term biology response treatment envisage targeted treatment future render key decipher heterogeneity two cooperative group fralle french center eortcclcg decide elaborate common protocol treatment childhood adolescent acute lymphoblastic leukemia childhood adolescent acute lymphoblastic leukemiafrance two previous study group comparable result eventfree survival overall survival year year year year fralle pt eortc still major question field acute lymphoblastic leukemia optimal use lasparaginase asnase intrathecal injection know administer asnase result depletion asparagine circulating blood starve leukemic cell result death indeed use asnase varies protocol consider different brand dose administration modality rythm routeintramuscular iv three major form asnase currently available coli asparaginase kidrolase france erwinia asparaginase erwinase patient allergy pegylated form coli asparaginase oncaspar usa europe oncasparin usa oncaspar pegylated coli asparaginase pegaspargase manufacture initially enzon shire servier develop goal reduce immunogenicity native asnase addition oncaspar prolonged serum terminal halflife dose less frequently native asnase achievement similar pharmacodynamic usa pivotal clinical trial support firstline use oncaspar children standard risk acute lymphoblastic leukemia randomize receive native pegylated coli asparaginase api merck part induction delayed intensification di phase oncaspar administer intramuscularly im anti thrombin dose iu month induction phase two di phase native coli asparaginase merck elspar administer intramuscular anti thrombin dose iu month three time weekly dos induction dos di phase children treat oncaspar rapid clearance lymphoblast day day bone marrow aspirate prolonged asparaginase activity treat native form first di phase native asparaginase patient hightiter antibody compare patient receive oncaspar high titer antibody associate low asparaginase activity native arm oncaspar arm rate infection hospitalization safety profile similar arm avramis others oncaspar approve treatment acute lymphoblastic leukemia component multiagent chemotherapy usa since include firstline use since first line use transfer new oncaspar manufacture sigmatau pegaspargase asparaginase lonza shire oncasparin europe oncaspar currently available europe differ oncaspar market usa term asparaginase origin kyowahakko lonza although product pegylated sigmatau usa germany poland oncaspar kh kyowahakko register component antineoplastic combination therapy reinduction patient know hypersensitivity native lasparaginase secondline oncaspar kh use first line asparaginase preparation anti thrombin least three european acute lymphoblastic leukemia protocol uk mrc protocol acute lymphoblastic leukemia since uk bfmaieop protocol acute lymphoblastic leukemia since germany italy austria switzerland czech republic israel interfant protocol dedicate infant since many country since january european commission grant marketing authorization use oncaspar combination therapy acute lymphoblastic leukaemia paediatric patient birth year adult patient approval baxalta authorize market oncaspar member country european union eu well iceland liechtenstein norway authorization relate onacaspar incorporate active pharmaceutical ingredient manufacture lonza current status asparaginase preparation france january kidrolase register first line use erwinase available patient allergic native pegylated asparaginase maa france oncaspar oncaspar kh available named patient program atuon november oncaspar receive marketing authorization january different dose schedule use oncaspar induction therapy currently propose accord firstline acute lymphoblastic leukemia protocol iu month one infusion cog dfci protocol us use oncaspar lonza iu month one infusion st jude protocol us oncaspar lonza iu month two infusion aieopbfm protocol europe oncaspar kh iu month two infusion eortc protocol belgium oncaspar kh iu month one infusion interfant protocol mainly europe oncaspar kh iu month two infusion ukall protocol uk oncaspar kh iu month two infusion dcog protocol nl oncaspar kh result protocol ukall interest eventfree survival anti thrombin year overall survival anti thrombin year vora others lancet oncol obtain use low dosage per infusion oncaspar kh iu month im repeat anti thrombin day interval induction subgroup patient treat ukall cyk fong others ash show dose provide adequate asparaginase activity iu sample study second injection",
    "OBJECTIVE": "child adolescent standard medium risk acute lymphoblastic leukemia study two primary objective assess superiority term pharmacokinetic anti thrombin day fractionated scheme assess equivalence tolerance scheme day induction day high high risk group two primary objective define assess pharmacokinetic anti thrombin day assess toxicity intensified scheme day induction day adequate asparaginase activity iu anti thrombin day induction toxicity incidence severe toxicity grade directly asparaginase relate cns thrombosis pancreatitis anaphylaxia hyperbilirubinemia day day treatment anyway day consolidation linked study drug pharmacokinetics pharmacodynamics immunogenicity comparison arm make patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups criterion include cid asparaginase activity asparagine level anti thrombin define timepoints cid incidence asparaginase antibody cid incidence silent inactivation arm induction consolidation intensification phase cid allergic reaction rate arm induction consolidation intensification phase cid percentage patient without switch erwinia asparaginase cid percentage patient receive intend dose asparaginase efficacy comparison arm make patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups criterion efficacy include cid morphological complete remission rate assess whole population subgroup blineage acute lymphoblastic leukemia tcell cid minimal residual disease mrd anti thrombin end induction anti thrombin late timepoint subgroup patient assess ig tcrbased rqpcr evaluation make whole population within subgroup cid cumulative incidence relapse overall cid cumulative incidence bone marrow relapse central nervous system relapse gonadal relapse combine relapse toxicity comparison arm undertake patient standardrisk mediumrisk acute lymphoblastic leukemia non comparative assessment make patient belong highrisk high riskgroups cid acute lymphoblastic leukemia adverse event ae relate asparaginase occur within first week day treatment anyway day consolidation hyperglycemia induce diabetes coagulopathy allergy hyperlipidemia hypertriglyceridemia hypercholesterolemia non central nervous system thrombosis grade adverse event pancreatitis hyperbilirubinemia cid adverse event relate asparaginase occur day induction anyway anti thrombin day consolidation cid incidence acute lymphoblastic leukemia grade adverse event whatever imputability survival timepoints eventfree survival diseasefree survival overall survival classical outcome measure evaluation survival child acute lymphoblastic leukemia eventfree survival survival time free treatment failure relapse secondary malignancy day treatment randomization randomize arm disease free survival eventfree survival responder measure time complete remission follow induction treatment failure define induction anti thrombin day anti thrombin least blast minimal residual disease case available minimal residual disease blast criterion require secondary objective cid evaluate incidence rare subgroup acute lymphoblastic leukemia prognostic value socalled bother subgroup bcrabl like include cid year eventfree survival diseasefree survival overall survival rare patient suboptimal reponse therapy induction failure ablclass fusion alls treat imatinib cid imatinib related adverse event immediate long term cf appendix rare patient suboptimal reponse therapy induction failure ablclass fusion alls treat imatinib",
    "DESIGN": "french prospective multicentric cohort study child adolescent acute lymphoblastic leukemia stratify type acute lymphoblastic leukemia ii anticipate risk stratify group bcpacute lymphoblastic leukemia group tcell randomized clinical trial perform population patient compose bstandard risk bmedium risk tstandard risk check eligibility criterion use two paralell arm randomization design patients allocate either receive one infusion oncaspar iu month vs infusion iu month induction therapy dose per infusion induction therapy dose per infusion attribute initial randomization randomized question ask high high risk group lineage patient receive infusion oncaspar iu month induction iu month infusion afterwards nevertheless patient submit evalauation term pharmacokinetic pharmacodynamic toxicity efficacy acute lymphoblastic leukemia patient include study day induction treatment randomization take place day day day first infusion pegaspargase day patient belong bstandard risk bmedium risk tstandard risk group",
    "INCLUSION CRITERIA": "cid children adolescent age month yearsblineage lineage acute lymphoblastic leukemia cid written informed consent obtain day treatment nb patient syndrome include randomize see detail protocol section",
    "EXCLUSION CRITERIA": "cid burkitt leukemia lmb type protocol cid mixed phenotype acute leukemia criteria cid infant acute lymphoblastic leukemia age day interfant protocol cid secondary leukemia cid patients previously treat chemotherapy steroid expose pt include stratify accord section known allergy pegylated product cid pregnancy women childbearing potential define acute lymphoblastic leukemia woman physiologically capable become pregnant must negative serum pregnancy inclusion reliable contraception exceptoral contraceptive contraception maintain throughout study month treatment discontinuation cid known human immunodeficiency virus positivity cid central nervous system thrombosis prophase cid hydrogen ion concentration+ bcrabl acute lymphoblastic leukemia esphall protocol cid central nervous system thrombosis day",
    "TREATMENT": "national cancer institute standardrisk acute lymphoblastic leukemia criterion cid bcell precursor acute lymphoblastic leukemia cid day age year cid white blood cell count giga liter national cancer institute highrisk acute lymphoblastic leukemia cid bcell precursor acute lymphoblastic leukemia cid age year white blood cell count giga liter tcell acute lymphoblastic leukemia acute lymphoblastic leukemia tcell lineage central nervous system involvement status accord current standard definition traumatic lumbar puncture tlp testis involvement clinical enlargement one testis confirm ultrasonography prednisone response measure anti thrombin day induction therapy cid good prednisone response gpr less blast cells cubic millimeter day prednisone milligrams month day one intrathecal injection methotrexate cid poor prednisone response ppr good prednisone response minimal residual disease mrd measure induction consolidation evaluation real time quantitative pcr search two ig tcr marker possible anti thrombin least one minimum sensitivity accord esgminimal residual disease recommendation detectable minimal residual disease mean signal anti thrombin least one marker anti thrombin sensitivity level case failure less case flow cytometry evaluation minimal residual disease reference centre iamp pt status uncontrolled question two infusion pegaspargase iu month induction pegaspargase iu month consolidation subsequent phase treatment hematopietic stem cell transplantation strategy subgroup non responder bvery high risk patient stratification switch occur either induction induction failure day assessment status minimal residual result later result refer protocol switch section tcell acute lymphoblastic leukemia subgroup patient pretreated corticosteroid refer protocol standard risk tsr patient day good prednisone response minimal residual disease anti thrombin randomized question arm pegaspargase iu month one infusion induction delayed intensification arm pegaspargase infusion iu month induction infusion iu month delayed intensification high risk thr highrisk tvhr patient day poor prednisone response central nervous system minimal residual disease anti thrombin uncontrolled question two infusion pegaspargase iu month induction pegaspargase iu month consolidation subsequent phase hematopietic stem cell transplantation strategy subgroup non responder tvery high risk patient stratification switch occur either induction induction failure minimal residual disease evaluation subgroup patients refer protocol switch table section oncaspar pegaspargase supply sterile solution anti thrombin beginning trial replace powder solution injection package type singleuse vial contain international units native asparaginase per ml solution oncaspar store refrigeration anti thrombin product must shake frozen must protect light refer protocol",
    "STATISTICAL": "perform base acute lymphoblastic leukemia patient randomize january request data safety monitor board study november"
  },
  "HAPLO-EMPTY": {
    "TITLE": "haploidentical allogeneic hematopoietic stem cell transplantation posttransplant cyclophosphamide patient acquired refractory aplastic anemia nationwide phase ii study",
    "JUSTIFICATION": "outcomes patient severe aplastic anemia saa world health organization refractory firstline immunosuppressive therapy ist world health organization lack match unrelated donor mud remain poor recently use eltrombopag elt show blood count improvement patient however refractory patient respond elt secondline treatment therefore expose lifethreatening infection bleed past decade significant decrease infection related mortality patient severe aplastic anemia unresponsive initial ist clonal evolution include paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome mds acute myeloid leukemia aml still occur longterm grim prognosis overall overall survival patient acquired refractory severe aplastic anemia elt anti thrombin year hematopoietic stem cell transplantation hsct use alternative donor source mismatch unrelated donor cord blood cbt haploidentical family donor may curative patient refractory severe aplastic anemia despite carry much high rate complication transplantation match relate unrelated donor recently group show cbt valuable curative option young adult refractory severe aplastic anemia however acute lymphoblastic leukemia patient available cb cbt treatment related mortality high adult patient haploidentical haplo relate donor stem cell transplantation haplosct improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy preliminary result little number patient refractory severe aplastic anemia anti thrombin kings college london uk john hopkins baltimore usa seem promise retrospectively analyze data patient median age year transplant europe behalf severe aplastic anemia work party european blood marrow transplantation group overall survival suggest approach might valid option particular poor clinical situation",
    "OBJECTIVE": "main objective demonstrate benefit term overall survival rate historical rate patient acquired refractory idiopathic aplastic anemia use haplostem cell transplantation ptcy primary endpoint overall survival rate secondary objective clinical biological outcome graft failure graft versus host disease gvhd progression free survival relapse nonrelapse mortality overall survival quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment anti thrombin day consecutive day neutrophile giga liter consecutive day platelet absolute number neutrophil platelet anti thrombin month month month month month day last platelet red blood cell transfusion incidence use growth factor poor hematopoietic reconstitution acute graft versus host disease incidence anti thrombin month month date maximum grading first line treatment response steroid treatment course case steroid refractory gvhd chronic graft versus host disease incidence date grading anti thrombin month relapse incidence anti thrombin month month progression free survival anti thrombin month month incidence cmv ebv infection anti thrombin month severe infection ctae grade month month month month nonrelapse mortality month incidence cardiac toxicity anti thrombin month overall survival anti thrombin month quality life questionnaire anti thrombin inclusion post transplantation month month month month chimerism anti thrombin month month month month month immune reconstitution analyze nk regulatory cell level peripheral blood anti thrombin month month month month posttransplantation ferritin level anti thrombin month month month month",
    "DESIGN": "phase ii multicenter national prospective cohort study risks relate stem cell transplantation cardiac toxicity hemorrhagic cystitis particularly monitor indication allograft context acquired refractory aplastic anemia",
    "INCLUSION CRITERIA": "patients age year acquired refractory idiopathic aplastic anemia indication haploidentical allogeneic hematopoietic stem cell transplantation patients aged year old suffering refractory acquire idiopathic aplastic anemia least one course immunosuppression antithymocyte globulin absence genoidentical donor match donor identification haploidentical donor brother sister parent adult child cousin absence donor specific antibody detect patient mfi antibody direct towards distinct haplotype donor recipient usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanineaminotransferase total bilirubin creatinine mol health insurance coverage contraception method must prescribe acute lymphoblastic leukemia duration research women men childbearing age must use contraceptive method within month month last dose cyclophosphamide respectively sign write informed consent parent patient age less nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "patients morphologic evidence clonal evolution patient isolated bone marrow cytogenetic abnormality also eligible uncontrolled infection seropositivity human immunodeficiency virus active hepatitis define positive pcr hbv hcv associate hepatic cytolysis cancer last year except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breastfeeding world health organization receive attenuated vaccine within month transplantation uncontrolled coronary insufficiency recent myocardial infarction month current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction heart failure accord new york heart association ii preexisting acute hemorrhagic cystitis renal failure creatinine clearance min urinary tract obstruction contraindication treatment use research world health organization debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup tutorship curatorship",
    "TREATMENT": "conditioning regimen fludarabine month day day day pretransplant cyclophosphamide milligrams kilograms day day day total body irradiation gray stem cell source bone marrow graft versus host disease prophylaxis rabbit anti thymoglobulin dose anti thrombin milligrams kilograms day milligrams kilograms day cyclophosphamide milligrams kilograms day anti thrombin tacrolimus residual microg mycophenolate mmf absence graft versus host disease mycophenolate mofetil stop anti thrombin day tacrolimus anti thrombin day prevention ebv reactivation rituximab month intravenously anti thrombin post hematopoietic stem cell transplantation infusion rituximab precede administration antipyretic antihistaminic paracetamol diphenhydramine additional test specific examination",
    "STATISTICAL": "justification sample size hypothesize overall survival os versus historical control twosided onesample logrank test calculate sample subject achieve power anti thrombin significance level detect proportion overall survival new group proportion overall survival historic control group anti thrombin year terminal analysis realize observation required number event"
  },
  "KAPVEC": {
    "TITLE": "phase ii multicenter study talimogene laherparepvec classic endemic kaposi sarcoma",
    "JUSTIFICATION": "kaposi sarcoma ks lymphangioproliferation associate human herpes virus promote immunosuppression human immunodeficiency virusrelated ks iatrogenic posttransplantation ks treat immune restoration association local systemic therapy chemotherapy require conversely classic endemic ks underlie relative immunosuppression directly target treatment poorly codify mostly base surgery radiotherapy localized ks aggressive form visceral involvement treat chemotherapy interferon give anti thrombin best transient response may well tolerate elderly patient talimogene laherparepvec first oncolytic immunotherapy approve fda metastatic unresectable melanoma injectable nodal cutaneous lesion intrathecal injection design induce tumor regression injected lesion direct lytic effect uninjected lesion induction systemic antitumor immunity merkel cell carcinoma mcc another virusinduced tumor treatment axis inhibitor prove efficacy thus provide proof principle immunotherapy could effective virusinduced tumor two case metastatic mcc succesfully treat talimogene laherparepvec recently report suggest talimogene laherparepvec may also effective therapeutic option considering high immunogenicity viral epitope ks tumor role immune evasion development ks cutaneous manifestation patient easily inject classic endemic ks good tumor model target talimogene laherparepvec",
    "OBJECTIVE": "main objective assess whether talimogene laherparepvec clinically inactive partial+complete response probability truly active partial+complete response probability classic endemic kaposi sarcoma primary endpoint best overall response rate borr define occurrence complete response partial response injected lesion follow pga criterion pga record start treatment month beginning specific therapy kaposi sarcoma intrathecal injection occur month secondary objective safety profile talimogene laherparepvec classic endemic kaposi sarcoma parameter efficacy best response response rate duration response efficacy injected uninjected lesion quality life exploratory objectives characterize efficacy talimogene laherparepvec relate immunologic viral assessment tumor biopsy blood sample secondary endpoint adverse event follow common terminology criterion adverse event borr accord actg criterion response rate anti thrombin month response rate lymphedema time response duration response response injected uninjected target lesion deaths cause ksadapted dlqi score exploratory endpoint characterize immune tumor infiltrate immune cell quantification viral infiltrate tumor necrosis treatment viral load blood tumor cell sequence",
    "DESIGN": "phase ii multicentre single arm open label trial risk",
    "INCLUSION CRITERIA": "adult patient classic endemic histologically confirm kaposi sarcoma ks progressive require systemic therapy injectable measurable disease define anti thrombin least cutaneous lesion large diameter previously irradiated field anti thrombin least cutaneous lesion large diameter available repeat cutaneous biopsy previously irradiate field nb cutaneous lesion replace cluster small lesion edge edge distance millimeter big diameter cluster meet previous criterion willing provide tissue cutaneous biopsy anti thrombin least week washout acute lymphoblastic leukemia ks specific therapy include topical treatment chemotherapy radiotherapy immunotherapy include interferon provide write informed consent prior performance study specific procedure year age day sign informed consent performance status eastern cooperative oncology group performance scale demonstrate adequate organ function haematological absolute neutrophil count anc cubic millimeter platelets cubic millimeter haemoglobin deciliter renal serum creatinine upper limit normal uln calculate creatinine clearance min use mdrd formula subject creatinine level upper limit normal hepatic aspartate amino transferase sgot alanine amino transferase sgpt serum total bilirubin direct bilirubin upper limit normal subject total bilirubin level ptt tca female subject childbearing potential negative serum pregnancy within hour prior receive first dose study medication health insurance",
    "EXCLUSION CRITERIA": "known history organ transplantation include allogeneic stemcell transplantation human immunodeficiency virus hiv antibody detect anti thrombin selection symptomatic visceral involvement ks include brain metastasis active autoimmune disease require systemic treatment require systemic treatment past year use disease modify agent corticosteroid immunosuppressive drug replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc consider form systemic treatment patients vitiligo type diabetes mellitus hypothyroidism psoriasis non require systemic treatment permit enrol evidence clinically significant immunosuppression following primary immunodeficiency state severe combined immunodeficiency disease concurrent opportunistic infection receiving systemic immunosuppressive therapy include oral steroid dose milligrams day prednisone equivalent within day prior enrolment clinically significant cardiac dysfunction symptomatic heart failure clinically significant arrhythmia conduction disorder active herpetic skin lesion prior complication hsv infection eg herpetic keratitis encephalitis intermittent chronic systemic intravenous oral treatment antiherpetic drug eg acyclovir intermittent topical use previous treatment talimogene laherparepvec oncolytic virus prior radiotherapy field overlap injection sit prior immunosuppressive chemotherapy radiotherapy biological cancer therapy major surgery within day prior enrollment recover common terminology criterion adverse event grade good adverse event due ks therapy administer day prior enrollment prior therapy tumor vaccine received live vaccine within day prior enrolment currently treatment another investigational device drug study less day since end treatment another investigational device drug study acute chronic active hepatitis hbs ag detect infection hcv rna detect anti thrombin inclusion active tuberculosis bacillus tuberculosis known additional malignancy currently progress require active treatment within last year exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergo potentially curative therapy situ cervical cancer sensitivity product component administer psychiatric substance abuse disorder would interfere cooperation requirement trial pregnant breastfeeding expect conceive father child within projected duration trial month last dose talimogene laherparepvec subjects world health organization unwilling minimize exposure blood body fluid individual world health organization anti thrombin high risk induced complication immunosuppressed individual individual know human immunodeficiency virus infection pregnant woman infant age month talimogene laherparepvec treatment day last dose talimogene laherparepvec pregnant breastfeeding expect conceive father child within projected duration trial female subject childbearing potential world health organization unwilling use acceptable method effective contraception study treatment month last dose talimogene laherparepvec sexually active subject partner unwilling use male female latex condom avoid potential viral transmission sexual contact treatment within day treatment talimogene laherparepvec addition male participant donate sperm month last dose vulnerable subject prisoner incarcerate follow administrative court decision subject psychiatric disorder world health organization involuntary hospitalize subject legal protection measure subject world health organization express consent",
    "TREATMENT": "talimogene laherparepvec dose pfu ml anti thrombin week ml anti thrombin week every week injection route intralesional injection duration treatment month cycle immunovirologic evaluation base tumor tissue collection cutaneous biopsy correlative blood sampling",
    "STATISTICAL": "simon stage optimal design interim analysis plan patient"
  },
  "FIBRAPLO": {
    "TITLE": "haploidentical transplantation patient myelofibrosis phase prospective multicentric study",
    "JUSTIFICATION": "curative treatment patient primary secondary myelofibrosis allogeneic hematopoietic stem cell hsct intrathecal injection report intermediate high risk patient accord international prognostic score benefit hematopoietic stem cell transplantation term survival kroger et al conduct france prospective trial test use ruxolitinib transplantation jakallo study outcome patient well patient transplant matched sibling donor unrelated donor confirm study kroger others rondelli others jakallo trial acute graft versus host disease incidence high often hyperacute severe recently ebmt group report registry study familial haploidentical transplantation haplo patient myelofibrosis raj others posttransplant cyclophosphamide use case oneyear overall survival os diseasefree survival dfs favorably compare outcome unrelated transplantation genova team also report impressive result haploidentical transplantation center bregante et al bregante others report outcome cohort transplant main difference period frequent use haplo second period versus outcome much well second period overall survival anti thrombin versus author suggest improvement relate best outcome among haplo transplantation improvement outcome haplo attribute good graft versus host disease prophylaxis especially use posttransplant cyclophosphamide given poor outcome unrelated transplantation especially human leukocyte antigen mismatch unrelated setting encouraging result family haplo identical transplantation current study proposes test haploidentical transplantation myelofibrosis patient without match related donor",
    "OBJECTIVE": "main objective diseasefree survival without rejection one year haploidentical transplantation patient primary secondary myelofibrosis main criterion judgement disease rejection free survival month hematopoietic stem cell transplantation assess incidence acute graft versus host disease grade anti thrombin day incidence acute graft versus host disease grade anti thrombin day engraftment anti thrombin day incidence chronic graft versus host disease anti thrombin month nonrelapse mortality anti thrombin month overall survival anti thrombin month relapse progression incidence anti thrombin month rejection incidence anti thrombin month time neutrophil engraftment anti thrombin day time platelet engraftment anti thrombin day infection incidence anti thrombin day anti thrombin month cytokine profile transplantation day day day day impact genetic alteration overall survival anti thrombin month nonrelapse morality anti thrombin month",
    "DESIGN": "phase multicentric study risk",
    "INCLUSION CRITERIA": "patients myelofibrosis world health organization contraindication transplant world health organization advanced disease international score could propose trial human leukocyte antigenmatched donor patients age year primary myelofibrosis myelofibrosis secondary essential thrombocythemia polycythemia vera proven marrow biopsy myelofibrosis combine anti thrombin least following criterion constitutional symptom weight loss one year fever without infection recurrent muscle bone join pain extreme fatigue anemia hemoglobin gr deciliter red blood cell transfusion requirement thrombocytopenia giga liter peripheral blast count anti thrombin least find time white blood cell count giga liter cytoreductive treatment karyotype inv performance status accord eastern cooperative oncology group anti thrombin health insurance coverage sign write informed consent women agree take nomegestrol acetate contraception month treatment treosulfan men agree conceive child month treatment treosulfan",
    "EXCLUSION CRITERIA": "myelofibrosis transform acute leukemia poor performance status eastern cooperative oncology group cardiac failure ef currently past even correct treatment renal failure creatininemia mol clearance min respiratory function alter vital capacity force expired volume biological significant liver abnormality aspartate amino transferase alanineaminotransferase normal range bilirubin normal range human leukocyte antigen match donor available tutorship curatorship unwilling unable comply protocol pregnant woman breastfeed contraindications treosulfan hypersensitivity active substance active noncontrolled infectious disease fanconi anaemia dna breakage repair disorder administration live vaccine contraindications circumstance preclude use drug involve protocol especially thiotepa fludarabine",
    "TREATMENT": "treosulfan investigational medicinal product use condition regimen haploidentical transplantation treosulfan receive euwide approval toxicity reduce conditioning therapy prior allogeneic haematopoietic stem cell transplantation june provide medac treosuflan conditioning regimen administer followed gr month per day anti thrombin iv route intrathecal injection use combination standard association thiotepa milligrams kilograms day fludarabine milligrams month per day day day therefore thiotepa fludarabine indissociable treosulfan also consider medicinal product na haploidentical transplantation use treosulfan thiotepa fludarabine condition regimen additional plasma sample additional blood sample ml additional blood sample ml",
    "STATISTICAL": "analysis base intenttotreat basis include acute lymphoblastic leukemia patient whatever administer treatment study sensitivity analysis perform patient world health organization actually receive graft patient consent withdrawal positive report use data exclude baseline summary statistic namely percentages median interquartile range iqr perform right censor endpoint estimate use nonparametric method kaplan meier curve cumulative incidence curve consider case noninformative informative censoring base logrank test gray test respectively adjustment potential confounders use cox proportional hazard model model assumption check use test proportional hazard spline smoothing residual loglinearity assumption statistical analysis perform sas sas inc cary nc http www rproject org software package"
  },
  "SONIMEL": {
    "TITLE": "safety efficacy blood brain barrier bbb open implantable device sonocloud combine nivolumab use alone association ipilimumab brain metastasis patient malignant melanoma",
    "JUSTIFICATION": "anti monoclonal antibody nivolumab pembrolizumab alone association ipilimumab establish indisputable treatment metastatic melanoma unprecedented overall survival indicate firstline treatment include patient braf mutation given high molecular weight penetration brain sanctuary uncertain relies disruption bbb occur occasionally sonocloud implantable device deliver low intensity pulse ultrasound us along systemic injection us resonator sonocloud demonstrate safe efficient anti thrombin repetitively open bbb anticipate bbb opening could help anti thrombin increase brain penetration monoclonal antibody potentially boost immunity brain could translate control brain disease magnitude extracranial disease would also open avenue optimize treatment brain metastasis combination checkpoint inhibitor many cancer",
    "OBJECTIVE": "one single objective one single endpoint main objective determination successful dose msd define dose high probability bbb open efficacy without toxicity directly relate ultrasound emission primary endpoint success define grade bbb opening disruption pulsed us use sonocloud system without toxicity relate device assess clinically use brain magnetic resonance imaging dlt evaluate first week treatment nivolumab alone week treatment nivolumab ipilimumab thus primary endpoint success define efficacy without toxicity first week treatment nivolumab alone week treatment nivolumab ipilimumab secondary objective clinical efficacy nivolumab ipilimumab context bbb opening study population safety nivolumab alone combine ipilimumab context bbb open secondary endpoint best overall response rate orr anti thrombin month best intracranial overall response rate bicorr icorr anti thrombin month best extracranial overall response rate becorr ecorr anti thrombin month progression free survival pfs anti thrombin month month month intracranial progression free survival intracranial ipfs anti thrombin month month month extracranial progression free survival extracranial epfs anti thrombin month month month overall survival os anti thrombin month month month safety use common terminology criterion adverse event version clinical activity assess use tep tomodensitometry scans extracranial lesion magnetic resonance imaging intracranial metastasis clinical objective response rate orr define rano immunotherapy rano recist version immunerelated response criteria progression free survival define time day immunotherapy perfusion sonication disease progression accord recist version rano immune relate response criteria death whichever first",
    "DESIGN": "patient treat anti thrombin maximum considering maximum would withdraw participate research budget patient consider",
    "INCLUSION CRITERIA": "advanced brain metastasis melanoma patient age year patients histologically confirm metastatic melanoma patients must recover acute lymphoblastic leukemia side effect recent systemic local treatment metastatic melanoma grade anti thrombin least one measurable brain metastasis diameter previously treat surgery radiosurgery locate less cm skull patients may receive prior radiosurgery surgery brain metastasis receive prior local treatment must anti thrombin least rano recist assessable brain metastasis braf status wild type mutate case previous treatment braf inhibitor mek inhibitor allow eastern cooperative oncology group ecog performance status ps age year hemoglobin deciliter platelets neutrophils cubic millimeter creatinine clearance mn aspartate amino transferase alanine amino transferase total bilirubin alkaline phosphatase inr prothrombin tca hepatocellular insufficiency unhealed wound head allergy poly isoprene signed informed consent patient health insurance coverage life expectancy month",
    "EXCLUSION CRITERIA": "ocular melanoma symptomatic leptomeningeal involvement symptomatic hemorrhagic brain metastasis symptoms incoercible intracranial pressure patient receive corticosteroid patient present intermittent seizure enrol stable dose corticosteroid day corticotherapy antiepileptic treatment since anti thrombin least week enrolment indication urgent neurosurgery radiotherapy prior malignancy active within previous year except locally curable cancer apparently cure stage untreated chronic lymphoid leukemia known human immunodeficiency virus infection ongoing infectious disease significant background concurrent administration anticancer therapies administer study treatment cytotoxic investigational drug target therapy week halflives targeted therapy chemotherapy prior day study prior whole brain radiotherapy pregnant lactate woman patient auto immune disease contraindications nivolumab alone association ipilimumab define summary product characteristic http www vidal shortening fraction substances nivolumab serious uncontrolled medical disorder opinion investigator may increase risk associate study participation study drug administration impair ability patient receive protocol therapy interfere interpretation study result allergy iodine gadolinium lidocaine contraindications sonovue hypersensibility sulfur hexafluoride recent acute coronary syndrome unstable ischemic heart disease congestive heart failure class iii intravenous infusion define new york heart association concurrent treatment dobutamine severe pulmonary arterial hypertension uncontrolled systemic hypertension respiratory distress syndrome concurrent treatment central nervous system benzodiazepin sedative hypnotic antihistaminic pro convulse drug butyrophenons phenothiazin conventional antipsychotic barbituric mao inhibitor anticholinergic drug accord investigator cause cerebral toxicity due bbb open concurrent anticoagulant antiplatelet therapy uncontrolled epilepsy magnetic resonance image contra indication claustrophobia intracorporal metallic material phlebitis active pulmonary embolism prisoners subject world health organization involuntarily incarcerate psychological familial sociological geographical condition potentially hamper compliance study protocol followup schedule condition discuss subject registration trial treatment drug authorize special condition stable dosage month prior inclusion inhibitors acetylcholine esterase donepezil aricept galantamine rivastigmine memantine atypical antipsychotic eg quetiapine antidepressants mao inhibitor anticholinergic dose milligram kilogram thyroid hormone implantation sonocloud possible accord neurosurgeon patient morphological characteristic skin characteristic bone thickness neurosurgeon opinion prevent implantation device may impair ability patient receive treatment sonocloud would exclude",
    "TREATMENT": "",
    "STATISTICAL": "adaptive bayesian doseescalation model continual reassessment method crm use selected version crm modelbased design dose dlt relationship model cumulative function correspond oneparameter power model parameter sequentially estimate data via bayesian estimation setting mtd populationparameter refers percentile dosetoxicity relationship total us dose level evaluate mpa minimum three patient include anti thrombin dose level october patient treat anti thrombin level patient anti thrombin level side effect toxicity observe good tolerance since crm design recommend new patient could treat anti thrombin high level patient receive dose"
  },
  "DREPA-RIC": {
    "TITLE": "prospective multicenter trial compare allogeneic match related haematopoietic stem cell transplantation reduced intensity condition regimen standard care adolescent adult severe sickle cell disease",
    "JUSTIFICATION": "although survival child sickle cell disease scd dramatically improve last decade us europe mortality remain high adult moreover many child adult develop chronic debilitating condition due organ damage allogeneic hematopoietic stem cell transplantation hsct currently unique curative approach intrathecal injection allow cure child transplant match relate donor mrd myeloablative conditioning regimen date study address role hematopoietic stem cell transplantation sickle cell disease adult due risk graft versus host disease gvhd toxicity expect old patient high risk organ damage development safe nonmyeloablative conditioning regimen allow stable mixed chimerism avoid graft versus host disease appear attractive option hematopoietic stem cell transplantation cure adult severe sickle cell disease four group previously report encouraging result total patient transplant match related mobilized peripheral blood cell non myeloablative conditioning regimen alemtuzumab low dose total body irradiation tbi follow posttransplant sirolimus study demonstrate high sickle cell disease free survival rate death relate transplant graft failure graft versus host disease ninety two percent patient cure normalized hemoglobin level resolution hemolysis stable hemoglobin level identical proportion observe donor however outcome comparison patient transplant patient transplant lack design prospective multicenter trial target patient year severe sickle cell disease compare nonmyeloablative transplant match relate donor mrd identify versus hematopoietic stem cell transplantation patient lack mrd",
    "OBJECTIVE": "main objective assess benefit hematopoietic stem cell transplantation year event free survival calculate inclusion compare standard care primary endpoint event free survival event define death cause acute grade iiintravenous infusion graft versus host disease accord magic consortium appendix moderate severe chronic graft versus host disease accord nih classification hospitalization voc define accord usual criterion one acs define usual clinical criterion pulmonary infiltrate chest film thoracic computedtomography ct scan stroke define clinical event confirm magnetic resonance imaging cerebral cervical stenosis new territory evaluate magnetic resonance imaging mra apparition silent infarct increase anti thrombin least tricuspid regurgitation velocity confirm echocardiography perform delay anti thrombin least month compare pre inclusion value patient trv anti thrombin inclusion hypothesize event free survival hematopoietic stem cell transplantation versus notransplant group secondary objective compare group anti thrombin year overall survival total day require hospitalization first month postinclusion acute complication sickle cell disease voc acs priapism stroke silent infarct cerebral cervical stenosis mra magnetic resonance image hemolytic index hematologic biochemical parameter organ function kidney eye heart lung liver bone grade iiiintravenous infusion infectious complication need transfusion month postinclusion alloimmunization rate iron overload chronic use oral opioids nutritional involvement gonadic function fertility quality life anxiety depression cost evaluate transplant group chimerism engraftment graft versus host disease patient free sirolimus anti thrombin year posttransplant secondary end point death number day require hospitalization exclusion first month postinclusion clinical adverse event number voc acs require hospitalization number hospitalization intensive care unit number priapism number stroke changes biological parameter ldh aminotransferase gamma glutamyl transpeptidase alkaline phosphatase bilirubin professor aptt hemoglobin level hematocrit mean corpuscular volume percentage hemoglobin variant reticulocyte white blood cell platelet count estimate glomerular function rate microalbuminuria creatininuria ratio ferritin transferrin saturation level gonadic function spermogram men lh fsh oestrogen woman testosterone men anti thrombin month number amenorrhea woman number parity eye function heart pulmonary hypertension auricular ventricular dilatation leave ventricular mass function transthoracic echocardiography lung function pulmonary function test min walk test bone function new episode avascular osteonecrosis fracture central nervous system function mra mri liver heart magnetic resonance imaging iron overload evaluation patient ferritin microg anti thrombin inclusion month month number red blood cell pack transfuse month postinclusion number delayed hemolytic transfusion reaction dhtr oral opioid consumption quality life questionnaire mos hospital anxiety depression scale hads questionnaire change weight severe infection ctae score grade graft versus host disease incidence grading hematopoietic stem cell transplantation patient chimerism hematopoietic stem cell transplantation assess total blood population lymphocyte subset cost evaluate day hospitalization inclusion",
    "DESIGN": "quasi experimental design phase prospective control multicenter cohort study group patient define genetic randomization eligibility criterion informed consent obtain human leukocyte antigen typing perform identify potential human leukocyte antigen match related donor define group group expose patient human leukocyte antigen identical sibling identify patient receive hematopoietic stem cell transplantation group unexposed patient patient lack human leukocyte antigen identical sibling receive best standard care transplant arm redcell exchange perform reduce hemoglobin level less month precede transplant condition regimen consist total body irradiation anti thrombin day alemtuzumab intravenous infusion total dose kg day day day stem cell source gcerebro spinal fluid mobilize peripheral blood stem cell target dose per kilogram body weight graft versus host disease prophylaxis consist sirolimus year sirolimus taper stop anti thrombin month post transplant transplant arm patient receive best standard care accord situation previous treatment initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation transfusion program tp initiation new drug prove improve sickle cell disease authorization use france hematopoietic stem cell transplantation transplant arm risk complication disease despite supportive care include hydroxyurea transfusion program chronic transfusion lead iron overload alloimmunization hydroxyurea lead hypofertility arm consultation every month month transplant arm hospitalization week follow weekly consultation first month post transplant monthly consultation month consultation every month month common toxicity associate transplantation include reduced conditioning regimen graft versus host disease prophylaxis graft versus host disease accord magic consortium appendix criterion chronic graft versus host disease accord nih classification infection fever aplasia pancytopenia neutropenia thrombopenia anemia gastrointestinal nausea vomit cardiovascular arterial hypertension neurological disorder visual disorder miscellaneous serum sickness skin rash pain swelling joint anaphylaxis hypotension difficulty breathing severe hive mucositis transplant may potentially lead transplant related mortality graft versus host disease case observe first case report literature risk long term complication infertility remain evaluate setting ric transplant",
    "INCLUSION CRITERIA": "adolescents young adult year sickle cell disease patient ss aged year anti thrombin least one nonsickle cell disease sibling year parental couple world health organization present anti thrombin least one following criterion voc require hospitalization last year anti thrombin least severe acs within past year define follow acs require red cell transfusion hospitalization intensive care unit acs arterial blood hydrogen ion concentration need liter mn reach voc require hospitalization last year history recurrent acs three history ischemic stroke cerebral cervical arterial stenosis apparition silent infarct last year pulmonary hypertension define mean pulmonary artery pressure mmhg anti thrombin rest determine right heart catherization osteonecrosis anti thrombin least joint include one diagnose past year sickle nephropathy estimate glomerular filtration rate ckd epi formula ml min persistant microalbuminuria microalbuminuria creatininuria ratio milligrams mmol without cause nephropathy requiring treatment hydroxyurea chronic transfusion already treat hydroxyurea transfusion program tp anti thrombin inclusion patients already receive chronic transfusion voc acs respond hydroxyurea eligible provide beginning chronic transfusion anti thrombin least voc require hospitalization last year anti thrombin least severe acs within past year define follow acs require red cell transfusion hospitalization intensive care unit acs arterial blood hydrogen ion concentration need liter mn reach voc require hospitalization last year history recurrent acs three contraception acute lymphoblastic leukemia study period sirolimus woman child bear potential signed informed consent amenable human leukocyte antigen typing hematopoietic stem cell transplantation human leukocyte antigenidentical sibling available patients affiliate french health care insurance age year hb electrophoresis aplastic anemia ac donor usual clinical biological eligibility criterion gcerebro spinal fluid mobilization peripheral blood stem cell bone collection include legal viral serology assessment authorize transplant human leukocyte antigen identical patient negative test anti thrombin time hematopoietic stem cell transplantation mobilization patient several potential donor several match sibling donor abo match donor choose priority",
    "EXCLUSION CRITERIA": "performance status eastern cooperative oncology group scale pulmonary function et force vital capacity theorical value post capillary severe precapillary pulmonary hypertension measured mean pulmonary artery pressure anti thrombin rest mmhg cardiac ejection fraction estimated glomerular fraction rate gfr mn conjugate bilirubin mole cirrhosis alanineaminotransferase severe uncontrolled infection known hypersensitivity alemtuzumab known hypersensitivity murin protein following excipients disodium edetate polysorbate potassium chloride potassium phosphate monobasic sodium chloride dibasic sodium phosphate water injection positivity human immunodeficiency virus pregnancy breastfeeding woman alloimmunization delayed hemolytic transfusion reaction preclude red cell transfusion previous solid organ transplant hematopoietic stem cell transplant uncontrolled hypertension history arterial dissection cervicocephalic artery history angina pectoris myocardial infarction",
    "TREATMENT": "patients transplant within month inclusion human leukocyte antigen matched relate hematopoietic stem cell transplantation redcell exchange perform reduce hemoglobin level less month precede transplant consider fertility preservation technique accord patient age pregnancy wish evaluation ovarian function condition regimen consist total body irradiation anti thrombin day alemtuzumab intravenous infusion total dose kg day day day stem cell source gcerebro spinal fluid mobilize peripheral blood stem cell target dose per kilogram body weight number cell obtain one leukapheresis second plan next day reach goal graft versus host disease prophylaxis consist sirolimus year sirolimus taper stop anti thrombin month posttransplant patients receive best standard care accord situation previous treatment initiation hydroxyurea continuation optimization dose hydroxyurea initiation continuation time point initiation new drug prove improve sickle cell disease authorization use france",
    "STATISTICAL": "single efficacy analysis plan eventfree survival compare two group use logrank test effect hematopoietic stem cell transplantation assess hazard ratio use cox model primary endpoint event free survival anti thrombin year calculate inclusion event define followed death cause acute grade iiintravenous infusion graft versus host disease accord magic consortium appendix moderate severe chronic graft versus host disease accord nih classification hospitalization voc define accord usual criterion one acs define usual clinical criterion pulmonary infiltrate chest film thoracic computedtomography ct scan stroke define clinical event confirm magnetic resonance image cerebral cervical stenosis new territory evaluate magnetic resonance imaging mra increase anti thrombin least tricuspid regurgitation velocity confirm echocardiography perform delay anti thrombin least month compare pre inclusion value patient trv anti thrombin inclusion apparition silent infarct cerebral cervical stenosis new territory increase previous stenosis evaluate magnetic resonance imaging mra event free survival anti thrombin year calculate inclusion also describe hematopoietic stem cell transplantation group overall survival define time date inclusion death due cause date last followup propensity score matching analysis also perform sensitivity analysis handle potential residual imbalance arm confounders sequential analysis tolerance data perform use bayesian method hypothesize event free survival hematopoietic stem cell transplantation versus notransplant group"
  },
  "PARADISE": {
    "TITLE": "prospective randomized controlled trial crohn disease exclusion diet corticosteroids adult pediatric patients active crohn disease",
    "JUSTIFICATION": "",
    "OBJECTIVE": "main objective assess whether crohn disease exclusion diet superior corticosteroid term endoscopic response patient mildly moderately active luminal inflammatory crohn disease primary endpoint endoscopic response anti thrombin week without corticosteroid far therapeutic intervention assess centralized pseudonymized blind double lecture panel panenteric pillcam crohn capsule pcc endoscopic response define decrease anti thrombin least lewis score patient small bowel crohn disease decrease sescrohn disease anti thrombin least patient colonic crohn disease patient small bowel colonic crohn disease compare baseline value compare arm trial steroidfree clinical remission hbi response decrease anti thrombin least point hbi steroidfree clinical remission cdai response decrease anti thrombin least point cdai need therapeutic intervention steroid immunosuppressant new biologic surgery decrease fecal calprotectin anti thrombin least steroid fecal calprotectin less less less creactive protein serum level median harveybradshaw index crohn disease activity index calprotectin creactive protein endoscopic remission define lewis score small bowel sescrohn disease colon without therapeutic intervention surgery biologics dietary intervention endoscopic response remission grade eliakim score segmental endoscopic response remission gut microbiota composition pcr pcr fungi protist metabolomics shotgun metagenomics compliance corticosteroid treatment medication adherence report scale compliance crohn disease exclusion diet dietary habit questionnaires food diary body weight arterial pressure fast serum glucose safety assess adverse event either severe suspect unexpected serious adverse reaction quality life assess short inflammatory bowel disease questionnaire work productivity activity assess work productivity index questionnaire",
    "DESIGN": "multicentre openlabel comparative randomize control single blind superiority far risk associate exclusion diet exclusive partial enteral nutrition crohn disease exclusion diet crohn disease identify yet crohn disease exclusion diet burdensome intrathecal injection consist avoidance many food item pillcam crohn capsule carry risk intestinal obstruction perforation capsule block intestinal stricture risk avoid systematic use patency capsule prior administration real capsule two panenteric capsule endoscopy need bowel preparation however patient whose endoscopic lesion confine small bowel anti thrombin first pillcam crohn capsule prepare ml pegaspargase pegylated asparaginase minute second pillcam crohn capsule moreover pillcam crohn capsule caries risk delayed excretion capsule risk lesion mucosal bleeding risk level study somewhat high risk standard medical care see chart",
    "INCLUSION CRITERIA": "patients active crohn disease patients age year mild moderate luminal active crohn disease define harveybradshaw index involve small bowel colon treat corticosteroid anti thrombin baseline patients either naive previously expose maximum two class biologics currently receive biologic therapy expose maximum two class biologic therapy include current one patent small bowel assess patency capsule active endoscopic lesion define lewis score small bowel sescrohn disease colon eligibility patient determine anti thrombin least one central reader informed consent participate study patient france israel world health organization age less parent informed consent participate study parent agreement require patient age netherlands affiliation social security health insurance",
    "EXCLUSION CRITERIA": "inability follow crohn disease exclusion diet week prior intolerance corticosteroid ongoing infection evolve virus disease live vaccine psychotic state control treatment arthritis uveitis main presenting symptom patients severe predominant rectal perianal disease heavy smoker cigarette per day infliximab adalimumab vedolizumab ustekinumab rizankizumab upadacitinib methotrexate azathioprine initiate less month inclusion trial change methotrexate azathioprine infliximab adalimumab vedolizumab upadactinib risankizumab ustekinumab dosage less month inclusion severe pubertal delay tanner tanner height velocity zscore bone mineral density zscore hip lumbar spine know pregnant lactating woman patients already include biomedical research observational study registry cohort biobank persons deprive liberty judicial administrative decision person subject psychiatric care section person admit health social institution purpose research france present past history eat disorder include anorexia nervosa",
    "TREATMENT": "crohn disease exclusion diet cded oral corticosteroid prednisolone budesonide two panenteric pillcam crohn capsule crohn disease exclusion diet biological collection stool serum collection pregnancy test",
    "STATISTICAL": "intrathecal injection base intenttotreat principle itt based available literature hypothesize patient reach primary endpoint crohn disease exclusion diet arm versus corticosteroid arm plan screen patient include patient randomize crohn disease exclusion diet corticosteroid"
  },
  "MARVEL": {
    "TITLE": "exploring venlafaxine pharmacokinetic variability phenotyping approach",
    "JUSTIFICATION": "regarding direct cost social value depression decision antidepressant treatment prescription must optimize much possible development personalized medicine psychiatry may reduce treatment failure intolerance resistance hence burden cost affective disorder hope biomarkers find guide treatment selection intrathecal injection might decisive interest able assess individual metabolism activity propose explore relationship activity drugmetabolizing enzyme dme transporters assess phenotypic approach efficacy antidepressant focus venlafaxine provide reasonable secondstep choice patient depression use extensively psychiatric practice metabolism involve several cytochrome cyp enzyme transporter pgeneral practitioner oral extend release venlafaxine regardless dose anti thrombin selection increase study accord psychiatric followup necessary",
    "OBJECTIVE": "study correlation concentration metabolite odesmethylv v+odv drug metabolism variability assess phenotypic approach compare responder non responder well patient without side effect activity prevalence profile metabolism activity prevalence profile metabolism activity prevalence profile metabolism pgeneral practitioner activity prevalance profile transport study correlation v+odesmethylv concentration dose v+odesmethylv concentration antidepressant efficacy tolerance study correlation ratio odesmethylv activity study correlation concentration anti thrombin hour area curve hour metabolic ratio hydroxyomeprazole omeprazole conduct exploratory association analysis blood biomarkers candidate mrna mirna tolerance efficacy analyse role genetic variation dna determination phenotype patient picomolar profile v+odv concentration activity omeprazole anti thrombin hour area curve metabolic ratio hour omeprazole oral administration activity dextrorphan dextromethorphan ratio two hour dextromethorphan oral administration activity midazolam ratio two hour midazolam oral administration pgeneral practitioner activity fexofenadine area curve base fexofenadine concentration anti thrombin hour fexofenadine oral administration antidepressant efficacy madrs hamd qids antidepressant tolerance prisem fisber antidepressant observance mars circulating mrna mirna transcript allelic variation",
    "DESIGN": "interventional study recherche biomedicale dosage venlafaxine odemethylv odv collect dna circulating mrna mirna transcript assessment drug efficacy tolerance adherence use standardized questionnaire administration cocktail drug current authorization study two blood sample one blood sample one blood sample three blood spot risque selection visit take place usual medical followup include measurement madrs hamd score visit carry part traditional hospitalization intrathecal injection need regard patient psychiatric condition conversely day hospitalization consultation systematically supervise practitionner inclusion take place day increase dosage include verification inclusion non inclusion criterion signature consent screen tobacco use fagerstrom test characteristics mood disorder anxiety scale tyrer criteria rating medication trial antidepressant failure level resistance mars score prisem score fisber score visit take place day visit include sampling dosage venlafaxine odemethylv odv collect dna circulate mrna mirna transcript phenotypic study administration cocktail probe drug capsule omeprazole ml oral liquid formulation dextromethorphane bromhydrate tussidane ml syrup milligram injectable solution midazolam oral administration midazolam ml injectable solution tablet fexofenadine pill liquid formulation take orally successively glass water followed capillary blood sample anti thrombin hour cocktail administration drop hour small finger prick dbs device measurement cocktail drug concentration drug parent metabolite visit take place day week day week visit psychologist doctor include assessment drug efficacy tolerance adherence mars score prisem score fisber score madrs hamd",
    "INCLUSION CRITERIA": "patient major depressive disorder madrs despite week regardless dose patient hospitalized outpatient major depressive disorder madrs anti thrombin visit selection patients non responder week regardless dose decision psychiatrist increase dose anti thrombin visit selection male female age year understanding french language able give write inform consent informed consent sign participate study individuals cover social security regimen",
    "EXCLUSION CRITERIA": "patients treat one antidepressant mirtazapine mianserine patients currently treat one drug substrate cocktail esomeprazole sensitivity contraindication substrate drug use current pregnancy desire get pregnant breastfeed bipolar disorder schizophrenia",
    "TREATMENT": "",
    "STATISTICAL": "statistical analysis perform sample size reach acute lymphoblastic leukemia end point measure available hypothesis prevalence patient um profile twice high nonresponders comparison responder world health organization metabolic profile comparable caucasians demonstrate prevalence two fold observe nonresponders type error anti thrombin statistical power sample size tabulate accord prevalence response thus anticipate potential large disproportion responders non responder define study inclusion decide include patient allow control type type ii error rate comparison prevalence um profile among group addition sample size allow study sufficient number picomolar intramuscular um determine effect variation odesmethylv plasma level efficacy risk adverse event type error rate fix anti thrombin acute lymphoblastic leukemia test twosided compare thus multiple imputation popular approach handle pervasive problem miss data biostatistics use intrathecal injection usually perform missing anti thrombin random mar assumption multiple imputation chained equation knowledge flexible approach handle complex pattern miss data include categorical data quantitative data survival data primary analysis perform intenttotreat basis secondary exploratory analysis consider population compliers world health organization complete treatment accord schedule protocol"
  },
  "PIPAC": {
    "TITLE": "pressurized intraperitoneal aerosol chemotherapy pipac gastric carcinomatosis phase ii randomize study",
    "JUSTIFICATION": "peritoneal metastasis common pattern advanced gastric cancer lead terminal condition short time whatever recent progress regard systemic chemotherapy use multi drug association median survival limit month altered quality life qol month acute lymphoblastic leukemia patient postulate new innovative health technology deliver intraperitoneal pressurize aerosol chemotherapy doxorubicin cisplatin laparoscopy transform situation offering double survival quality life preservation interestingly pipac procedure make apply repeatedly every week week therapeutic strategy allow improve ip drug impregnation maintain intravenous infusion chemotherapy meanwhile pipac estok project support six main carcinomatosis national center gather medical surgical team daily support peritoneal carcinomatosis demonstrate efficacy pipac procedure gastric carcinomatosis make radical shift management patient break past strategy",
    "OBJECTIVE": "main objective clinical study primary objective evaluate compare month progression freesurvival patient peritoneal carcinomatosis gastric cancer treat either intravenous infusion chemotherapy pressurized intraperitoneal aerosol chemotherapy pipac intravenous infusion chemotherapy alone preservation quality life primary endpoint primary endpoint corresponds progression freesurvival define number patient clinical morphological sign progression death month treatment secondary objectives assessment criterion patients relate morbidity evaluate postoperative day claviendindo classification comprehensive complication index range calculate website https www assessurgery com cci calculator evaluation treatmentrelated toxicity base ct cae classification postoperative pain measure use numeric rating scale postoperative day day every hour obligatory sleep night break quality life evaluate anti thrombin visit patient eortc questionnaire specific gastric cancer annexe eortc questionnaire annexe quality health status evaluate anti thrombin visit patient euroqol questionnaire annexe treatment relate feasibility successive pipac procedure define possibility perform pipac problem access peritoneal cavity disease relate overall survival anti thrombin month define time randomization death secondary resecability rate define ipc anti thrombin laparoscopy treatment",
    "DESIGN": "prospective multicenter randomize openlabel control parallelgroup phase ii clinical trial design evaluate effect pipac doxorubicin cisplatin patient gastric peritoneal metastasis pci risk",
    "INCLUSION CRITERIA": "major subject peritoneal carcinomatosis gastric cancer patients relate age year performance status white blood cell cubic millimeter neutrophil cubic millimeter platelet cubic millimeter creatinemia milligrams deciliter creatinine clearance ml min serum total bilirubin milligrams deciliter acceptable nutritional condition body mass index kilograms month albumin giga liter pre albumin milligrams effective contraception patient childbearing age written consent obtain prior act research patient social insurance disease relate patient synchronous metachronous peritoneal ovarian metastasis pathologically proven gastric siewert iii adenocarcinoma cancer include adci adenocarcinoma independent cell linitis patients without primary gastric tumor include pci peritoneal cancer index",
    "EXCLUSION CRITERIA": "patients relate weight loss total body weight last three month presence uncontrolled comorbidities include severe chronic disease organ insufficiency contraindication drug contain chemotherapy regimen accord summary product characteristic rcp contraindication cisplatin intravenous infusion doxorubicin intravenous infusion accord summary product characteristics force allergy severe toxicity cisplatin renal function impairment contraindicate calculated cockcroft formula measure creatinine clearance less ml min measure creatinine adequately reflect renal function cisplatin cumulative nephrological toxicity doxorubicin risk cardiotoxicity occur immediately delay sinus tachycardia electrocardiogram abnormality cf rcp following website http agence prd agence nationale de securite du medicament et des produits de sante sante shortening fraction php ecodex rcp htm complete deficiency enzyme dihydropyrimidine dehydrogenase patient arm pipac debulking surgery ovariectomy omentectomy permit pipac surgical procedure schedule accordance protocol successive pipac debulking surgery pipac procedure authorize pregnancy breastfeed patient guardianship disease relate malignancy within last year curatively treat basal cell carcinoma skin situ carcinoma cervix systemic metastasis liver lung bone brain lomboaortic lymph node involvement pleural effusion require evacuation respiratory failure small bowel occlusion possible food intake ascites liter participation clinical trial treatment gastric peritoneal metastasis year precede inclusion",
    "TREATMENT": "intraperitoneal pressurize aerosol chemotherapy cisplatin milligrams month doxorubicin milligrams month laparoscopy give min anti thrombin mmhg anti thrombin week interval anti thrombin least successive pipac schedule protocol patient receive pipac procedure progression toxicity nonfeasibility procedure research open sponsor center already practice pipac procedure part treatment investigator world health organization declare part research undergo training use new pipac procedure patient receive standard poly chemotherapy propose oncologist eox epirubicin oxaliplatin capecitabine ecx epirubicin cisplatin capecitabine folfox folfiri ecf epirubicin cisplatin fluorouracil flot new standard validate study progression toxicity every pipac surgical procedure perform general anaesthesia biopsy tumor peritoneum patient generally hospitalize one night two day pipac procedure intraperitoneal pressurize aerosol chemotherapy cisplatin milligrams month doxorubicin milligrams month laparoscopy give min anti thrombin mmhg anti thrombin week interval successive pipac schedule explorative laparoscopy final assessment perform patient progression clinic radiological assessment",
    "STATISTICAL": "progression freesurvival estimate use kaplan meier estimator total sample per arm estimation confidence intervals ci give test survival curve perform use logrank test hazard ratio estimate use cox model sensitivity analysis perform consider per protocol population"
  },
  "JAKAHDI": {
    "TITLE": "jak inhibitor acquired hemophagocytic syndrome intensive care unit",
    "JUSTIFICATION": "hemophagocytic syndrome hs rare condition responsible severe organ failure therapeutic guideline mainly base observational study expert opinion therapeutic advance develop year explain mortality hs remain high icu mortality range etoposide remain gold standard critically ill hs patient nearly patient refractory therapy treatment escalation common often require administration intensive treatment generate high toxicity ruxolitinib first approve jak inhibitor intrathecal injection associate improvement hs manifestation survival preclinical murine model data human scarce promising",
    "OBJECTIVE": "aim demonstrate ruxolitinib association standard care may reverse organ failure represent sofa score good standard care alone critically ill patient acquire hs primary end point survival decrease sofa score point anti thrombin day demonstrate ruxolitinib may improve overall survival hs critically ill patient demonstrate ruxolitinib may reverse clinical temperature sofa score biological ferritin level soluble receptor dosage fibrinogen level triglyceride level hemoglobin level white blood cell count platelet count manifestation relate hs analyse impact ruxolitinib biological inflammatory marker gmcerebro spinal fluid ifn gamma tnf alpha demonstrate safety ruxolitinib critically ill hs patient",
    "DESIGN": "multicenter national uncontrolled phase ii trial base fleming design patients admit participate icus include study meet eligibility criterion patient consultation perform study investigator data collection investigator research assistant clinical research technician crts",
    "INCLUSION CRITERIA": "adult patient old year adult patient old year acquire hemophagocytic syndrome regardless etiology define presence criterion hscore admission intensive care unit need symptomatic treatment hs relation organ failure define sofa score informed consent sign patient inform consent sign family members trustworthy person condition allow express consent write per emergency situation absence family members trustworthy person patient enrol consent participate research request soon condition patient allow inclusion woman childbearing potential require use highly effective contraceptive measure contraception maintain treatment one day",
    "EXCLUSION CRITERIA": "moribund define life expectancy hour pregnant lactating patient woman childbearing potential must negative urine blood human chorionic gonadotropin pregnancy test prior trial entry affiliation health insurance known hypersensitivity ruxolitinib lactose intolerance hypersensitivity cellulose microcrystalline magnesium stearate silica colloidal anhydrous sodium starch glycolate type povidone hydroxypropylcellulose cps preexisting decision withholding withdrawing care history progressive multifocal leukoencephalopathy uncontrolled cutaneous cancer persons psychiatric care would impede understanding informed consent optimal treatment followup adults subject legal protection measure guardianship curatorship safeguard justice patients deprive liberty judicial administrative decision participation another interventional research",
    "TREATMENT": "patients receive oral ruxolitinib twice day milligram day association standard care hs none ruxolitinib cytokines dosage sample tube anti thrombin day day day day soluble dosage sample tube anti thrombin day day day day",
    "STATISTICAL": "based fleming design interim analysis perform day status consecutively enrolled patient observe terminal analysis base intentiontotreat population perform acute lymphoblastic leukemia patient recruit unless early stopping"
  },
  "GRAALL-2014/B": {
    "TITLE": "",
    "JUSTIFICATION": "multicenter open control study sr patient phase ii multicenter open non control graallquest high risk patient",
    "OBJECTIVE": "primary objective prospectively validate new risk model base mental retardation autosomal dominant response level lysine methyltransferase mll ikaros family zinc finger protein gene status compare historical result graall identical population patient ph lineage acute lymphoblastic leukemia age year old evaluate efficacy blinatumomabbased consolidation maintenance therapy term disease free survival high risk patient graallquest substudy compare historical result identical population patient high risk feature graallquest study secondary objective appreciate tolerance blinatumomabbased consolidation cycle bridge allostem cell transplantation within consolidation maintenance therapy evaluate match related donor level monitor igtcr evaluate cumulative incidence relapse cir nonrelapse mortality nrm diseasefree survival dfs overall survival os evaluate relapsefree survival cumulative incidence relapse non relapse relate mortality overall survival censor anti thrombin stem cell transplantation first complete remission",
    "DESIGN": "standardrisk sr patient classify highrisk hr highrisk matched relate donor vhrmrd patient highrisk hr patient define induction havingat least one following criterion ikaros family zinc finger protein gene deletion lysine methyltransferase mll fusion lysine methyltransferase mll gene rearrangement mental retardation autosomal dominant level sensitivity anti thrombin least include salvage cure require reach hematological high risk patient treat graallquest study receive blinatumomab part consolidation maintenance phase patients high risk non eligible graallquest study treat standard risk arm follow highrisk match related donor vhrmrd patient define inductionas anti thrombin least one following criterion mental retardation autosomal dominant sensitivity anti thrombin least sensitivity anti thrombin least almost acute lymphoblastic leukemia high riskmatched relate donor patient high risk patient thus eligible graallquest study acute lymphoblastic leukemia high riskmatched relate donor patient donor receive allostem cell transplantation consolidation primary evaluation criterion disease free survival dfs anti thrombin year depend status lysine methyltransferase mll ikaros family zinc finger protein gene mental retardation autosomal dominant assess induction cure day consolidation disease free survival anti thrombin year graallquest study secondary evaluation criterion cumulative incidence relapse non relapse relate mortality overall survival disease free survival cumulative incidence relapse non relapse relate mortality overall survival censor anti thrombin allostem cell transplantation first complete remission match related donor followup anti thrombin different treatment time cf infra match related donor monitoring adverse event blinatumomab graallquest",
    "INCLUSION CRITERIA": "patient whose blood bone marrow exploration complete steroid prephase aged year old previously treat include intrathecal injection blineageacute lymphoblastic leukemia newly diagnose accord world health organization definition bone marrow blast whose karyotype show absence molecular biology bcrabl eastern cooperative oncology group without central nervous system cns testis involvement without evolve cancer except basal cell carcinoma skin situ carcinoma cervix radiotherapy chemotherapy treatment finish anti thrombin least since month sign write informed consent efficient contraception woman childbearing age exclude estrogen iud health insurance coverage world health organization receive receive steroid prephase secondary acute lymphoblastic leukemia antecedent chemo radiotherapy include patient included high risk bacute lymphoblastic leukemia eastern cooperative oncology group complete remission one two induction cure receive three block consolidation without allogeneic donor",
    "EXCLUSION CRITERIA": "patient lymphoblastic lymphoma bone marrow blast burkitttype acute lymphoblastic leukemia antecedent chronicmyelogenous leukemia myeloproliferative neoplasm contraindication anthracyclines general visceral contraindication intensive therapy except consider relate acute lymphoblastic leukemia aspartate amino transferase sgot alanineaminotransferase sgpt upper limit normal total bilirubin upper limit normal creatinine upper limit normal creatinine clearance ml mn myocardial infarction within month prior inclusion trial cardiomyopathy nyha grade iii iv lvef rf human immunodeficiency virus htlvi hcv seropositivity chronic hbv hepatitis hbsagpositive pregnant hcg positive nurse woman able bear procedure frequency visit plan trial unable consent tutelage curatorship judiciary safeguard women childbearing potential willing use effective form contraception participation study anti thrombin least three month thereafter patients willing ensure beget child participation study anti thrombin least three month thereafter treated investigational agent participation another trial within day prior enter study patient eastern cooperative oncology group status consolidation abnormal laboratory value define consolidation aspartate amino transferase sgot alanine amino transferase sgpt upper limit normal total bilirubin upper limit normal creatinine upper limit normal creatinine clearance ml min serum amylase lipase upper limit normal active uncontrolled infection concurrent disease medical condition deem interfere conduct study judge investigator new york heart association grade cardiac disease infection human immunodeficiency virus hiv chronic infection hepatitis virus hbsag positive hepatitis virus antihcv positive primary monitoring asparaginase activity ammoniemia annex injection theoretically day secondary monitoring injection theoretically day acute lymphoblastic leukemia patient year old sample collection must perform immediately injection able bear procedure frequency visit plan trial",
    "TREATMENT": "blinatumomab blincyto high risk patient enrol graallquest study cyclophosphamide methotrexate vincristine cytarabine etoposide dexamethasone mercaptopurin daunorubicin idarubicin prednisone lasparaginase granulocyte colony stimulate factor gcsf induction acute lymphoblastic leukemia patient receive induction course patients without hematologic complete remission anti thrombin end induction receive salvage therapy differential diagnosis hydrogen ion concentration+ blineageacute lymphoblastic leukemia prephase patient receive igtcr mental retardation autosomal dominant level evaluate anti thrombin end induction cycle orat day first consolidation phase consolidation acute lymphoblastic leukemia patient hematologic complete remission induction eventually follow salvage receive interim standby block first consolidation comprise block chemotherapy block standby block allow recover potential toxicity induction notably hepatic avoid modify order following consolidation block respect dosage intensity high risk versus standard risk patients attribute risk group first consolidation accord mental retardation autosomal dominant level need salvage obtain chr presence ikaros family zinc finger protein gene deletion lysine methyltransferase mll gene rearrangement acute lymphoblastic leukemia high risk patient propose phase ii graallquest study inclusion number reach high risk patient world health organization would eligible graall quest continue participate study followup plan graall igtcr level evaluate anti thrombin end consolidation day one consolidation consolidation first consolidation standard risk patient continue standard protocol receive consolidation block high risk patient traited phase ii graallquest study receive blinotumomab consolidation compose block blina hdarac hd mtx high risk versus high riskmatched related donor high riskmatched relate donor define mental retardation autosomal dominant need salvage cure reach hematologic complete remission patients eligible allostem cell transplantation suitable donor receive blinatumomab continuous infusion condition regimen igtcr level evaluate anti thrombin day late intensification prior stem cell transplantation allografted patient late intensification administer acute lymphoblastic leukemia nonallografted patient whatever risk group consolidation late intensification patient standard risk receive third consolidation block high risk patient receive second investigational blinatumomabbased consolidation compose block blina hdarac hdmtx igtcr level evaluate anti thrombin day maintenance therapy day sct maintenance therapy whole duration two year intrathecal classical maintenance therapy acute lymphoblastic leukemia patient base association mercaptopurin methotrexate monthly reinductions associate vincristine prednisone first year patients high risk patient receive blinatumomab course instead vincristine pulse anti thrombin month allogeneic stem cell transplantation sct allogeneic stem cell transplantation first complete remission offer acute lymphoblastic leukemia high riskmatched relate donor patient genoidentical familial unrelated donor allostem cell transplantation early possible second consolidation phase patient year old conditioning myeloablative total body irradiation gy fractionate cyclophophamide milligrams kilograms anti thymoglobulin myelo ablative conditioning myelo ablative conditioning case unrelated allosct patients age year old comorbidity criterion benefit reduce intensity condition total body irradiation fractionate gy dose fludarabine milligrams month anti thymoglobulin myelo ablative conditioning myelo ablative conditioning case unrelated allosct patients high risk becarfull stem cell transplantation earlier end first blinatumomab cycle central nervous system involvement patients central nervous system disease anti thrombin diagnosis receive intensified intrathecal therapy lumbar puncture induction central nervous system irradiation perform consolidation intrathecal central nervous system irradiation maintenance induction prednisone milligrams month po day vincristine milligrams ivd day day day day daunorubicin milligrams month iv min day day day milligrams month iv min day day cyclophosphamide month iv day day lasparaginase ui month siv day day day day day day day day gcerebro spinal fluid kilograms sc iv day neutrophil intrathecal methotrexate cytarabine depomedrol day day day day age reduce milligrams month age anti thrombin day day day day day day age substitute erwinase immunization coli lasparaginase salvage idarubicin milligrams month iv day day day aracytine milligrams month iv day day day day gcerebro spinal fluid kilograms sc iv day neutrophil standard consolidation sr patient weekly standby block need etoposide milligrams month iv day aracytine milligrams month sc day day blocks aracytine milligrams month iv day day dexamethasone milligrams iv day day gcerebro spinal fluid kilograms sc iv day blocks methotrexate milligrams month civ day vincristine milligrams ivd day milligrams month po day gcerebro spinal fluid kilograms sc iv day intrathecal methotrexate cytarabine depomedrol day start mtx milligrams month minute hour minute follow folinic acid rescue reduce milligrams month age block cyclophosphamide milligrams month iv day day etoposide milligrams month iv day day methotrexate milligrams month iv day gcerebro spinal fluid kilograms sc iv day neutrophil intrathecal methotrexate cytarabine depomedrol day late intensification patient world health organization receive salvage induction prednisone milligrams month po day vincristine milligrams ivd day day day day daunorubicin milligrams month iv min day day day day day cyclophosphamide month iv day day lasparaginase ui month siv day day day day day day day day gcerebro spinal fluid kilograms sc iv day neutrophil intrathecal methotrexate cytarabine depomedrol day day day day age day age anti thrombin day day day day day day age substitution erwinase immunization coli lasparaginase late intensification patient world health organization receive salvage induction idarubicin milligrams month iv day day day aracytine milligrams month iv day day day day gcerebro spinal fluid kilograms sc iv day neutrophil intrathecal methotrexate cytarabine depomedrol day day maintenance therapy year vincristine milligram ivd day month prednisone milligrams month po day day methotrexate milligrams month wk po month milligrams month po month intrathecal methotrexate cytarabine depomedrol day month blinatumomab consolidation hr patient proceed asct begin block blocks dexamethasone milligram day blina blinatumomab ivc day day intrathecal methotrexate cytarabine depomedrol day blocks aracytine milligrams month iv day day dexamethasone milligrams iv day day gcerebro spinal fluid kilograms sc iv day blocks max methotrexate milligrams month civ day vincristine milligrams ivd day milligrams month po day day gcerebro spinal fluid kilograms sc iv day intrathecal methotrexate cytarabine depomedrol day start mtx milligrams month minute hour minute follow folinic acid rescue reduce milligrams month age late intensification patient world health organization receive salvage induction prednisone milligrams month po day vincristine milligrams ivd day day day day daunorubicin milligrams month iv min day day day day day cyclophosphamide month iv day day lasparaginase ui month siv day day day day day day day day gcerebro spinal fluid kilograms sc iv day neutrophil intrathecal methotrexate cytarabine depomedrol day day day day age day age anti thrombin day day day day day day age substitution erwinase immunization coli lasparaginase late intensification patient world health organization receive salvage induction idarubicin milligrams month iv day day day aracytine milligrams month iv day day day day gcerebro spinal fluid kilograms sc iv day neutrophil intrathecal methotrexate cytarabine depomedrol day day blinatumomabbased maintenance therapy year dexamethasone milligram day blinatumomab blinatumomab ivc day day month vincristine milligram ivd day month prednisone milligrams month po day day month methotrexate milligrams month wk po month milligrams month po month intrathecal methotrexate cytarabine depomedrol day month except blinatumomab month blinatumomab consolidation hr patient proceed asct begin block dexamethasone milligram day blina blinatumomab ivc day day intrathecal methotrexate cytarabine depomedrol day high risk patient suitable donor receive blinatumomab continuously allostem cell transplantation condition regimen stop day",
    "STATISTICAL": "year approximately patient hydrogen ion concentrationnegative bcpacute lymphoblastic leukemia may recruit frontline trial hematologic complete remission achievement one may anticipate approximately standard risk patients year high risk patients year include high riskmatched relate donor patient consolidation acute lymphoblastic leukemia standard risk patient treat standard graall protocol without new agent haematopoietic stem cell transplantation first chr objective demonstrate uncontrolled study noninferiority term disease free survival must anti thrombin least control group historical reference margin inferiority justify absence allostem cell transplantation first complete remission unilateral alpha risk power calculated sample size patient high risk patients year eligible graallquest study disease free survival primary endpoint disease free survival compare historical result anti thrombin year objective demonstrate disease free survival improvement alpha risk power twosided setting calculated sample size patient considering dropout rate patient include present study ref sample size table clinical study machin campbell others wiley"
  },
  "METIMGAST": {
    "TITLE": "phase ii trial evaluate combination capmatinib spartalizumab advanced oesogastric adenocarcinoma",
    "JUSTIFICATION": "oesoastric advance adenocarcinoma poor prognosis without improvement last decade recently immunotherapy antibody provide encouraging result subset patient capmatinib met inhibitor show imunomodulatory effect synergy spartalizumab inhibitor combination currently evaluate treatment hepatocellular carcinoma whatever met expression",
    "OBJECTIVE": "evaluate tumor response regimen anti thrombin month inclusion overall response rate orr assess image every week define proportion patient anti thrombin least one objective tumour response complete partial accord recist criterion within month evaluate safety regimen first second cycle administration day day cf chap evaluate safety tolerability regimen whole course treatment acute lymphoblastic leukemia kind toxicity year immunotherapyrelated toxicity cf chap characterize tumor response regimen duration time response estimate progression free survival year inclusion estimate overall survival year inclusion according result interim analysis evaluate tolerance efficacy spartalizumab monotherapy patient nonamplified met tumor ancillary study evaluate pharmacokinetics capmatinib accord presence gastrectomy concurrent treatment proton pump inhibitor evaluate tumor response specific subgroup according residual level capmatinib anti thrombin cycle according met amplification level fish archival tumor sample according baseline neutrophil count circulate hgf level",
    "DESIGN": "multicenter singlearm phase ii trial cohort accord met amplification level cohort tumor without met amplification copy cohort tumor met amplification copy treatment capmatinib milligram milligramstwice day milligrams maximum month progression patient refusal unacceptable toxicity cohort interim analysis primary endpoint first evaluable enrolled patient rule stop continue trial specify table paragraph risks associate toxicity investigational drug risks associate blood sampling pharmacokinetics screening visit verification eligibility criterion information signature consent form registration patient selection connect electronic case report form website cleanweb patient research identification number assign collection patient data demographic patient history tumour characteristic clinical assessment eastern cooperative oncology group performance status weight height blood pressure met amplification determination fish archival material met amplification determination already perform part care intrathecal injection need repeat screening patient inclusion biological examination radiological assessment electrocardiogram inclusion visit review eligibility criterion review result examination assessment carry selection collection patient data demographic patient history tumour characteristic radiological assessment thoracoabdomino pelvic ctscan abdominal magnetic resonance imaging thoracic ct scan case contraindication measurement target lesion accord recist criterion clinical assessment performance status weight height blood pressure biological examination electrocardiogram determination met amplification pregnancy test urine blood applicable blood sample ancillary study prescription allocation treatment treatment cycle toxicities assess clinical evaluation blood test first cycle anti thrombin day day cycle anti thrombin day cycle blood sample ancillary study cycle every week complete clinical evaluation eastern cooperative oncology group performance status weight blood pressure clinical laboratory assessment toxicities evaluate national cancer institutectc classification adverse event efficacy assessment every week radiological evaluation thoracoabdominopelvic ctscan abdominal magnetic resonance imaging thoracic ctscan inject contraindication",
    "INCLUSION CRITERIA": "patients advanced oesogastric adenocarcinoma receive anti thrombin least one previous chemotherapy line platinium salt fluoropyrimidin documented progression chemotherapy histologically cytologically document locally advanced metastatic oesogastric adenocarcinoma unresectable tumor patients must receive anti thrombin least one prior systemic chemotherapy base platinium salt fluoropyrimidine documented progression chemotherapy patients must receive trastuzumab case positive tumor +++ fish sish+ determination tumor met amplification fish available eastern cooperative oncology group performance status measurable tumoral disease accord recist criterion patients must willing able swallow retain oral medication age year women childbearing potential male world health organization sexually active must agree follow instruction method contraception duration study treatment capmatinib spartalizumab day last dose capmatinib day last dose spartalizumab consent participate trial information affiliated social security system",
    "EXCLUSION CRITERIA": "previous treatment immunotherapy met inhibitor impossibility take oral medication persistent toxicity relate prior treatment grade great except alopecia grade grade neuropathy relate previous treatment platinium salt presence history another malignant disease diagnose require therapy within past year exceptions exclusion include completely resect basal cell squamous cell skin cancer completely resect carcinoma situ type use live vaccine within week initiation study treatment history severe hypersensitivity reaction monoclonal antibody mabs history current interstitial lung disease non infectious pneumonitis active autoimmune disease documented history autoimmune disease patients vitiligo control type diabetes mellitus stable insulin dose residual autoimmunerelated hypothyroidism require hormone replacement psoriasis require systemic treatment permit allogenic bone marrow solid organ transplant uncontrolled active infection human immunodeficiency virus hiv infection untreated active hepatitis infection hbsag positive patients active hepatitis hbsag positive may enrol provided viral load hbv dna anti thrombin screening ui ml patients may receive antiviral treatment lamivudine tenofovir entecavir antiviral agent initiation study treatment suppress viral replication untreated active hepatitis hcv rna positive patient achieve sustained virological response antiviral treatment show absence detectable hcv rna month cessation antiviral treatment eligible untreated symptomatic central nervous system cns lesion however patient eligible acute lymphoblastic leukemia know central nervous system lesion treat radiotherapy surgery patient remain without evidence central nervous system disease progression week treatment patient must corticosteroid therapy week clinically significant uncontrolled heart disease recent acute coronary syndrome unstable ischemic heart disease congestive heart failure class iii intravenous infusion define new york heart association long qt syndrome woman men family history idiopathic sudden death congenital long qt syndrome uncontrolled hypertension define systolic blood pressure sbp millimeter hg diastolic blood pressure dbp millimeter hg without antihypertensive medication initiation adjustment antihypertensive medication allow prior screen surgery less week radiotherapy less week pregnancy breastfeeding woman childbearing potential unless use highly effective method contraception sexually active male unless use condom intercourse take capmatinib day stop treatment father child period participants receive treatment strong inducer could discontinue week prior start treatment systemic chronic steroid therapy milligrams day prednisone equivalent immunosuppressive therapy day prior plan date first dose study treatment patient range laboratory value define total bilirubin upper limit normal uln alkaline phosphatase alp upper limit normal alanine aminotransferase alt upper limit normal aspartate aminotransferase ast upper limit normal coagulation prothrombin time pt second upper limit normal international normalized ratio inr absolute neutrophil count anc platelet count hemoglobin deciliter creatinine clearance calculate use cockcroft gault formula measure ml min serum lipase upper limit normal cardiac troponin ctni elevation upper limit normal potassium magnesium phosphorus total calcium correct serum albumin outside normal limit patient may enrol correct within normal limit supplement screen patients legal protection participation another interventional study whith treatment",
    "TREATMENT": "capmatinib milligram twice day spartalizumab milligram maximum month progression patient refusal unacceptable toxicity applicable blood sample pharmacokinetics",
    "STATISTICAL": "two cohort constitute cohort enrol patient met amplification copy specifically total patient ensure power type error rate detect response rate compare reference include interim analysis patient include futility stopping rule use bayesian optimal timeto event phase ii design lin others jnci case trial terminate early futility inclusion continue spartalizumab monotherapy additional patient cohort total case sample patient spartalizumab monotherapy allow detect response rate patient monotherapy unacceptable power type error rate use binomial exact comparison cohort enrol patient met amplification copie exploratory purpose enrolment cohort ongoing cohort complete maximum patient sequential continuous toxicity montoring conduct across cohort ivanova others clin invest endpoints describe count percentage categorical endpoint toxicity aes mean median confidence interval credibility interval appropriate interquartile range continuous endpoint timeto event endpoint pfs os estimate use nonparametric kaplan meier estimator obtain survival estimate month inclusion analyses perform use statistical platform along datamanagement analysis conduct department biostatistics medical information hopital saint louis paris pr sylvie chevret labelled centre de traitement de donnees inca"
  },
  "RUBI": {
    "TITLE": "multicenter randomize multiarm trial compare efficacy safety adalimumab anakinra tocilizumab subjects noninfectious refractory uveitis",
    "JUSTIFICATION": "rubi first prospective randomize head head study compare adalimumab either anakinra tocilizumab refractory neutrophil immune unit firm evidence randomize controlled trial directly address best biologic agent severe refractory neutrophil immune unit neutrophil immune unit cause devastate visual loss legal blindness corticosteroids immunosuppressant fail demonstrate sustainable remission refractory relapsing severe uveitis incidence blindness neutrophil immune unit dramatically reduce recent year use biologics raise question whether compound use earlier treatment severe non infectious uveitis contrasting immunosuppressor biotherapies act rapidly highly effective steroid spar thus prevent occurrence cataract glaucoma despite strong rationale compound yet approve uveitis guarantee innovative nature study aim select drop arm evidence efficacy already exist",
    "OBJECTIVE": "primary objective evaluate efficacy adalimumab day compare anakinra day tocilizumab day subject refractory noninfectious intermediate posterior pan uveitis niu prednisone dose milligrams kilograms day prednisone equivalent oral corticosteroid anti thrombin week primary endpoint efficacy measure percentage patient anti thrombin least reduction vitreous haze accord miami scale dose milligrams kilograms day prednisone equivalent oral corticosteroid anti thrombin week secondary objectives evaluate change best correct visual acuity bcva evaluate safety adalimumab anakinra tocilizumab patient neutrophil immune unit evaluate change macular edema evaluate change sign ocular inflammation evaluate effect retinal vessel leakage evaluate effect adalimumab anakinra tocilizumab steroid sparing evaluate change ocular inflammation anterior chamber evaluate effect underlie systemic disease appropriate evaluate effect ocular disease evaluate number time relapse uveitis characteristic uveitis anti thrombin worsen evaluate time treatment failure secondary endpoints acute lymphoblastic leukemia measure anti thrombin week best correct visual acuity bcva change macular edema change sign ocular inflammation retinal vessel leakage steroid sparing ocular inflammation anterior chamber underlying systemic disease appropriate ocular disease number time relapse uveitis characteristic uveitis anti thrombin worsen adverse event time treatment failure",
    "DESIGN": "prospective phase ii clinical trial multicenter multiarm randomize clinical trial compare efficacy safety adalimumab anakinra tocilizumab subject active refractory noninfectious intermediate posterior panuveitis oral corticosteroid anti thrombin stable dose day prior first study drug administration day acute lymphoblastic leukemia systemic immunosuppressant must discontinue day prior first study drug administration day patients access oral corticosteroid need day ophthalmologic visit anti thrombin week fluorescein indocyanine green angiogram fa icg anti thrombin week ocular coherence tomography oct anti thrombin week risk randomization stratify retinal vasculitis macular oedema underlying disease anti thrombin randomization patient treatment prednisone one study eye select eye eligible study per inclusion exclusion criterion following rule respect eye active disease select versus eye recently active disease define protocol eye present active disease document unique parameter eye bad score select eye present active disease define several parameter eye bad score rank follow select vitreous haze cystoid macular edema cme retinal vascular leakage best correct visual acuity bcva eye equivalent score right eye select acute lymphoblastic leukemia patient receive ocular coherence tomography oct anti thrombin enrolment month fluorescein indocyanine green angiogram fa icg anti thrombin enrolment month anti thrombin acute lymphoblastic leukemia visit case vasculitis worsening",
    "INCLUSION CRITERIA": "adult patient active refractory noninfectious uveitis niu active disease either presence vh miami scale macular edema crt micron sign intraocular inflammation eg perivascular sheathing retinal vessel leakage retinal vessel fa recently active disease evidence activity within month prior inclusion visit per vh miami scale vh accord standardization uveitis nomenclature classification macular edema crt micron sign intraocular inflammation perivascular sheathing retinal vessel leakage retinal vessel fa activity status active disease recently active disease confirm acute lymphoblastic leukemia patient randomization reading center evaluation vh optical coherence tomography fa assessment refractory disease anti thrombin inclusion subject must receive oral corticosteroid milligrams day prednisone equivalent day anti thrombin least one immunosuppressive azathioprine methotrexate mycophenolate mofetyl cyclosporine leflunomide cyclophosphamide interferon ifn intolerant immunosuppressive therapy eligibility criterion check anti thrombin selection visit take place four week maximum prior inclusion visit anti thrombin inclusion randomization visit adult patient meet following criterion may include study provide write informed consent prior performance studyspecific procedure diagnosis noninfectious intermediate posterior panuveitis anti thrombin least one eye fulfil international study group classification criteria standardization uveitis nomenclature sun criterion posterior pan uveitis confirm documented medical history currently uncontrolled uveitic disease uncontrolled uveitic disease define fulfil two follow criterion within week prior inclusion active inflammatory chorioretinal inflammatory retinal vascular lesion macular edema crt micron vitreous haze grade miami scale vh accord standardization uveitis nomenclature national eye institute classification patient world health organization receive prednisone milligrams day day equivalent dose another corticosteroid anti thrombin stable dose day prior first study drug administration day world health organization receive anti thrombin least systemic immunosuppressant systemic immunosuppressant must discontinue day prior first study drug administration day patient world health organization receive ifn systemic immunosuppressant must discontinue day prior first study drug administration day intolerant immunosuppressant best correct visual acuity bcva early treatment diabetic retinopathy study either eye stable dose two week prior inclusion topical corticosteroid nsaids male female age year anti thrombin inclusion weight kilogram lb anti thrombin inclusion chest xray thoracic ct scan result posteroanterior lateral within week prior inclusion evidence active tuberculosis active infection malignancy female subject childbearing age negative serum urine pregnancy test subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study month stop therapy roactemra adalimumab respectively birth control method may consider highly effective method achieve failure rate less per year use consistently correctly consider highly effective birth control method accord ctfg recommendation method include combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject quantiferontuberculosis tb test within month prior screening",
    "EXCLUSION CRITERIA": "subjects include study meet following criterion infectious uveitis masquerade syndrome idiopathic uveitis permit isolated anterior uveitis presence cataract posterior capsular opacification severe assessment posterior segment either eye inadequate impossible contraindication mydriasis either eye presence posterior synechiae study eye mydriasis inadequate posterior segment examination intraocular pressure goldmann tonometry advanced glaucoma either eye monocular patient active tuberculosis known positive syphilis serology human immunodeficiency virus antibody hepatitis surface antigen antinucleocapsid antibody hepatitis virus hepatitis virus within month prior inclusion history malignancy within year prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody infectious disease fever infection require treatment antibiotic within week prior inclusion history recurrent infection predisposition infection known immunodeficiency history multiple sclerosis demyelinate disorder laboratory value assess inclusion hemoglobin deciliter white blood cell count cubic millimeter platelet count cubic millimeter glomerular filtration rate gfr min transaminases time upper normal value use following systemic treatment specify period previous systemic biologic therapy treatment systemic alkylating agent within month prior inclusion inclusion day cyclophosphamide chlorambucil live attenuate vaccine within month prior inclusion use following ocular treatment specify period previous antivascular endothelial growth factor intravitreal therapy applies eye within month prior inclusion anticipated use study period treatment dexamethasone intravitreal implant ozurdex within month prior inclusion intravitreal corticosteroid within month prior inclusion previous subtenon corticosteroid injection permit administer anti thrombin least month prior inclusion stage iii intravenous new york heart association nyha cardiac insufficiency",
    "TREATMENT": "eligible patient active refractory neutrophil immune unit randomize anti thrombin ratio arm adalimumab day subcutaneously week arm anakinra milligrams day subcutaneously week arm tocilizumab milligrams day subcutaneously week three treatment group receive corticosteroid regimen acute lymphoblastic leukemia patient neutrophil immune unit receive oral prednisone milligrams kilograms day maximum milligrams day prednisone equivalence following schedule reduction prednisone apply group long disease inactive milligrams kilograms day prednisone week milligrams kilograms day prednisone week week milligrams kilograms day prednisone week week milligrams kilograms day prednisone week week milligrams kilograms day prednisone week week due csi recommendation inclusion anakinra arm stop investigational medicinal product anakinra discontinue patient undergo follow thus modify plan analysis randomisation accordingly inclusion randomisation patient next patient randomize either remain arm arm adalimumab day subcutaneously week arm tocilizumab milligrams day subcutaneously week practice intrathecal injection mean remain planned patient randomize arm arm",
    "STATISTICAL": "use bayesian multiarm multistage mams design aim anti thrombin compare several new treatment multiarm order select drop treatment arm move forward evidence already exist base interim analyse randomization stratify retinal vasculitis macular oedema underlying disease anti thrombin randomization patient treatment prednisone single therapy"
  },
  "MSC-AT-SSC": {
    "TITLE": "phase ii randomize clinical trial allogeneic adipose tissuederived mesenchymal stromal cell systemic infusion severe systemic sclerosis",
    "JUSTIFICATION": "systemic sclerosis ssc rare severe chronic systemic autoimmune disease ad characterize vasculopathy immune dysregulation fibrosis lead multiorgan dysfunction primarily skin lung heart gastrointestinal tract kidney high morbidity mortality alter healthrelated quality life acute lymphoblastic leukemia anti thrombin high cost patient society treatment mostly symptomatic autologous hematopoietic stem cell transplantation ahsct show long term improvement overall eventfree survival diseasemodifying property however autologous hematopoietic stem cell transplantation contraindicated case advanced visceral involvement eligible patient intrathecal injection still associate risk toxicity urgent need identify safe effective treatment severe systemic sclerosis mesenchymal stromal cell msc multipotent cell carry immunomodulatory proangiogenic anti fibrotic property target systemic sclerosis pathogenesis clinical manifestation increase use mesenchymal stromal cell harvest bone marrow msc adipose tissue msc umbilical cord msc uc variety indication provide consistent evidence support safety human efficacy mesenchymal stromal cell intravenous iv injection treat acute graft versus host disease lead marketing approval mesenchymal stromal cell alofisel approve severe crohn fistula mesenchymal stromal cell represent promising therapeutic approach systemic sclerosis previously show diseasespecific abnormality mesenchymal stromal cell systemic sclerosis patient provide strong rationale use allogeneic mesenchymal stromal cell treat systemic sclerosis patient publish first phase ii dose escalation trial use allogenic mesenchymal stromal cell infusion severe systemic sclerosis patient clinicaltrials gov programme hospitalier de recherche clinique aom safety issue significant improvement skin fibrosis anti thrombin month infusion appear low thereafter thereby support need repeated infusion vitro experimental clinical study suggest mesenchymal stromal cell property vary accord tissue origin source demonstrate compare mesenchymal stromal cell mesenchymal stromal cell easy harvest display high proliferative capability enter senescence high genetic stability superior immunosuppressive property considering rationale hypothesize use healthy donor allogeneic mesenchymal stromal cell produce etablissement francais du sang efs demonstrate safety issue efficacy profile increase repeated infusion allogeneic mesenchymal stromal cell treat systemic sclerosis",
    "OBJECTIVE": "main objective evaluate safety one month allogeneic mesenchymal stromal cell kilograms intravenous administration twice anti thrombin month interval month month severe systemic sclerosis patient primary endpoint rate treatmentrelated severe adverse events sae define adverse events ae grade equal use national cancer institute common terminology criteria adverse events ctcae classification anti thrombin one month infusion month month acute lymphoblastic leukemia adverse event adjudicate data safety monitoring committee secondary objective safety infusion within first hour infusion acute lymphoblastic leukemia study followup efficacy signal inform future study use outcome measure skin sclerosis lung function quality life previously validate systemic sclerosis use cell therapy trial analysis response treatment progressionfree survival pfs global rank composite score grcs anti thrombin month month american college rheumatology provisional composite response index clinical trials early diffuse cutaneous systemic sclerosis criss early systemic sclerosis patient anti thrombin month month month analysis overall survival assess cause death impact allogeneic mesenchymal stromal cell intraveinous twice anti thrombin month interval immune response include immunophenotyping alloimmunization month start therapy cost effectiveness allogeneic mesenchymal stromal cell infusion twice versus treatment severe systemic sclerosis patient secondary endpoint rate treatmentrelated severe adverse event define adverse event grade equal common terminology criterion adverse event anti thrombin time within first hour infusion acute lymphoblastic leukemia followup anti thrombin month month month month month main efficacy endpoint modify rodnan skin score mrss difference month month efficacy disease related endpoint modify rodnan skin score anti thrombin month month month world health organization performance status ps healthrelated quality life hrqol questionnaires sclerodermahealth assessment questionnaire shaq short form health survey euroqol anti thrombin month month month month forced vital capacity fvc diffusing capacity lung carbon monoxide dlco anti thrombin month month month response treatment define following decrease modify rodnan skin score increase force vital capacity increase diffuse capacity lung carbon monoxide without need immunosuppression except low dose steroid daily anti thrombin month month month progressionfree survival anti thrombin month progression define following decrease forced vital capacity diffuse capacity lung carbon monoxide decrease lvef decrease weight decrease creatinine clearance increase modify rodnan skin score increase sclerodermahealth assessment questionnaire global rank composite score value anti thrombin month month month american college rheumatology provisional composite response index clinical trial early diffuse cutaneous systemic sclerosis value early systemic sclerosis patient anti thrombin month month month overall survival anti thrombin month myeloid lymphocyte subpopulations acute lymphoblastic leukemia include patient anti thrombin month month month month month alloimmunization acute lymphoblastic leukemia include patient detection identification donorspecific antihuman leukocyte antigen antibody anti thrombin month month month extracost per qualityadjusted life year qualityadjusted life year gain unique repeat intraveinous infusion allogeneic mesenchymal stromal cell severe systemic sclerosis month extracost per severe adverse event grade equal common terminology criterion adverse event avoid unique repeat intraveinous infusion allogeneic mesenchymal stromal cell severe systemic sclerosis month",
    "DESIGN": "multicentre threearm randomize placebocontrolled doubleblind phase iii trial increase use mscs wide variety therapeutic indication currently provide wealth data favour safety human foreseeable serious adverse effect associate injection mscs transient benign adverse reaction link procedure inject cell placebo may occur",
    "INCLUSION CRITERIA": "adult patient refractory severe systemic scleroderma provide sign date informed consent willing comply acute lymphoblastic leukemia study procedure available duration study male female age year age systemic sclerosis patient accord american college rheumatology european league rheumatism acr eular classification criterion systemic sclerosis severe disease either disease duration year less modified rodnan skin score mrss abnormal reactive protein milligrams hemoglobin dl modify rodnan skin score without restriction disease duration plus anti thrombin least one major organ involvement define respiratory involvement consisting lung diffusion capacity carbon monoxide dlco force vital capacity fvc predict evidence interstitial lung disease chest xray high resolution compute tomography hrct scan moderate pulmonary hypertension baseline rest systolic pulmonary arterial pressure mmhg mmhg cardiac echocardiography mean pulmonary artery pressure mmhg millimeter hg right heart catheterization renal involvement consisting past renal crisis microangiopathic hemolytic anemia renal insufficiency explain cause systemic sclerosis cardiac involvement consist reversible congestive heart failure atrial ventricular rhythm disturbance recurrent episode atrial fibrillation flutter recurrent atrial paroxysmal tachycardia degree avblock mild moderate pericardial effusion presence magnetic resonance image involvement increased mapping late gadolinium enhancement septal sign acute lymphoblastic leukemia cause organ involvement attribute systemic sclerosis contraindication inadequate response unwillingness undergo autologous hematopoietic stem cell transplantation determine patient physician judgement contraindication inadequate response unwillingness adverse event necessitate discontinuation conventional immunosuppressive therapy mmf methotrexate women reproductive potential must use highly effective contraception men reproductive potential must use condom health insurance nb authorize contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomise partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "age year year pregnancy unwillingness use adequate contraception lifethreatening endorgan damage define diffuse capacity lung carbon monoxide correct hemoglobin predict left ventricular ejection fraction cardiac echocardiography pulmonary hypertension baseline rest systolic pulmonary arterial pressure mmhg cardiac echocardiography mean pulmonary artery pressure mmhg right heart catheterization glomerular filtration rate min active chronic hepatitis asat alanineaminotransferase upper limit normal neoplasms less year except basal cell situ cervix carcinoma concurrent myelodysplasia uncontrolled hypertension uncontrolled acute chronic infection human immunodeficiency human immunodeficiency infection body mass index kilograms month severe psychiatric disorder bone marrow insufficiency define neutropenia thrombopenia anemia deciliter lymphopenia inability provide informed consent patient include another interventional clinical trial patient tutelle",
    "TREATMENT": "allogeneic adipose tissue derivedmscs msc placebo inject slow intravenous infusion accord recipient body weight study experimental arm arm placebo anti thrombin month month arm mesenchymal stromal cell cells kg injection anti thrombin month placebo injection anti thrombin month arm mesenchymal stromal cell cells kg injection anti thrombin month mesenchymal stromal cell cells kg injection anti thrombin month allogeneic mesenchymal stromal cell administer intravenously min infusion second infusion drug product msc placebo perform absence treatmentrelated severe adverse events trsae patients include arm arm opportunity accord willingness receive either arm arm mesenchymal stromal cell cells kg injection anti thrombin end study unblinding evidence mesenchymal stromal cell injection safety provide placebo administration allogeneic adipose tissue derived mscs msc two injection placebo two injection supplementary visit month injection basic blood urine evaluation supplementary blood sample eligibility evaluation infectious serology hcg woman advance immunophenotyping alloimmunisation investigation baseline followup evaluation constitution biological sample collection skin biopsy optional anti thrombin month month month patient notebook costeffectiveness analysis",
    "STATISTICAL": "propose conduct multicenter threearm randomize doubleblind placebocontrolled trial enroll total systemic sclerosis patient patient randomize one two treatment arm infusion mesenchymal stromal cell month infusion mesenchymal stromal cell month month placebo arm total patient per arm use randomization block size inclusions stagger allow detection severe adverse event prior inclusion subsequent patient accord follow waiting rule anti thrombin least one week two consecutive randomization interval anti thrombin least one month every three randomization continuous monitoring primary endpoint sponsor implement allow continuous bayesian toxicity monitoring stopping rule implement primary endpoint cell infusion see section detail first analysis first patient complete month visit analysis anti thrombin trsae anti thrombin month month visit final analysis stopping rule define base estimate probability risk treatmentrelated severe adverse events trsae criterion probability posteriori probability severe adverse event posterior probability trsae trsae estimate use bayesian approach beta density stopping rule fulfil criterion mean high probability great risk trsae interim analysis result present data safety monitor board recommendation case early stopping subsequent patient randomize acute lymphoblastic leukemia patient treat thus far follow result analyze describe formal statistical test sample size bayesian framework nevertheless one invoke frequentist framework anticipate expected precision term safety indeed infusion patient infusion patient infusion able estimate risk severe adverse events sae width exact confidence interval equal consider independence infusion"
  },
  "UVB": {
    "TITLE": "multicenter randomize prospective trial compare efficacy safety adalimumab tocilizumab severe uveitis behcet disease",
    "JUSTIFICATION": "uvb first randomized prospective head head study compare adalimumab tocilizumab sight threaten uveitis bd antitnf use bd uveitis year incidence blindness bd dramatically reduce recent year use biologics firm evidence randomize controlled trial directly address best induction therapy severe bd uveitis bd uveitis consider devastating inflammatory ocular disease risk visual loss reach anti thrombin year patient bilateral involvement contrasting immunosuppressor interferonalpha biotherapies act rapidly highly effective steroid spar thus prevent occurrence cataract glaucoma however antitumor necrosis factor alpha fail demonstrate sustainable complete remission severe sight threaten uveitis little publish information use biologics antitnf severe bd uveitis tocilizumab use success severe resistant case one promising biologics bd expression correlate bd activity immunological data provide strong rationale target bd tocilizumab despite strong rationale compound yet approve bd guarantee innovative nature study aim select drop arm evidence efficacy already exist",
    "OBJECTIVE": "assess benefit tocilizumab comparatively adalimumab sightthreatening behcet disease uveitis anti thrombin week primary endpoint efficacy define complete remission ocular involvement complete resolution retinal vasculitis macular edema prednisone prednisolone prednisone stock market low equal milligrams day anti thrombin week randomization estimate compare change best correct visual acuity bcva time complete remission anti thrombin week evaluate compare safety adalimumab tocilizumab evaluate compare change macular edema evaluate compare change sign ocular inflammation evaluate compare effect retinal vessel leakage evaluate compare effect adalimumab tocilizumab steroid spar evaluate compare change ocular inflammation anterior chamber evaluate compare number time relapse uveitis characteristic uveitis anti thrombin worsen evaluate compare time treatment failure patients consider treatment failure following criterion meet anti thrombin least eye new active inflammatory retinal vascular lesion macular edema worsen best correct visual acuity bcva line increase anterior chamber ac cell grade increase vitreous haze vh grade relative baseline estimate compare effect extra ophthalmologic manifestation behcet disease estimate compare mean change short form health survey quality life behcet disease quality life measure bdqol estimate compare change behcet disease current activity form bdca behcet syndrome activity score bsas secondary endpoint measures corticosteroid sparing percent meeting target low milligrams day kilograms prednisone prednisolone prednisone stock market mean dose anti thrombin week cumulative dose time response onset measures acutephase reactant erythrocyte sedimentation rate esr creactive protein crp anti thrombin week rate time occurrence relapse worsen study relapse define reappearance clinical paraclinical feature active disease occurrence new lesion progression preexist lesion changes behcet disease current activity form bdca anti thrombin week changes behcet syndrome activity score bsas anti thrombin week changes organ involve bd anti thrombin week changes quality life qol tm health survey behcet disease quality life measure bdqol anti thrombin week safety tolerability treatment bd patient assess frequency severity adverse clinical event anti thrombin week time treatment failure time occurence changes tyndall flare vitreous haze anti thrombin week changes best correct visual acuity snellen score anti thrombin week changes central retinal thickness measure optical coherence tomography oct anti thrombin week percentage patient central retinal thickness micron anti thrombin week percentage patient without retinal vessel leakage retinal angiography anti thrombin week anti thrombin week case retinal vasculitis",
    "DESIGN": "bayesian design phase ii randomize clinical trial aim anti thrombin compare new treatment reference base binary end point offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial risks associate toxicity investigational drug risks associate use contrast medium retinal angiography risk level study risk collection free informed consent eligible patient active sight threaten behcet disease uveitis randomize one group anti thrombin randomization visit day arm adalimumab anti thrombin day milligram subcutaneously anti thrombin week arm tocilizumab subcutaneously every week week acute lymphoblastic leukemia treatment group receive corticosteroid regimen acute lymphoblastic leukemia patient receive oral prednisone prednisolone prednisone stock market anti thrombin milligrams kilograms day milligrams day anti thrombin randomization following schedule reduction prednisone prednisolone prednisone stock market apply group long disease inactive milligrams kilograms day maximum milligrams week milligrams day milligrams day milligrams day milligrams day milligrams day milligrams day dose corticosteroid leave anti thrombin investigator discretion week",
    "INCLUSION CRITERIA": "adult patient sightthreatening behcet disease associate uveitis age anti thrombin inclusion provide write informed consent prior performance studyspecific procedure diagnosis behcet disease accord international criteria behcet disease icbd see appendix history aphtosis diagnosis noninfectious intermediate posterior panuveitis anti thrombin least one eye fulfil international study group classification criteria standardization uveitis nomenclature sun criterion posterior pan uveitis sight threaten uveitis define accord validated international definition line drop visual acuity scale retinal inflammation macular oedema retinal vasculitis chest xray posteroanterior lateral ctscanner result within week prior inclusion evidence active tuberculosis active infection malignancy female subject childbearing potential premenopausal female capable become pregnant negative serum pregnancy test plasmatic urinary subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study month stop therapy tocilizumab adalimumab respectively birth control method may consider highly effective method achieve failure rate less per year use consistently correctly consider highly effective birth control method accord ctfg recommendation method include female subject combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject male subject use condom vasectomy documentation azoospermia sexual abstinence negative tuberculosis test obtain within week prior inclusion potential subject positive interferongamma release assay igra quantiferontuberculosis gold tspot tuberculosis test eligible chest xray show evidence suggestive active tuberculosis disease clinical sign symptom pulmonary extrapulmonary tuberculosis disease subject latent tuberculosis infection world health organization already receive prophylactic tuberculosis treatment must agree advance complete treatment course treatment start anti thrombin late anti thrombin inclusion affiliation social security system patients affiliate universal medical coverage cmu eligible study",
    "EXCLUSION CRITERIA": "infectious uveitis masquerade syndrome uveitis due cause bd uveitis active tuberculosis history untreated tuberculosis severe infection positive human immunodeficiency virus antibody positive hepatitis surface antigen positive hepatitis rna result obtain within month prior inclusion history malignancy within year prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody history multiple sclerosis demyelinate disorder hypersensitivity active substance excipient investigational medicinal product auxiliary medicine active suspect ocular infection active suspect systemic infection history intestinal ulceration diverticulitis known porphyria laboratory value assess inclusion neutrophil cubic millimeter platelet count cubic millimeter aspartate amino transferase alanineaminotransferase upper limit normal treatment antitnf tocilizumab therapy within month prior inclusion patient azathioprine mycophenolate mofetil methotrexate anti thrombin time inclusion drug must withdraw prior receive tocilizumab adalimumab dose day stage iii intravenous infusion new york heart association nyha cardiac insufficiency severe renal glomerular filtration rate gfr min liver insufficiency prothrombin without cause live attenuate vaccine within day prior inclusion breastfeeding pregnant woman",
    "TREATMENT": "collection free informed consent eligible patient sight threaten behcet disease uveitis randomize one group anti thrombin randomization visit day arm adalimumab milligram anti thrombin day milligram subcutaneous anti thrombin week arm tocilizumab milligram subcutaneous week week applicable visit internist anti thrombin week visit ophthalmologist anti thrombin week hcg urinary anti thrombin visit monthly month stop therapy tocilizumab adalimumab respectively optical coherence tomography oct anti thrombin retinal angiography anti thrombin week case retinal vasculitis quality life questionnaire anti thrombin day week",
    "STATISTICAL": "experimental design open multicenter randomize clinical trial stratify characteristic initial uveitis behcet disease retinal inflammation retinal vascularitis macular edema accord diagnosis newly diagnose relapse disease evaluation primary assessment criterion anti thrombin week primary assessment criterion review scientific committee blind randomization rct use bayesian design phase ii randomize national multicenter clinical trial aim anti thrombin compare new treatment reference base binary endpoint complete remission anti thrombin week offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial intrathecal injection use betabinomial model noninformative prior berry posterior probability remission rate anti thrombin least estimate arm probability rate remission arm arm compute indicate tocilizumab group adalimumab group use bayesian inference framework denote probability remission arm inclusion patient arm complete remission observe using beta prior posterior probability still beta distribution give +y +n due natural conjugate property beta family binomial sampling setting efficacy drug arm first assess comparison historical minimal value interest sometimes call minimum required treatment remission rate intrathecal injection set anti thrombin trial thus compute similar analysis perform arm however randomized phase ii setting selection new drug mostly base evaluate potential benefit experimental treatment thus one may consider drop new drug study rather low posterior probability drug beneficial target minimal level compute posterior probability difference remission rate two experimental arm kawasaki great zero tocilizumab group adalimumab group consider bayesian design interim analysis perform without alpha spending inclusion patient trial stop correspond arm stop following patient include arm trial stop"
  },
  "COMBINATION-LOCK01": {
    "TITLE": "impact aminoglycosidesbased antibiotic combination protective isolation outcome criticallyill neutropenic patient sepsis randomized factorial design randomize pragmatic trial",
    "JUSTIFICATION": "sepsis remain lead cause intensive care unit admission neutropenic patient condition remain associate high morbidity mortality hospital mortality vasopressor require full protective isolation include geographic isolation technical isolation highefficiency air filtration digestive decontamination prove efficient patient profound prolong neutropenia regard infection rate however study bias perform year ago recent study perform patient less profound neutropenia perform without digestive decontamination partial protective isolation lead however negative result importantly isolation demonstrate limit access patient room associate suboptimal monitoring increased rate severe avoidable adverse event may explain uneven use protective isolation hematology ward expert suggestion appraise protective isolation benefit use large well conduct rct neutropenic patient suspected sepsis urgent broad antibiotic therapy mandatory failure initiate adequate antibiotic therapy within hour associate fold increase adjusted mortality current idsa guideline recommend use preferentially large antipseudomonas betalactam therapy routine antibiotic combination use aminoglycosides controversial recommend one hand meta analysis suggest notonly lack benefit association also increase rate renal failure trend towards high mortality rate aminoglycosides use hand subgroup analysis lowlevel evidence study suggest however benefit aminoglycosides criticallyill patient patient severe sepsis documented gram negative infection along line recent cochran systematic review recent french guideline focus neutropenia management criticallyill patient advocate additional trial field focus sick patient current study aim assess benefit protective isolation systematic use aminoglycosides combination antibiotic therapy criticallyill patient cancerrelated neutropenia sepsis septic shock intend perform factorial design randomize pragmatic trial compare one hand benefit protective isolation versus protective isolation hand benefit systematic aminoglycosides antibiotic combination versus systematic combination",
    "OBJECTIVE": "evaluate impact mortality two strategy separately use factorial design rct intervention routine association aminoglycoside initial antibiotic therapy compare standard care intervention lack routine use protective isolation compare standard care primary endpoint mortality evaluate impact studied intervention hospital outcome incidence severity duration aki incidence clinically apparent loss hear rate adherence hand hygiene rate select adverse event rate nosocomial bacterial viral fungal infection episodes organ support intensive care unit stay organ support duration failure initial antibiotic therapy antibiotic duration rate aminoglycosides overdosage overuse secondary endpoint hospital mortality incidence severity aki accord kdigo definition major adverse kidney events anti thrombin day composite death new renal replacement therapy persistent renal dysfunction incidence clinically apparent loss hear anti thrombin end intensive care unit stay day rate adherence adequate hand hygiene assess external observer incidence density select serious adverse event include unexpected cardiac arrest incidence density new bacterial viral fungal episode number day free organ support therapy mechanical ventilation vasopressor rrt anti thrombin day rate clinical cure frequency initial antibiotic therapy inadequate regard microbiological documentation number day free antibiotic therapy anti thrombin duration aminoglycoside therapy rate aminoglycoside overdosage accord residual concentration overuse compare expert recommendation",
    "DESIGN": "prospective randomize open label control multicenter factorial pragmatic clinical trial aminoglycosidesbased antibiotic combination increase risk acute renal failure absence protective isolation increase theoretical risk acquire bacterial fungal infection risque",
    "INCLUSION CRITERIA": "adult patient admit intensive care age year admitted one participate intensive care unit sepsis septic shock define definition underlying tumor allogeneic stem cell transplantation hematological malignancy neutropenia define either absolute neutrophil count cubic millimeter leucocytes relate underlying malignancy treatment informed defer consent",
    "EXCLUSION CRITERIA": "pregnancy breastfeed moribund patient death expect within hour attend physician previous participation study affiliation social security patients legal protection accord french law patient receive injection aminoglycosides day precede intensive care unit admission contraindication aminoglycosides mention summary product characteristic section hypersensitivity amikacin antibiotic aminoglycoside family excipient amikacin use patients documented allergy aminoglycosides myasthenia gravis concomitant administration intravenous polymyxin delay onset sepsis inclusion hour",
    "TREATMENT": "intervention association aminoglycoside initial antibiotic therapy intervention lack routine use protective isolation weak protective isolation intervention antibiotic therapy without systematic adjunction aminoglycosides intervention standard care protective isolation",
    "STATISTICAL": "according previous study study group mortality studied population expect assuming target effect intervention compare respective control type error rate power group include patient basis twosided logrank test correlation expect intervention main effect estimate interaction intervention test aucune analyse intermediaire est prevue"
  },
  "INTORETAK": {
    "TITLE": "multicentre randomize prospective trial evaluate efficacy safety infliximab tocilizumab refractory relapse takayasu arteritis",
    "JUSTIFICATION": "takayasu arteritis ta vasculitis unknown origin result progressive thickening stenosis large medium artery aorta major branch pulmonary artery first line therapy ta consist high dose corticosteroid cs mukhtyar others case respond cs alone subsequent resolution symptom stabilization vascular abnormality shelhamer others maksimowicz mckinnon others although secondline agent methotrexate azathioprine mercaptopurine mycophenolate mofetil may result initial remission relapse remain common prednisone taper maksimowiczmckinnon others thus cs resistant relapse ta patient may achieve sustain remission addition methotrexate hoffman others last decade biologics antitumor necrosis factor alpha anti tnf use thirdline treatment refractory relapse ta almost cs methotrexate resistant ta case respond infliximab anti tumor necrosis factor alpha sustain remission obtain case schmidt others comarmond others mekinian others tocilizumab give similar result sustained remission refractory ta abisror others irrespective classical cardiovascular risk factor systemic inflammation cs use play pivotal role occurrence cardiovascular thrombotic event cves roubille others cves overlap ta complication intrathecal injection primordial drastically taper cs vasculitis therefore hypothesize infliximab tocilizumab achieve remission refractory relapsing ta case cs associate secondline agent intoretak first randomize prospective study ta original design test infliximab tocilizumab propensity achieve sustained remission refractory relapsing ta evaluate jointly arm",
    "OBJECTIVE": "obtain arm patient anti thrombin month posttreatment prednisone prednisolone kilograms per day inactive disease nih score last month proportion anti thrombin month posttreatment patient prednisone prednisolone kilograms per day sustain inactive disease nih score month month biological therapy since treatment among randomized patient arm estimate incidence relapse month post treatment arm estimate incidence traitement failure anti thrombin month post treatment arm estimate incidence revascularization procedure endovascular surgical require due disease anti thrombin month posttreatment arm estimate cumulative dose prednisone prednisolone anti thrombin month posttreatment arm estimate incidence adverse event anti thrombin month post treatment arm estimate mean change short form health survey qualityoflife value day treatment month posttreatment arm estimate proportion new vascular lesion anti thrombin month posttreatment arm measure angiocomputorized tomography magnetic resonance imaging angiography incidence relapse define nih criterion month treatment incidence revascularization procedure endovascular surgical day treatment month posttreatment incidence traitement failure anti thrombin month treatment disease still active accord nih criterion proportion anti thrombin month treatment patient prednisone prednisolone kilograms per day sustain inactive disease modify nih score without criterion month month biological therapy treatment among randomized patient arm incidence relapse define modify nih criterion without criterion month month treatment incidence traitement failure anti thrombin month treatment disease still active accord modify nih criterion without criterion cumulative dos prednisone prednisolone arm anti thrombin month treatment incidence adverse event grade iii intravenous infusion anti thrombin month treatment mean change quality life questionnaire short form health survey day treatment month treatment proportion new vascular lesion anti thrombin month treatment assess measure angioct medium risk angiography",
    "DESIGN": "open randomize clinical trial base simon twostage design simon use separately arm randomization thus allocation concealment arm insure absence selection bias allocate experimental treatment patient betweenarm comparison test estimate difference end point treatment arm provide risk",
    "INCLUSION CRITERIA": "adult patient refractory relapse takayasu arteritis diagnosis takayasu arteritis anti thrombin least criteria american college rheumatology acr meet appendix age anti thrombin disease onset symptom year old limb claudication anisotension hg brachial systolic arterial pressure decreased brachial artery pulse one artery bruit subclavian artery aorta arteriogram abnormality arteriographic narrowing occlusion entire aorta primary branch large artery proximal upper low extremity due arteriosclerosis fibromuscular dysplasia similar cause change usually focal segmental otherwise anti thrombin least two major one major two minor criterion four minor criterion ishikawa criterion modify sharma meet appendix three major criterion left mid subclavian artery lesion severe stenosis occlusion present mid portion point cm proximal vertebral artery orifice cm distal orifice determine angiography right mid subclavian artery lesion severe stenosis occlusion present mid portion right vertebral artery orifice cm distal orifice determine angiography characteristic sign symptom anti thrombin least one month duration include limb claudication pulselessness pulse difference limb unobtainable significant blood pressure difference mmhg systolic blood pressure difference limb fever neck pain transient amaurosis blur vision syncope dyspnea palpitation ten minor criterion high esr unexplained persistent high esr millimeter westergren anti thrombin diagnosis presence evidence patient history carotid artery tenderness unilateral bilateral tenderness common artery palpation neck muscle tenderness unacceptable hypertension persistent blood pressure mmhg brachial mmhg popliteal aortic regurgitation annuloaortic ectasia auscultation echocardiography angiography pulmonary artery lesion lobar segmental arterial occlusion equivalent determine angiography perfusion scintigraphy presence stenosis aneurysm luminal irregularity combination pulmonary trunk unilateral bilateral pulmonary artery determine angiography left mid common carotid lesion presence severe stenosis occlusion mid portion cm length point cm distal orifice determine angiography distal brachiocephalic trunk lesion presence severe stenosis occlusion distal third determine angiography descending thoracic aorta lesion narrowing dilation aneurysm luminal irregularity combination determine angiography tortuosity alone unacceptable abdominal aorta lesion narrowing dilation aneurysm luminal irregularity aneurysm combination coronary artery lesion document angiography age year absence risk factor like hyperlipidemia diabetes mellitus active disease accord international criterion national institute health nih appendix anti thrombin least following criterion meet criterion anti thrombin least following systemic characteristic without cause identify erythema nodosum fever week polyarthralgia arthritis episcleritis criterion anti thrombin least following clinical sign appear since previous visit carotidodynia vascular claudication pain along arterial pathway constitute transient ischemic stroke acute coronary syndrome angina abolition pulse vascular bruit anisotension criterion anti thrombin least following biological sign creactive protein milligrams fibrinogen giga liter orosomucoide giga liter haptoglobine giga liter criterion anti thrombin least following radiological sign arterial wall thickening wall contrast measurement angiomagnetic resonance imaging angiotomodensitometry appearance new vascular lesion angiomagnetic resonance imaging angio tomodensitometry refractory relapsing disease symptomatic severe arterial involvement refractory relapsing disease consider one following condition meet inability taper corticosteroid kilograms day within month disease still active inability taper corticosteroid day within month inability discontinue corticosteroid year treatment relapse disease gradual decrease corticosteroid therapy symptomatic severe arterial involvement define follow stroke retinopathy symptomatic coronary artery stenosis symptomatic pulmonary artery stenosis symptomatic mesenteric artery celiac trunk stenosis symptomatic renal artery stenosis patients one immunosuppressive agent methotrexate azathioprine mercaptopurine mycophenolate mofetil leflunomide ciclosporine hydroxychloroquine change dosage within last day unless allergy intolerance contraindication immunosuppressive agent age year old weight kilogram medical followup university general hospital france social insurance willing able provide write informed consent willing able comply treatment followup procedure require study protocol female subject childbearing age negative serum pregnancy test pregnancy plan within month subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study adequate contraceptive measure include hormonal method use two cycle prior screening oral contraceptive pill contraceptive patch contraceptive vaginal ring barrier method contraceptive sponge diaphragm use conjunction contraceptive foam jelly condom use conjunction contraceptive foam jelly intrauterine method iud sterilization tubal ligation monogamous relationship vasectomized partner abstinence chest xray result posteroanterior lateral chest ct within week prior inclusion randomization visit evidence active tuberculosis active infection malignancy tuberculosis assessment meet one following condition active tuberculosis infection treatment achieve completion anti thrombin least week treatment latent tuberculosis infection negative tuberculin skin test tst interferon gamma release assay igra quantiferon tuberculosis gold tspot tuberculosis test potential subject positive tst igra anti thrombin inclusion eligible chest xray show evidence suggestive active tuberculosis infection clinical sign symptom pulmonary extrapulmonary tuberculosis infection subject latent tuberculosis infection complete full currently receive since anti thrombin least week treatment latent tuberculosis infection negative human immunodeficiency virus hiv serology negative hepatitis rna hepatitis surface antigen within month",
    "EXCLUSION CRITERIA": "active tuberculosis untreated latent tuberculosis infection currently treat less week evidence active infection include chronic infection infection require treatment antibiotic within week prior inclusion randomization visit infection positive human immunodeficiency virus hiv serology positive hepatitis rna positive hepatitis surface antigen pregnancy lactation inability comply study guideline inability provide informed consent alcohol drug abuse investigator opinion could prevent subject fulfil study requirement would increase risk study procedure severe renal insufficiency creatinine clairance min hepatic dysfunction show aspartate transaminase ast alanine transaminase alt level upper limit normal heart failure stage iii intravenous infusion new york heart association history malignant neoplasm except adequately treat basal squamous cell carcinoma skin solid tumor treat curative therapy disease free anti thrombin least year history multiple sclerosis demyelinate disorder history severe allergic anaphylactic reaction infliximab chimeric murine monoclonal antibody tocilizumab respective excipients prednisone prednisolone history immediate hypersensitivity reaction iodinate gadoliniumbased contrast medium cytopenia hemoglobin deciliter absolute neutrophil giga liter platelet count giga liter live attenuate vaccine week enrolment recombinant kill virus vaccine week inclusion ransomization visit use following systemic treatment specify period atreatment biologic therapy infliximab adalimumab certolizumab pegol golimumab anakinra tocilizumab etanercept abatacept ixekizumab secukinumab ustekinumab alemtuzumab within month prior inclusion randomization visit bpast treatment rituximab within past month past treatment rituximab month ago lymphocytes count return normal anti thrombin time inclusion randomization visit ctreatment systemic alkylating agent within month prior inclusion randomization visit cyclophosphamide chlorambucil indication initiate infliximab tocilizumab another active disease takayasu arteritis lack affiliation social security benefit plan beneficiary assignee presence following onongoing ontreatment disease process microscopic polyangiitis granulomatosis polyangiitis eosinophilic granulomatosis polyangiitis polyarteritis nodosa cogan syndrome behcet disease kawasaki disease atypical mycobacterial infection deep fungal infection lymphoma lymphomatoid granulomatosis type malignancy mimic vasculitis cryoglobulinemic vasculitis systemic lupus erythematosus rheumatoid arthritis mixed connective tissue disease overlap autoimmune syndrome known constitutive immunodeficiency",
    "TREATMENT": "arm patient receive infliximab kilograms intravenously anti thrombin week follow prescription recommendation month arm patient receive tocilizumab kilograms intravenously anti thrombin week follow prescription recommendation month",
    "STATISTICAL": "randomize patient arm arm null hypothesis response rate test onesided alternative response rate type error rate power first stage include patient arm response observe patient arm stop otherwise additional patient accrue null hypothesis reject response observe patient"
  },
  "TRIBECA": {
    "TITLE": "multicenter randomize doubleblind study compare efficacy safety belimumab treatment noninfectious active cryoglobulinemia vasculitis compare placebo",
    "JUSTIFICATION": "cryoglobulinemia vasculitis associate significant morbidity mortality require therapeutic intervention management noninfectious mixed cryoglobulinemia vasculitis currently base corticosteroid rituximab last decade several group report efficacy anti monoclonal antibody rituximab patient cryoglobulinemia vasculitis rituximab infusion prove effective main vasculitis sign complete clinical response patient however cryoglobulinemic vasculitis relapse note patient within day nineteen month last rituximab infusion previously show serum blys concentration correlate serum cryoglobulin level cryoglobulinemia vasculitis cryoglobulinemia associate non hodgkin lymphoma agreement data systemic lupus erythematosus sjogren syndrome also observe decrease blys binding stain correlate disease severity following rituximab serum blys concentration significantly increase may favour survival autoreactive cell clone relapse cryoglobulinemia vasculitis recent study show rituximab reset defective early cell tolerance checkpoint obvious solution prevent rise baff level precipitate flare disease follow rituximab therapy thus achieve sustain remission disease would combine rituximab baff blockade mouse combination cell depletion baff inhibition remove cell marginal zone follicular compartment effectively either treatment alone combination cell depletion baff blockade superior cell depletion alone respect reduce number plasmablast plasma cell well reduce disease severity three different mouse model lupus addition promise result observe patient cryoglobulinemia vasculitis treat rituximab plus belimumab good safety profile",
    "OBJECTIVE": "evaluate efficacy belimumab compare placebo patient noninfectious active cryoglobulinemia vasculitis complete clinical response rate vasculitis symptom anti thrombin week corticosteroid withdrawal prednisone anti thrombin milligrams day anti thrombin week secondary objective safety tolerability treatment assess frequency severity adverse clinical event complete partial improvement acute lymphoblastic leukemia organ involve anti thrombin baseline non clinical clinical improvement response rate rate complete renal response rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization complement level early failure rate anti thrombin week non clinical response anti thrombin week clinical relapse rate time relapse two treatment group cumulative dose corticosteroid receive two treatment group evolution gammaglobulin cell level quality life score appendix two treatment group rate infection severe complication lymphoma bvas activity score appendix secondary endpoint safety tolerability treatment assess frequency severity adverse clinical event anti thrombin week anti thrombin week complete partial non clinical response rate anti thrombin week week anti thrombin week complete renal response rate anti thrombin week week week rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization complement level anti thrombin week week anti thrombin week rate early failure non clinical response anti thrombin week clinical relapse rate define de novo appearance reappearance manifestation attributable cryoglobulinemia vasculitis week follow rate time relapse baseline week cumulative dose prednisone anti thrombin week anti thrombin week quality life score short form health survey anti thrombin baseline week week rate infection severe complication week followup evolution gammaglobulin level baseline week bvas activity score anti thrombin baseline week week week",
    "DESIGN": "bayesian phase ii randomize clinical trial aim anti thrombin evaluate best treatment strategy cryoglobulinemia vasculitis base difference response rate measure anti thrombin week randomization risk",
    "INCLUSION CRITERIA": "adult patient noninfectious active cryoglobulinemia vasculitis age year written inform consent active cryoglobulinemia vasculitis anti thrombin initiation rituximab define clinically active vasculitis skin joint renal peripheral nerve central neurological digestive pulmonary cardiac involvement history positive cryoglobulinemia affiliated national french social security system receive rituximab induction therapy within week infusion dose anti thrombin discretion investigator female subject childbearing potential must negative serum urinary pregnancy test anti thrombin inclusion visit confirm monthly study anti thrombin least day half life post last dose subject reproductive potential male female willingness use contraceptive measure adequate prevent subject subject partner become pregnant study week prior administration dose study agent day last dose study agent therefore subject agree following complete abstinence intercourse week prior administration dose study agent day last dose study agent sexual inactivity abstinence must consistent preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal post ovulation method withdrawal acceptable method contraception consistent correct use follow acceptable method birth control month prior start study agent study day last dose study agent oral contraceptive either combine progestogen alone injectable progestogen implants levonorgestrel etonogestrel estrogenic vaginal ring percutaneous contraceptive patch intrauterine device iud intrauterine system ius failure rate state product label male partner sterilization vasectomy documentation azoospermia prior female subject entry study male sole partner subject definition document refers outcome investigator designee medical examination subject review subject medical history study eligibility obtain via verbal interview subject subject medical record double barrier method condom occlusive cap diaphragm cervical vault cap plus spermicidal agent foam gel film cream suppository allow method contraception effective use consistently correctly accordance product label investigator responsible ensure subject understand properly use method contraception human immunodeficiency virus negative serology negative hbs ag test hbc ab test hcv negative serology negative hcv rna positive hcv serology within month inclusion neutrophils anc",
    "EXCLUSION CRITERIA": "patient vasculitis unrelated cryoglobulinemia patient non active cryoglobulinemia vasculitis anti thrombin initiation rituximab patients inactive vasculitis follow rituximab administration may include excluded concomitant medication day prior investigational medicinal product belimumab placebo biologic investigational agent abetimus sodium anti antibody idec investigational agent applies drug approve sale country intrathecal injection use days prior investigational medicinal product belimumab placebo intravenous cyclophosphamide days prior investigational medicinal product belimumab placebo half life whichever great nonbiologic investigational agent investigational agent applies drug approve sale country intrathecal injection use live vaccine within day prior baseline concurrently investigational medicinal product belimumab placebo history malignant neoplasm within last year carcinoma situ cervix excise basal cell squamous cell carcinoma skin lowgrade hemopathy indication specific treatment progressive multifocal leukoencephalopathy evidence serious suicide risk include history suicidal behaviour last month suicidal ideation last month world health organization investigator judgment pose significant suicide risk history primary immunodeficiency significant igg deficiency igg level milligrams dl significant iga deficiency iga level milligrams dl accord result obtain within month prior inclusion visit history major organ transplant hematopoietic stem cell marrow transplant renal transplant infection history currently suppressive therapy chronic infection tuberculosis pneumocystis cytomegalovirus infection require hospitalization use parenteral iv im antibiotic antibacterial antiviral antifungals antiparasitic agent within day inclusion visit current drug alcohol abuse dependence history drug alcohol abuse dependence within day prior inclusion visit historically positive human immunodeficiency virus test accord result obtain within month prior inclusion visit hepatitis status accord result obtain within month prior inclusion visit serologic evidence current past hepatitis hb infection base result test hbsag hbcab follow patients positive hbsag hbcab exclude positive test hepatitis rna history hypersensitivity anaphylactic reaction parenteral administration belimumab corticosteroid excipients treatment administer study women child bearing potential wcbp included please see special instruction inclusion criterion pregnant breast feeding woman intercurrent significant medical psychiatric illness investigator considers would make candidate unsuitable study patients legal protection unable consent participation another interventional study",
    "TREATMENT": "belimumab benlysta administer subcutaneously milligram weekly week week placebo belimumab administer subcutaneously weekly week week",
    "STATISTICAL": "bayesian phase ii randomize clinical trial aim anti thrombin evaluate treatment strategy cryoglobulinemia vasculitis base difference response rate measure anti thrombin week randomization randomized phase ii trial still poorly use still large use singlearm phase ii trial result interpret relative historical control subject introduce selection bias confound may limit validity conclusion thus plan phase ii randomize trial appear worthy investment consider finite patient financial resource design adapt binary outcome observed anti thrombin end fixed followup period analyze use absolute difference proportion show greatly reduce sample size requirement thus use approach phase ii randomize trial propose simon wittes ellenberg ss aim anti thrombin control probability detect give difference response rate hypothesize patient receive placebo belimumab treat belimumab achieve complete remission cryoglobulinemia vasculitis anti thrombin week week steroid therapy stop milligrams day anti thrombin week"
  },
  "MSC-SLE": {
    "TITLE": "treatment severe refractory systemic lupus erythematosus injection allogeneic mesenchymal stem cell derive umbilical cord",
    "JUSTIFICATION": "systemic lupus erythematosus sle rare prevalence person heterogeneous autoimmune autoinflammatory disease ad affect sex acute lymphoblastic leukemia race peak incidence prevalence among black people predilection woman decade life systemic lupus erythematosus characterize successive period flare remission may acute lymphoblastic leukemia vary duration quality prognosis severe form systemic lupus erythematosus affect lung heart brain addition renal involvement improve still evolution remain pejorative subset patient whose year mortality remain even tertiary referral center year new prospective clinical trial course systemic lupus erythematosus demonstrate effectiveness new biological therapy yet make long awaited breakthrough treatment severe systemic lupus erythematosus antiblys monocolonal antibody gain indication moderately active systemic lupus erythematosus addition serious adverse side effect progressive multifocal leukoencephalopathy observe several biologics autoimmune disease patient dampen expect benefit systemic lupus erythematosus subject resistant line conventional treatment need develop effective therapy long term side effect base new immunomodulatory immunosuppressive strategy according vitro immunomodulatory property ability induce tissue repair mechanism mesenchymal stem cell msc propose new therapy several autoimmune disease include systemic lupus erythematosus use allogeneic umbilical cordderived mesenchymal stromal cell base experimental human clinical data particularly produce nanjing team pr sun china intrathecal injection also logical select systemic lupus erythematosus patient severity criterion use worldwide validate efficacy antiblys therapy similarly analysis expected result take account criterion similar comparable use pivotal clinical trial trial unique opportunity set collaboration saintlouis assistance publique hopitaux de paris clinical expert center cell therapy autoimmune disease university college london cell manufacturing",
    "OBJECTIVE": "main objective assess tolerance allogeneic umbilical cord derive mesenchymal stromal cell administration severe systemic lupus erythematosus refractory standard therapy cyclophosphamide mycophenolate mofetil corticosteroid without anti primary endpoint immediate tolerance assess first injection day allogeneic mesenchymal stromal cell injection accord standard common terminology criterion adverse event side effect secondary objective feasibility allogeneic ucmesenchymal stromal cell administration treatment severe systemic lupus erythematosus subject refractory conventional therapy tolerance three month injection consider observed morbidity overall survival systemic lupus erythematosus treat subject year procedure analysis biological clinical response routine clinical biological examination criterion monitor lupus use selena sledai bilag sri sliccsystemic lupus erythematosus score analysis efficacy anti thrombin injection allogeneic uc mscs accord proportion subject major clinical response rcm percentage subject partial clinical response cpr month followup study evaluation immunomodulatory effect mesenchymal stromal cell routine laboratory criterion include immunophenotyping every month followup period analysis specific cytokine production anti thrombin month month month analysis mesenchymal stromal cell immunogenicity anti thrombin month month month secondary endpoint safety tolerance assess injection within first day follow mesenchymal stromal cell injection anti thrombin month month month month accord side effect define common terminology criterion adverse event standard miller results cancer treatment cancer treatmentrelated toxicity analyze accord international world health organization maximum degree toxic attack body injection consider tolerate toxicity criterion grade proportion subject major clinical response mcr proportion subject partial response clinic pcr month study followup anti thrombin month month month month month disease activity measure bilag score selenasledai every month compare inclusion end followup period month month month month sri response rate measure every three month month month month month followup sri response define point reduction selena sledaiscore new bilag score organ one new bilag score worsening increase overall evaluation physician compare inclusion value presence comorbidities accord scliccsystemic lupus erythematosus index anti thrombin month every three month study followup month month month month charlson comorbidity index anti thrombin eligibility quality life assess short form version injection every month end monitoring period month month month month anti thrombin month percentage subject average dose prednisone reduce compare month world health organization milligram day week average daily corticosteroid dose measure every month end monitoring period mo month month month month number treatment failure define one following end stage renal disease require dialysis transplantation sustain double creatinine value two low value observe screen baseline confirm four week later active lupus nephritis attribute active systemic lupus erythematosus define either two criterion double value proteinuria proteinuria hour subject world health organization hour anti thrombin baseline proteinuria hour subject world health organization hour anti thrombin baseline ii nephropathy increase serum creatinine respect value anti thrombin baseline simultaneously value proteinuria double anti thrombin least hour hematuria two positive urine test strip presence cell cylinder two criterion must confirm twice anti thrombin interval need steroid therapy intravenously plasmapheresis immunoglobulin intravenous infusion immunosuppressive therapy treat aggravation systemic lupus erythematosus standard immunological biological marker include lymphocyte immunophenotyping complete blood count creatinine proteinuria autoantibody antidna antibody native anas complement system immunophenotyping anti thrombin month month every three month followup period study month month month month specific cytokine production anti thrombin month month month inclusion analysis mesenchymal stromal cell immunogenicity anti thrombin month month month accord antihuman leukocyte antigen antibody dosage crossmatch analysis",
    "DESIGN": "single center phase iii open study national recruitment within network risks level",
    "INCLUSION CRITERIA": "systemic lupus erythematosus active subject refractory prior standard therapy patient age year year diagnosis systemic lupus erythematosus sle accord american college rheumatology criterion positive antinuclear antibody subjects sustained disease activity define selena sledai systemic lupus erythematosus activity index anti thrombin baseline inefficacy adverse effect necessitate discontinuation first second line therapy systemic lupus erythematosus include prednisone orally milligram day equivalent anti thrombin least day anti thrombin least one following immunosuppressive therapy month total cyclophosphamide intravenous infusion bolus milligram month month minimum ii mycophenolate mofetil orally equivalent anti thrombin dose milligram day anti thrombin least day iii azathioprine orally anti thrombin dose milligram kilogram day anti thrombin least day intravenous infusion methotrexate orally parenterally anti thrombin dose week anti thrombin least day leflunomide orally anti thrombin dose day anti thrombin least day vi rituximab intravenous bolus milligram month week four week total dose twice day two week vii cyclosporine orally anti thrombin dose milligram kilogram day anti thrombin least day viii belimumab intravenously subcutaneous anti thrombin monthly bolus milligram kilogram infusion anti thrombin least month patient world health organization receive treatment systemic lupus erythematosus anti thrombin stable dos minimum day prior eligibility include one following treatment prednisone equivalent alone combine antimalarial treatment antiinflammatory steroidal immunosuppressant negative pregnancy test woman childbearing age men woman using effective contraceptive method treatment within month end treatment men partner childbearing age signed informed consent affiliation social security",
    "EXCLUSION CRITERIA": "subjects pregnancy breastfeeding lack appropriate contraception study duration presence renal failure calculated creatinine clearance ml min cardiac failure clinical sign congestive heart failure leave ventricular ejection fraction echocardiography uncontrolled ventricular arrhythmia hepatitis define abnormal level transaminase ast alanine amino transferase normal relate disease activity respiratory disease mean pap mmhg echocardiography respiratory failure define rest blood pressure oxygen anti thrombin pao mmhg mmhg without oxygen severe psychiatric disorder include severe psychosis relate systemic lupus erythematosus would prevent give informed consent undergo procedure active neoplasia concomitant myelodysplasia except basal cell carcinoma squamous cell carcinoma situ cervix carcinoma bone marrow failure define neutropenia thrombocytopenia anemia deciliter lymphopenia cause another disease systemic lupus erythematosus acute chronic uncontrolled infection human immunodeficiency virus hepatitis hbs ag surface antigen hepatitis positive pcr optional pcr patient receive belimumab intravenously subcutaneous within month baseline receive rituximab cell deplete biologic therapy within month baseline current substance abuse recent within day history substance abuse patient period exclusion national roster researcher patient linguistic psychological incapacity sign informed consent patient already include another study anti thrombin time poor patient compliance patient legal protection",
    "TREATMENT": "phase iii allogeneic umbilical cord derivedmscs inject slow intravenous infusion accord weight recipient patient group study anti thrombin dos csm kilogram csm kilogram csm kilograms injection intravenous infusion na na",
    "STATISTICAL": "initially subject anti thrombin initial dose csm kilograms recipient weight include follow subject enrol dose ms kilograms high probability excessive toxicity anti thrombin mesenchymal stromal cell kilogram csm kilograms low probability excessive toxicity csm kilograms toxicity criterion describe common terminology criterion adverse event classification patient cohort scan sequential bayesian approach estimate probability toxicity administer dose allow adaptation function toxicity observe dose previous subject"
  },
  "PCL-2": {
    "TITLE": "primary plasma cell leukemia prospective phase ii study incorporating daratumumab chemotherapy stem cell transplantation",
    "JUSTIFICATION": "primary plasma cell leukemia ppcl rare form plasma cell malignancy multiple myeloma poor prognosis overall survival os month conventional chemotherapy bortezomibbased regimen show promising result small retrospective study transplantation auto allograft may improve overall survival select young patient ifm group recently publish prospective study ppcl patient alternate bortezomibdexamethasone doxorubicin cyclophosphamide pad vcd induction high dose melphalan plus autologous stem cell transplantation hdm asct follow reduced intensity conditioningallograft ricallo second hdm autologous stem cell transplantation plus consolidation maintenance bortezomiblenalidomidedexamethasone lenalidomide overall patient responder induction achieve good partial response good one patient underwent syngeneic allograft hdm autologous stem cell transplantation subsequently receive ricallograft second transplant follow consolidation maintenance median progressionfree survival overall survival month respectively overall survival seem superior double transplant maintenance group compare allotransplant group landmark analysis italian group also recently report prospective trial ppcl involve patient treat lenalidomidedexamethasone overall median progressionfree survival overall survival month respectively nine patient eligible transplant could receive hdm autologous stem cell transplantation induction progressionfree survival overall survival month reach respectively daratumumab monoclonal antibody highly express plasma cell highly effective relapsed refractory patient multiple myeloma mm alone combination lenalidomide combination daratumumab bortezomiblenalidomidedexamethasone daravrd recently test newly diagnose multiple myeloma patient impressive result acceptable tolerability subcutaneous formulation daratumumab also test context new safety concern aim improve hematological response survival ppcl patient propose combine daratumumab subcutaneous bortezomiblenalidomidedexamethasone daravrd induction follow double hdm autologous stem cell transplantation prolonged consolidation year darabortezomiblenalidomidedexamethasone year lenalidomide year",
    "OBJECTIVE": "primary objective determine best overall response rate anti thrombin completion induction phase good partial response good primary endpoint good partial response good rate anti thrombin completion induction phase accord international myeloma work group response criterion main secondary objective evaluate progressionfree survival secondary objective assess overall hematological response rate evaluate overall survival assess safety toxicity accord national cancer institute common terminology criterion adverse event assess cytogenetic abnormality tumoral plasma cell analyze prognostic value minimalresidual disease mrd sequence ngs completion induction second consolidation len consolidation anti thrombin end treatment evaluate quality life eortc domain score secondary endpoint progressionfree survival overall survival time progression duration response overall hematological response rate assess safety type frequency severity relationship adverse event study treatment change vital sign physical exam incidence treatment emergent adverse event teae serious adverse event sae laboratory abnormality use national cancer institute nci common toxicity criterion cctae evaluate response accord chromosomal structural abnormality del amp del minimal residual disease mrd assess nextgeneration sequence quality life eortc domain score",
    "DESIGN": "induction phase inclusion trial patient receive day dexamethasone according local practice one dose doxorubicine milligrams month iv cyclophosphamide milligrams month iv may also add reduce tumoral mass minimize risk tumor lysis syndrome tls induction treatment month subject receive day cycle darabortezomiblenalidomidedexamethasone induction therapy describe agent dose day route cycle day daratumumab milligram cycle cycle bortezomib milligrams month lenalidomide milligrams day day cycle dexamethasone milligram intravenous infusion start dose lenalidomide reduce depend renal function patients impaired renal function calculate measure creatinine clearance ml minute lenalidomide dose reduction otherwise receive full dose lenalidomide tumorlysis prophylaxis monitoring require induction treatment accord local practice ii disease assessment local assessment perform anti thrombin end induction determine patient continue study responding patient response sd circulate plasma cell pursuit study nonresponding patient response sd circulate plasma cell study mobilization harvesting stem cells stem cell mobilization perform use cyclophosphamide recommend dose month cycle stem cell harvest base response mobilization use gcsf plerixafor permit per institutional practice sufficient stem cell harvest enable two transplant kg high dose melphalan autologous stem cell transplantation acute lymphoblastic leukemia eligible patient start intensification high dose melphalan week stem cell collection mephalan month conditioning therapy patient creatinine clearance ml min melphalan dose reduce milligrams month stem cell reinfusion subject single reinfusion stem cell minimum kg hour highdose melphalan permit tolerance engraftment recovery day post asct subjects monitor successful engraftment support therapy administer accord institutional study group standard first consolidation day consolidation therapy start anti thrombin time complete hematological recovery accord investigator opinion subject fit enough tolerate subsequent systemic therapy within month asct subjects receive cycle darabortezomiblenalidomidedexamethasone daratumumab milligram day day bortezomib milligrams month day day day day lenalidomide milligram day day dexa milligram intravenous infusion day day day day high dose melphalan autologous stem cell transplantation subjects receive melphalan month conditioning therapy patient creatinine clearance ml min melphalan dose reduce milligrams month stem cell reinfusion subject single reinfusion stem cell minimum kg hour highdose melphalan permit tolerance engraftment recovery day post asct second consolidation phase year consolidation therapy start anti thrombin time complete hematological recovery accord investigator opinion subject fit enough tolerate subsequent systemic therapy within month asct phase conduct accord two step consolidation year patients receive darabortezomiblenalidomidedexamethasone every month cycle daratumumab milligram day bortezomib milligrams month day day day day lenalidomide milligram day day dexamethasone milligram intravenous infusion day day day day consolidation year patient receive lenalidomide every day lenalidomide milligram day day day note acute lymphoblastic leukemia treatment period lenalidomide dose readjust accord patient renal function status dose adaptation follow usual recommendation safety darabortezomiblenalidomidedexamethasone induction consolidation therapy context intensive therapy autologous stem cell transplant also report blood study conduct compliance protocol good clinical practice gcp applicable regulatory requirement international conference harmonization ich guideline",
    "INCLUSION CRITERIA": "screening eligibility investigator responsible keep record acute lymphoblastic leukemia subject world health organization sign informed consent form entry study acute lymphoblastic leukemia subject screen eligibility must take place within day prior initiation therapy patient must meet eligibility criterion enter study male female patient year old patient primary plasma cell leukemia disease define recent international myeloma working group imwg circulate plasma cell peripheral blood smear voluntary write consent must give performance study related procedure part standard medical care understanding consent may withdraw patient anti thrombin time without prejudice future medical care eastern cooperative oncology group ecog performance status performance status eligible high dose melphalan therapy autologous stem cell transplantation total bilirubin upper limit normal range uln alanine aminotransferase alt aspartate aminotransferase ast upper limit normal range calculated creatinine clearance ml min mdrd formula use calculate creatinine clearance value female patient world health organization postmenopausal anti thrombin least year screening visit surgically sterile childbearing potential agree practice effective method contraception anti thrombin time time sign informed consent form day last dose study drug agree practice true abstinence line preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal postovulation method withdrawal acceptable method contraception male patient even surgically sterilize status post vasectomy must agree one following agree practice effective barrier contraception entire study treatment period day last dose study drug agree practice true abstinence line preferred usual lifestyle subject periodic abstinence calendar ovulation symptothermal postovulation method withdrawal acceptable method contraception patients agree share study medication person return acute lymphoblastic leukemia unused study drug investigator abstain donate blood take study drug therapy one week follow discontinuation study drug therapy must able adhere study visit schedule protocol requirement affiliated appropriate social security system",
    "EXCLUSION CRITERIA": "male female patient year old history malignancy within year date inclusion exception squamous basal cell carcinoma skin carcinoma skin carcinoma situ cervix breast noninvasive lesion opinion investigator concurrence coordinate investigatior consider cured minimal risk recurrence within year prior history symptomatic myeloma previous chemotherapy myeloma except corticotherapy dexamethasone milligrams day max uncontrolled medical condition comorbidity might interfere subject participation pregnant breast feeding females known positive human immunodeficiency virus known seropositive hepatitis except setting sustained virologic response svr define viremia anti thrombin least week completion antiviral therapy seropositive hepatitis define positive test hepatitis surface antigen hbsag subjects resolved infection ie subject world health organization hbsag negative positive antibody hepatitis core antigen antihbc antibody hepatitis surface antigen antihbs must screen use realtime polymerase chain reaction pcr measurement hepatitis virus hbv dna level world health organization pcr positive exclude exception subjects serologic finding suggestive hbv vaccination anti hbs positivity serologic marker known history prior hbv vaccination need test hbv dna pcr patient severe renal failure require dialysis clairance creatinine ml min prior local irradiation within two week first dose however exception patient allow remain treatment phase study make radiation therapy pathological fracture site enhance bone healing treat postfracture pain refractory narcotic analgesic pathologic bone fracture fulfil criterion disease progression evidence central nervous system cns involvement unable take corticotherapy daratumumab bortezomib lenalidomide anti thrombin study entry ongoing active infection especially ongoing pneumonitis ongoing cardiac dysfunction specify uncontrolled hypertension mi within month unstable angina pectoris cardiac arrhythmia grade high patients left ventricular ejection fraction lvef use experimental drug therapy within day screen grade toxicity unresolved inability unwillingness comply birth control requirement unable take antithrombotic medicine anti thrombin study entry major surgery within day enrolment serious medical psychiatric illness could investigator opinion potentially interfere completion treatment accord protocol known allergy study medication analogue excipients various formulation agent known gastro intestinal disease gastro intestinal procedure could interfere oral absorption tolerance daratumumab lenalidomide include difficulty swallow adult guardianship curatorship legal protection",
    "TREATMENT": "bortezomib daratumumab lenalidomide dexamethasone",
    "STATISTICAL": "primary endpoint trial good partial response good rate anti thrombin completion induction phase accord international myeloma work group response criterion previous publish phase ii trial patient achieve good partial response good induction using phase one stage hern design lowest acceptable response rate expect response rate type type error level patient need account nonevaluable patient patient recruit"
  },
  "ITAC": {
    "TITLE": "multicenter randomize prospective trial compare efficacy safety infliximab cyclophosphamide severe behcet disease",
    "JUSTIFICATION": "itac first randomized prospective head head study compare infliximab cyclophophamide severe manifestation bd behcet disease bd systemic vasculitis arterial venous vessel size involve young patient year bd significantly increase morbidity mortality therape utic management bd depend clinical presentation organ involve although colchicine nonsteroidal antiinflammatory agent topical treatment often sufficient mucocutaneous joint involvement aggressive approach immunosuppressive agent warrant severe manifestation retinal vasculitis cardiovascular neurological involvement early recognition vigorous use immunosuppressive high dose steroid change prognosis patient severe bd bd severe systemic vasculitis lead mortality rate patient major vessel neurological involvement cyclophosphamide use lifethreatening bd year however outcome severe complication bd still poor european league rheumatism eular recommendation update management bd advocate cyclophosphamide antitnf plus glucocorticoid lifethreatening manifestation neurological major vessel involvement recommendation vascular disease neurological involvement base largely expert opinion uncontrolled evidence open trial observational study need properly design control clinical trial apparent tnfa antagonist use success severe resistant case addition incidence blindness bd dramatically reduce recent year use antitnf however firm evidence randomize controlled trial directly address best induction immunosuppressive therapy severe bd manifestation physicians still prescribe compound offlabel use therefore aim assess best induction therapy severe difficult treat bd patient",
    "OBJECTIVE": "assess benefit infliximab comparatively cyclophosphamide severe lifethreatening behcet disease primary assessment criterion complete clinical response anti thrombin week randomization estimate compare rate time occurrence relapse worsen estimate compare cumulative dose steroid estimate compare adverse event estimate compare mean change short form health survey qualityoflife see appendix estimate compare rate remission accord organ involve compare change acutephase reactant estimate compare change central nervous system involvement estimate compare change cardiovascular involvement survival event free survival estimate compare change bd manifestation estimate compare change behcet disease current activity form see appendix assess serum concentration measurement tnfa inhibitor secondary endpoint complete clinical response anti thrombin week remission central nervous system cardiovascular involvement anti thrombin week measures corticosteroid sparing percent meeting target milligrams day kilograms prednisone anti thrombin week mean dose anti thrombin week cumulative dose anti thrombin week time response onset measures acutephase reactant creactive protein crp every week relapse time relapse relapse define reappearance clinical paraclinical feature active disease occurrence new lesion anti thrombin week rate relapse worsening time occurrence worsen worsening define progression preexist lesion anti thrombin week rate worsen gobal survival anti thrombin week event free survival anti thrombin week define occurrence death relapse worsening safety tolerability treatment bd patient assess frequency severity adverse clinical event anti thrombin week change quality life qol health survey anti thrombin week see appendix changes central nervous system involvement physical exam cerebral medullar magnetic resonance image anti thrombin week changes vascular involvement physical exam vascular doppler us angioct imaging biologically normalization reactive protein anti thrombin week changes cardiological involvement physical exam echocardiography normalization left ventricular function disappearance cardiac thrombosis cardiac magnetic resonance imaging diseappearance gadolinium enhancement normalization left ventricular function biologically normalization troponin reactive protein anti thrombin week changes organ involve bd serum concentration measurement tnfa inhibitor anti thrombin week change behcet disease current activity form see appendix anti thrombin week",
    "DESIGN": "bayesian design phase ii randomize clinical trial aim anti thrombin compare new treatment reference base binary end point offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial risk intermediate",
    "INCLUSION CRITERIA": "adult pediatric patient severe lifethreatening behcet disease age year old written inform consent informed consent obtain legal guardian accordance regional law regulation patient year age diagnosis bd accord international criterion bd icbd see appendix life threaten active bd define following disease category accord validated international definition major vessel disease arterial aneurysm arterial stenosis myocarditis major deep vein thrombosis inferior vena cava superior vena cava cardiac cavity thrombosis pulmonary embolism supra hepatic vessel renal mesenteric vessel diagnosis major vessel involvement use vascular doppler sonography echocardiography angioct scan cardiac magnetic resonance imaging mri central nervous system involvement encephalitis meningoencephalitis myelitis diagnosis neurobehcet cns involvement base objective neurological symptom associate neuroimaging cns medullar mri finding suggestive bdrelated central nervous system involvement cerebrospinal fluid csf findings show aseptic inflammation may associate chest xray result posteroanterior lateral within week prior inclusion evidence active tuberculosis active infection malignancy female subject childbearing age negative pregnancy test subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study month stop therapy adequate contraceptive measure include hormonal method use two cycle prior inclusion oral contraceptive pill contraceptive patch contraceptive vaginal ring barrier method contraceptive sponge diaphragm use conjunction contraceptive foam jelly condom use conjunction contraceptive foam jelly intrauterine method iud sterilization tubal ligation monogamous relationship vasectomized partner abstinence potential subject positive interferon gamma release assay igra quantiferontuberculosis gold tspot tuberculosis test positive tuberculin skin test month eligible chest xray show evidence suggestive active tuberculosis disease clinical sign symptom pulmonary extrapulmonary tuberculosis disease subject latent tuberculosis infection world health organization already receive prophylactic tuberculosis treatment must agree advance complete treatment course human immunodeficiency virus negative serology negative hbs ag test month",
    "EXCLUSION CRITERIA": "subjects include study meet following criterion evidence active tuberculosis human immunodeficiency virus active hbv infection hbs ag+ pregnancy lactation take oral daily dose glucocorticoid milligram prednisone equivalent week continuously prior inclusion visit take milligram methylprednisolone week prior inclusion visit alcohol drug dependance severe renal creatinine clairance min preexisting hemorrhagic cystitis liver insufficiency hepatic encephalopathy urinary obstruction heart failure stage iii intravenous infusion new york heart association history malignancy within year prior inclusion carcinoma situ cervix excise basal cell squamous cell carcinoma skin history multiple sclerosis demyelinate disorder history severe allergic anaphylactic reaction cyclophosphamide infliximab infectious disease infection require treatment intravenous antibiotic within week prior inclusion history recurrent infection laboratory value assess inclusion hemoglobin deciliter white blood cell count cubic millimeter platelet count cubic millimeter use following systemic treatment specify period treatment systemic biologic therapy cyclophosphamide within month prior inclusion azathioprine mycophenolate mofetil methotrexate anti thrombin time inclusion drug must withdraw prior receive cyclophosphamide infliximab dose day live attenuate vaccine within week prior inclusion recombinant kill virus vaccine permit lack affiliation social security benefit plan beneficiary assignee patients affiliate universal medical coverage cmu eligible study",
    "TREATMENT": "infliximab kilograms intravenously anti thrombin week cyclophosphamide month month intravenously anti thrombin week evaluations serum concentration antitnf anti thrombin week",
    "STATISTICAL": "experimental design multicentric open multicenter randomize clinical trial stratify characteristic initial behcet disease evaluation primary assessment criterion anti thrombin week primary assessment criterion final measure corticosteroid sparing review scientific committee blind randomization rct use bayesian design phase ii randomize national multicentre clinical trial aim anti thrombin compare new treatment reference base binary endpoint complete clinical response anti thrombin week offer great flexibility simplicity inference monitoring patient safety evidence efficacy small randomized trial"
  },
  "FOCUS": {
    "TITLE": "randomized control multicenter study compare efficacy safety adalimumab mycophenolate mofetil steroid dependent non infectious uveitis",
    "JUSTIFICATION": "focus first prospective randomize study compare standard care mycophenolate mofetil adalimumab recently active non infectiuous uveitis niu steroid dependency firm evidence randomize trial compare classical immunosuppressive compound biological agent identify best treatment condition burden neutrophil immune unit reduce use immunosuppressive agent biologics raise question compound preferentially use recently active neutrophil immune unit steroid dependency",
    "OBJECTIVE": "primary objective objective compare efficacy adalimumab anti thrombin day day week week subcutaneously standard care mycophenolate mofetil day orally week recently active noninfectious intermediate posterior uveitis panuveitis steroid dependency primary endpoint primary efficacy endpoint treatment failure rate anti thrombin week treatment failure define follow anti thrombin least one eye new active inflammatory chorioretinal retinal vascular lesion worsening best correct visual acuity bcva line step increase anterior chamber cell grade vitreous haze relative baseline noabsence steroid discontinuation week week per protocol without aor additional immunosuppressive drug injectable steroid study treatment permanent discontinuation secondary objectives comparing adalimumab anti thrombin day day week week subcutaneously standard care mycophenolate mofetil day orally week evaluate cumulative incidence treatment failure week inclusion evaluate change best correct visual acuity bcva logmar baseline week week evaluate change ocular inflammation anterior chamber vitreous baseline week week evaluate change sign include vessel leakage baseline week week evaluate presence macular edema baseline week week evaluate quality life relate uveitis inclusion week evaluate steroid spar effect baseline week evaluate number time relapse uveitis characteristic uveitis anti thrombin worsen baseline week evaluate effect underlie systemic disease appropriate baseline week evaluate safety adalimumab mycophenolate mofetil week secondary endpoints time treatment failure week logmar best correct visual acuity eye anti thrombin week week week week week week week week week anterior chamber cell grade anti thrombin week week week week week week week week week vitreous haze grade sun criterion eye anti thrombin week week week week week week week week week central retinal thickness eye baseline anti thrombin week week week week week week week week week proportion patient central macular thickness micron anti thrombin week week week week week week week week week time optical coherence tomographic oct evidence macular edema anti thrombin least one eye week national eye institute visual functioning composite score anti thrombin week week week measures corticosteroid sparing percent meeting target milligrams kilograms day prednisone mean change mean dose anti thrombin week cumulative dose cumulative incidence relapse number relapse week clinical manifestation underlying disease depend underlying disease evaluate week safety tolerability treatment assess frequency severity adverse event treatment discontinuation baseline week",
    "DESIGN": "prospective phase iii clinical trial multicenter openlabel two arm randomize clinical trial compare efficacy safety adalimumab standard care mycophenolate mofetil subject recently active intermediate posterior uveitis panuveitis despite steroid use oral prednisone milligrams day prednisone available use oral corticosteroid replacement prednisone equivalent prednisone dose oral corticosteroid anti thrombin stable dose anti thrombin least week prior first study drug administration day risks associate toxicity investigational drug risks associate use concomitant medication risk level study risk collection free informed consent eligible patient randomize one group anti thrombin randomization visit day arm adalimumab anti thrombin day day week week subcutaneously arm mycophenolate mofetil gram per day orally week acute lymphoblastic leukemia patient receive corticosteroid regimen anti thrombin inclusion acute lymphoblastic leukemia patient receive corticosteroid milligrams day anti thrombin inclusion following schedule reduction prednisone apply group decrease discontinuation week week long disease inactive duration participation patient month week week total duration study month",
    "INCLUSION CRITERIA": "adult patient recently active noninfectious uveitis niu despite oral prednisone milligrams day equivalent prednisone doseoral corticosteroid anti thrombin equivalent dose prednisone stock market prednisone available use oral corticosteroid replacement prednisone equivalent dose oral corticosteroid equivalent recently active disease define presence anti thrombin least follow parameter either eye within month prior inclusion visit active chorioretinal retinal vascular lesion presence macular edema optical coherence anterior chamber cell standardization uveitis nomenclature sun criterion vitreous haze national eye institute nei standardization uveitis nomenclature criterion eligibility criterion check anti thrombin screening visit take place four week maximum prior inclusion visit anti thrombin inclusion randomization visit adult patient meet following criterion may include study provide write informed consent prior performance studyspecific procedure year age diagnosis noninfectious intermediate posterior panuveitis anti thrombin least one eye fulfil international study group classification criteria standardization uveitis nomenclature sun criterion posterior pan uveitis confirm documented medical history recent activity neutrophil immune unit define presence anti thrombin least follow parameter either eye within month prior inclusion visit despite day oral prednisone active chorioretinal retinal vascular lesion presence macular edema optical coherence anterior chamber cell standardization uveitis nomenclature sun criterion vitreous haze national eye institute nei standardization uveitis nomenclature criterion chest xray posteroanterior lateral ctscanner result within week prior inclusion evidence active tuberculosis active infection malignancy potential subject positive interferongamma release assay igra quantiferontuberculosis gold tspot tuberculosis test anti thrombin inclusion eligible chest xray show evidence suggestive active tuberculosis disease clinical sign symptom pulmonary extrapulmonary tuberculosis disease subject latent tuberculosis infection world health organization already receive prophylactic tuberculosis treatment must agree advance complete treatment course female subject childbearing potential negative pregnancy test anti thrombin inclusion subject reproductive potential willingness use contraceptive measure adequate prevent subject subject partner become pregnant study month month stop therapy mycophenolate mofetil adalimumab respectively unless sterility confirm simultaneous use two complementary method contraception preferable methods may consider highly effective method achieve failure rate less per year use consistently correctly consider highly effective birth control method accord ctfg recommendation method include female subject combine estrogen progestogen containing hormonal contraception associate inhibition ovulation oral intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation oral injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomise partner sexual abstinence context guidance sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment reliability sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle subject male subject use condom vasectomy documentation azoospermia sexual abstinence affiliated social security system",
    "EXCLUSION CRITERIA": "subjects include study meet following criterion infectious uveitis masquerade syndrome idiopathic uveitis permit isolated anterior uveitis monocular patient active tuberculosis positive human immunodeficiency virus serology hcv hbs ag test history malignancy within year prior inclusion carcinoma situ cervix nonmetastatic squamous basal cell carcinoma skin history severe allergic anaphylactic reaction monoclonal antibody mycophenolate mofetil rifampicin isoniazid fluorescein infection require treatment intravenous antibiotic within week prior inclusion history multiple sclerosis demyelinate disorder laboratory value assess inclusion hemoglobin deciliter white blood cell count cubic millimeter platelet count cubic millimeter glomerular filtration rate gfr min transaminases time upper normal value use following systemic treatment specify period treatment systemic alkylating agent within month prior inclusion cyclophosphamide chlorambucil live attenuate vaccine within week prior inclusion stage iii intravenous infusion new york heart association nyha cardiac insufficiency pregnancy breastfeed legal protection participation another interventional study involve human participant exclusion period anti thrombin end previous study involve human participant applicable",
    "TREATMENT": "eligible patient recently active neutrophil immune unit randomize anti thrombin ratio arm adalimumab anti thrombin day day week week subcutaneously arm standard care define mycophenolate mofetil gram per day orally week treatment group receive corticosteroid regimen acute lymphoblastic leukemia patient neutrophil immune unit receive oral prednisone milligrams day oral corticosteroid equivalent maximum milligrams day prednisone oral corticosteroid anti thrombin equivalent prednisone dose prednisone stock marketif prednisone available use oral corticosteroid replacement prednisone equivalent dose equivalence common prednisonetapering programme apply group decrease discontinuation week week long disease inactive arm standard care define mycophenolate mofetil gram per day orally week adalimumab anti thrombin day day week week subcutaneously visit anti thrombin week week hcg plasmatic urine pregnancy test anti thrombin inclusion urine pregnancy test anti thrombin week monthly week stop mycophenolate mofetil therapy month stop adalimumab therapy unless menopause sterility confirm fundoscopy optical coherence tomography oct anti thrombin week retinal angiography anti thrombin week quality life questionnaire anti thrombin day week week week",
    "STATISTICAL": "prospective twoarm randomize openlabel phase iii trial compare adalimumab standard care mycophenolate mofetil base binary primary endpoint treatment failure anti thrombin week treatment randomization stratify retinal vasculitis presence macular oedema underlie disease idiopathic uveitis underlying disease associate steroid dose anti thrombin inclusion vs trial conduct use group sequential design one interim analysis primary observation complete efficacy futility early stopping rule specifically assume probability treatment failure primary endpoint soc control population versus alternative hypothesis adalimumab total number patient per randomization arm require ensure power one sided type error risk account one interim analysis primary observation complete use lan demets brien flemingtype riskspending function define efficacy futility nonbinding early stopping rule moreover plan include total patient per randomization arm account potential losttofollowup"
  },
  "ICE": {
    "TITLE": "isatuximab type cryoglobulinaemia prospective pilot study",
    "JUSTIFICATION": "cryoglobulinaemia define presence immunoglobulin serum reversibly precipitate form gel temperature drop redissolve upon rewarming classification include three subgroup base ig composition type cryoglobulinaemia consists one isotype subclass immunoglobulin types ii iii classify mixed cryoglobulinaemia mc include igg igm component overall cryoglobulinaemia consider rare disease general european north american population although prevalence likely high area mediterranean basin mc vasculitis multiorganic disease involve kidney joint skin peripheral nerve type cryoglobulinaemic vasculitis search underlying plasmacell neoplasm mandatory cryoglobulinaemia compose igg often find multiple myeloma monoclonal gammapathy unknown significance mgus course mc vasculitis varies widely prognosis influence mcinduced damage vital organ co morbidity associate underlying disease type cryoglobulinaemic vasculitis plasma cell associate disorder anti thrombin crossroad autoimmunity plasmacell neoplasm treatment modulate accord underlie associated disease severity internal organ involvement overall survival diagnosis cryoglobulinaemic syndrome range case renal involvement main therapeutic goal must cure underlying haematological disease overwhelmingly plasmacell neoplasm common neoplasia multiple myeloma predominantly associate type cryoglobulinaemia hyperviscosity case treating underlying monoclonal disorder associate improvement stabilization cryoglobulinaemic symptom patient type cryoglobulinemia although negativation serum cryoglobulins achieve half patient alkylating agent bortezomib main therapeutic option associate side effect include neuropathy patients present symptomatic hyperviscosity require urgent therapeutic intervention use plasma exchange plasmapheresis remove cryoglobulins circulation standard care international guideline treatment type cryoglobulinemia isatuximab monoclonal antibody effective treat relapsed refractory multiple myeloma autoreactive plasma cell represent key player autoimmune disorder particularly type cryoglobulinemia type cryoglobulinemia model plasma cell associate disorder anti thrombin crossroad autoimmunity plasmacell neoplasm however rituximab fails target population poorly effective condition thus unmeet need plasma cell target therapy type cryoglobulinemia clonal plasma cell type cryoglobulinemia express surface provide rationale use isatuximab cryoglobulinemia although biology clonal plasma cell type cryoglobulinemia distinct al amyloidosis model hematological disease associate monoclonal ig whose tumor mass low al amyloidosis target therapy highly efficient monotherapy treatment naive patient relapsers thus isatuximab represent highly promising therapy type cryoglobulinemia could use monotherapy",
    "OBJECTIVE": "primary objective assess complete clinical response rate isatuximab type igg cryoglobulinemia primary endpoint complete clinical response rate cryoglobulinemia vasculitis symptom anti thrombin week secondary objective safety tolerability treatment assess frequency severity adverse clinical event early complete response rate anti thrombin week complete partial improvement acute lymphoblastic leukemia organ involve anti thrombin baseline non clinical clinical improvement response rate anti thrombin week week rate cryoglobulinemia clearance rate negativation rheumatoid factor activity rate normalization complement level early failure rate anti thrombin week non clinical response anti thrombin week clinical relapse rate time relapse course plasma cell associate disorder evolution gammaglobulin level quality life score appendix rate infection severe complication birmingham vasculitis activity score bvas appendix immunomonitoring deep immunophenotyping cytokine production spectrometry fish analysis single plasma cell repertoire secondary endpoint safety tolerability treatment assess frequency severity adverse clinical event anti thrombin week complete partial nonclinical response rate anti thrombin week anti thrombin week rate cryoglobulinemia clearance negativation rheumatoid factor activity normalization complement level anti thrombin week anti thrombin week rate early failure nonclinical response anti thrombin week rate renal complete remission define proteinuria proteinuria creatininuria milligrams mmol disappearance hematuria glomerular filtration rate min anti thrombin week anti thrombin week clinical relapse rate define de novo appearance reappearance manifestation attributable cryoglobulinemia vasculitis week followup rate time relapse baseline week course plasma cell associate disorder week anti thrombin week mean change gammaglobulin level baseline week quality life assess mean variation sf week rate infection severe complication week followup proportion patient remain remission bvas anti thrombin baseline week week evolution immunomonitoring deep immunophenotyping cytokine production spectrometry fish analysis single plasma cell repertoire anti thrombin baseline week week",
    "DESIGN": "phase pilot prospective study patient type igg cryoglobulinemia treat isatuximab isatuximab perform intravenously anti thrombin kilograms anti thrombin day week week week week every week total infusion risk",
    "INCLUSION CRITERIA": "adult patient type igg active cryoglobulinemia vasculitis age year written inform consent monoclonal gammopathy unknown significance mgus monoclonal igg component active cryoglobulinemia vasculitis define positive history positive type igg cryoglobulinemia clinically active cryoglobulinemia skin joint renal pulmonary cardiovascular muscular digestive central peripheral neurological involvement treated naive relapsers type cryoglobulinemia patient affiliated national french social security system contraception male participant male participant must agree use highly effective method contraception participation period anti thrombin least month last dose study treatment refrain donate sperm period female participant female participant eligible participate pregnant breastfeed anti thrombin least one following condition female childbearing potential fcbp fcbp world health organization must negative serum urine pregnancy test sensitivity anti thrombin least miu ml within hour start study medication must apply highly effective method contraception participation period anti thrombin least month last dose study treatment refrain donate oocyte period human immunodeficiency virus negative serology negative hbs ag test hcv negative serology negative hcv rna positive hcv serology within month prior inclusion",
    "EXCLUSION CRITERIA": "patient vasculitis unrelated cryoglobulinemia patient nonactive cryoglobulinemia vasculitis patient diagnosis multiple myeloma except indolent myeloma patient treat immunosuppressant alkylating agent rituximab chemotherapy plasma cell neoplasm introduce increase month prior inclusion live vaccine within day prior baseline concurrently isatuximab infection require hospitalization use parenteral iv im antibiotic antibacterial antiviral antifungals antiparasitic agent within day prior day active tuberculosis human immunodeficiency virus positive positive ag hbs positive hcv rna clinically significant uncontrolled medical condition investigator opinion would expose excessive risk patient may interfere compliance interpretation study result hypersensitivity history intolerance steroid mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer sucrose component study therapy amenable premedication steroid blocker would prohibit treatment agent hypersensitivity active substance isatuximab premedication excipients received investigational drug within day prior inclusion within halflives investigational drug whichever long participation another interventional study exclusion period anti thrombin end previous study vulnerable population pregnant breastfeed woman persons deprived liberty judicial administrative decision persons psychiatric care without consent adults subject legal protection measure persons unable express consent neutrophils cubic millimeter platelets cubic millimeter",
    "TREATMENT": "isatuximab administer intravenously anti thrombin kilograms anti thrombin day week week week week every week total infusion none immunomonitoring deep immunophenotyping cytokine production spectrometry fish analysis repertoire function single plasma cell anti thrombin baseline week premedication dexamethasone milligram per intravenous infusion milligram per intravenous infusion patient year age acetaminophen milligram milligram per equivalent montelukast milligram orally minute isatuximab infusion never minute equivalent diphenhydramine milligram milligram intravenous infusion per equivalent",
    "STATISTICAL": "use onesample multiple testing procedure phase ii clinical trial report definitions fleming biometrics volume page calculate sample size report definitions maximum response proportion poor drug minimum response proportion good drug sample size number response reject number response reject alpha probability reject true beta probability reject true summary statements ice study require subject decide whether proportion responding less equal great equal number response hypothesis reject target error rate actual error rate number response less hypothesis reject target error rate actual error rate pilot prospective phase ii clinical trial aim anti thrombin evaluate safety efficacy isatuximab type cryoglobulinemia vasculitis hypothesize patient receive isatuximab achieve complete remission cryoglobulinemia vasculitis anti thrombin week week continuous variable cf variable describe primary secondary objective present median iqr mean sem categorical variable present count proportion statistical comparison perform use mannwhitney test quantitative unpaired data ttest quantitative pair data kruskalwallis multiple comparison spearman correlation test correlation ttest quantitative pair data analysis use compare immunological change day week isatuximab acute lymphoblastic leukemia statistical test twotailed significance level"
  },
  "ETOLE": {
    "TITLE": "evaluation tomosynthesis characterization management breast",
    "JUSTIFICATION": "tomosynthesis innovative technique develop digital mammography obtain sectional image breast mammography main disadvantage image projection create overlay eliminate tomosynthesis",
    "OBJECTIVE": "evaluate birads classification obtain tomosythesis superior classification obtain conventional mammography term specificity noninferior term sensitivity joint analysis true negative false negative rate accord birads scale compare histological result followup outcome see gold standard evaluate tomosynthesis synthetic tomography allow good detection certain sign poor prognosis malignant lesion size multicentricity tumour lymph node extension skin pectoral infiltration tomosynthesis synthetic tomography modify number additional view number additional examination include ultrasound breast magnetic resonance imaging biopsy assess whether tomosynthesis reduce necessary number ultrasound compare difference rating birads obtain tomosynthesis synthetic mammography ultrasound difference obtain conventional mammography alone combine ultrasound tomosynthesis synthetic mammography change radiation dose receive patient tomosynthesis synthetic mammography improve reproducibility birads classification abnormality cost analysis tomosynthesis synthetic mammography compare mammography mammography ultrasound",
    "DESIGN": "randomized multicentric study phase iii diagnostic study accord classification gluud gluud inclusion phase month tomosynthesis system instal anti thrombin site manufacturer acute lymphoblastic leukemia patient clinical breast imaging abnormally anti thrombin site study period give informed consent randomize either conventional mammography tomosynthesis incidence synthetic mammography evaluation tomosynthesis characterization management breast conventional digital mammography conventional digital mammography tomosynthesis risk acute lymphoblastic leukemia patient refer clinical abnormality breast imaging center study period agree participate informed consent randomize conventional digital mammography arm atomosynthesis armwith synthetic mammography randomization balance group stratify center pregnant patient anti thrombin high risk breast cancer follow breast cancer may include",
    "INCLUSION CRITERIA": "women clinical breast imaging abnormality patient clinical breast imaging abnormality classify birads table patient year old signed informed consent",
    "EXCLUSION CRITERIA": "patients anti thrombin high risk breast cancer mutation brca carrier li fraumeni history thoracic radiation exclude great sensitivity ionize radiation patient unable give informed consent physical mental legal reason patient affiliate french social security insurance patient treatment breast cancer mammography recommended accord good practice french health authority pregnant patient",
    "TREATMENT": "",
    "STATISTICAL": "analysis comparison birads classification obtain mammography tomosynthesis rely construction simultaneous confidence interval ratio true negative rate specificity false negative rate obtain technics mammography tomosynthesis arm describe alonzo others"
  },
  "MAC-HAPLO-MUD": {
    "TITLE": "randomized prospective phase iii clinical trial compare human leukocyte antigen match unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative condition regimen myelo ablative conditioninghaplomatched unrelated donor",
    "JUSTIFICATION": "unrelated adult donor world health organization human leukocyte antigenmatched recipient anti thrombin allelelevel human leukocyte antigena consider best choice absence human leukocyte antigenmatched sibling patient need hematopoietic stem cell transplantation sct however use match unrelated donor mud limit prolonged time identify schedule donation match unrelated donor allow patient relapse transplantation perform limit availability fully human leukocyte antigenmatched unrelated donor noncaucasian population alternative donor single human leukocyte antigen mismatch unrelated donor unrelated umbilical cord blood graft haploidentical related donor still associate high nonrelapse mortality delay immune reconstitution recent strategy haploidentical haplo relate donor stem cell transplantation haplosct improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy target alloreactive cell generate early human leukocyte antigen mismatch transplant spar regulatory cell leave unaffected nondividing hematopoietic stem cell standard posttransplant immune suppression calcineurin inhibitor cni mycophenolate mofetil retrospective study haplostem cell transplantation ptcy associate similar overall progressionfree survival matched unrelated donor stem cell transplantation mud sct low rate toxicity graft versus host disease gvhd thus potentially good result matched unrelated donorsstem cell transplantation reduce intensity condition regimen phase iii randomize trial currently address question france elderly patient use reduced intensity condition regimen programme hospitalier de recherche cliniquek principal investigator blaise institut paoli calmettes randomized prospective phase iii clinical trial compare human leukocyte antigen match unrelated donor haplostem cell transplantation myeloablative conditioning regimen urgently need answer question",
    "OBJECTIVE": "main objective improve progression free survival without acute grade iiintravenous infusion graft versus host disease without moderate severe chronic graft versus host disease use haplo donor compare leukocyte antigen match unrelated donor myeloablative stem cell transplantation primary endpoint progression free survival without grade iiintravenous infusion acute graft versus host disease without moderate severe chronic graft versus host disease haplo stem cell transplantation versus leukocyte antigen match unrelated donor secondary objective compare two arm term clinical biological outcome kinetic haematopoietic reconstitution graft failure graft versus host disease progression free survival relapse non relapse mortality overall survival interval inclusion transplant rehospitalizations treatment related morbidity quality life chimerism immune reconstitution search prognostic factor main outcome globally arm search treatmentbycovariate interaction main outcome secondary endpoint interval inclusion transplant absolue number neutrophil platelet anti thrombin month month month month month chimerism anti thrombin month month month month month acute graft versus host disease incidence grade chronic graft versus host disease incidence grade relapse incidence progression free survival severe infection ctcadverse event grade incidence veinoocclusive disease incidence cardiac toxicity nonrelapse mortality overall survival quality life questionnaire ebmt number new day hospitalization hospitalization transplantation immune reconstitution anti thrombin month month month month month lymphocytes nk lymphocytes gammaglobulines",
    "DESIGN": "randomized prospective phase iii clinical trial compare human leukocyte antigen match unrelated donor haploidentical allogeneic hematopoietic stem cell transplantation myeloablative condition regimen risks relate stem cell transplantation randomization haplo match unrelated donor arm risk difference arm",
    "INCLUSION CRITERIA": "patients year age old high risk hematological malignancy indication allogeneic hematopoietic stem cell transplantation patients aged year old acute myeloid leukemia acute lymphoblastic leukemia smd smp require allogeneic stem cell transplantation anti thrombin least partial response malignant disease without human leukocyte antigen match related donor strong probability related haplo donor human leukocyte match donor available patient need anti thrombin least match unrelated donor identify outside book bmdw bone marrow donors worldwide use easy match software include usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanineaminotransferase total bilirubin creatinine mol except abnormality link hematological disease health insurance coverage understand informed consent optimal treatment followup prescription two effective contraception method must prescribe acute lymphoblastic leukemia duration study sign write informed consent parent patient age less",
    "EXCLUSION CRITERIA": "patients cancer last year except basal cell carcinoma skin situ carcinoma cervix uncontrolled infection seropositivity human immunodeficiency virus active hepatitis yellow fever vaccine heart failure accord new york heart association ii bile duct obstruction preexisting acute hemorrhagic cystitis renal failure creatinine clearance min pregnancy hcg positive breastfeeding debilitate medical psychiatric illness preclude realization stem cell transplantation understanding protocol protection law tutorship curatorship unwilling unable comply protocol",
    "TREATMENT": "haplo donor myeloablative stem cell transplantation use cyclophosphamide milligrams kilograms day intravenous route anti thrombin stem cell transplantation human leukocyte antigenmatched unrelated donor myeloablative stem cell transplantation conditioning regimen patient myeloid malignancy haploidentical stem cell transplantation thiotepa kilograms day day fludarabine month day intravenous infusion busulfan kilograms day human leukocyte antigenmatched unrelated donor stem cell transplantation fludarabine month day intravenous infusion busulfan kilograms day day patient acute lymphoblastic leukemia fludarabine milligrams month day day total body irradiation cgy twice daily day total dose cgy stem cell source bone marrow haploidentical stem cell transplantation peripheral blood stem cell pbsc human leukocyte antigenmatched unrelated transplantation graft versus host disease prophylaxis haploidentical stem cell transplantation cyclophosphamide milligrams kilograms day anti thrombin ciclosporine mycophenolate mmf human leukocyte antigenmatched unrelated donor stem cell transplantation antithymocyte globuline thymogobuline milligrams kilograms total dose kilograms anti thrombin day cyclosporine anti thrombin day mycophenolate mofetil anti thrombin day absence graft versus host disease mycophenolate mofetil stop anti thrombin arm randomization donor haplo matched unrelated donor blood sample biobanking month",
    "STATISTICAL": "justification sample size hypothesize progression free survival without grade iiintravenous infusion acute graft versus host disease without moderate severe chronic graft versus host disease haplo stem cell transplantation versus leukocyte antigen match unrelated donor patient arm overall require demonstrate difference base twosided logrank test power hr required total number event bayesian interim analysis inflate interim analysis anti thrombin midinclusion base bayesian computation stop rule base modeling log hazard ratio hr main endpoint spiegelhalter non informative prior loghr consider terminal analysis observation required number event"
  },
  "SHORTCUT": {
    "TITLE": "efficacy day versus day antibiotic therapy acute pyelonephritis kidney transplant recipient multicentre randomize noninferiority trial",
    "JUSTIFICATION": "infections major cause morbidity mortality solid organ transplant recipient kidney transplant recipient ktr urinary tract infection uti represent acute lymphoblastic leukemia infection acute lymphoblastic leukemia hospitalization sepsis acute transplant pyelonephritis common complication occur patient mainly first year transplantation associate increase risk acute kidney rejection longterm kidney graft dysfunction gram negative bacteria mainly coli account uti ktr infection favor urinary tract modifications defects immunosuppression often recurrent necessitate repeat course antibiotic selective pressure due antibiotic consumption along frequent hospital admission immunosuppression well know risk factor development antibiotic resistant infection multidrug mdr extensively xdr drug resistant enterobacteriaceae include esbl carbapenemaseproducing organism thus increasingly observe transplant unit represent global threat new antibiotic expect next decade one main strategy limit antimicrobial resistance reduce duration antibiotic treatment day course recommend simple acute pyelonephritis apn treat fluoroquinolones parenteral lactams prolong day presence underlie disease anti thrombin risk complication kt team treat patient day recommend american guideline however need extend treatment duration immunosuppressed patient poorly define concept optimal duration treatment apn ktr know patient exclude study urgent need reduce antibiotic consumption population anti thrombin high risk develop infection due resistant pathogen hypothesis daytreatment sufficient cure apn good clinical response treatment ktr effective day",
    "OBJECTIVE": "show dayantibiotic therapy inferior dayantibiotic therapy treatment acute pyelonephritis kidney transplant recipient primary endpoint clinical cure additional antibiotic treatment since end antibiotic treatment main evaluation anti thrombin day clinical cure define fever symptom uti compare arm clinical cure anti thrombin day day microbiological cure anti thrombin day tolerance safety antibiotic hospitalization length stay antibiotic consumption total follow acquisition antibiotic resistant enterobacteriaceae kidney graft function transplant rejection anti thrombin day day total cost evaluate risk factor failure relapse recurrence evaluate efficacy antibiotic treatment anti thrombin end treatment day experimental arm day control group secondary endpoint clinical cure anti thrombin day microbiological cure anti thrombin day incidence relapse recurrence day day incidence adverse event imputable antibiotic treatment kidney function assess accord mdrd modification diet renal disease ckd chronic kidney disease epidemiology collaboration epi hospitalization length stay define delay date inclusion date hospital discharge antibiotic consumption rectal carriage antibiotic resistant enterobacteriaceae anti thrombin inclusion day microbiological cure define sterile urine uropathogene cfu ml urine culture",
    "DESIGN": "multicenter control randomize noninferiority open label clinical trial parallel group day versus day antibiotic treatment randomization stratify date renal transplantation year year center sex potential confounders uti could relapse frequently short duration arm non inferiority demonstrate require new antibiotic treatment patient",
    "INCLUSION CRITERIA": "ktr acute pyelonephritis age year ktr apn define fever without clinical sign symptom uti pyuria white blood cells ml positive urine culture uropathogen cfu ml susceptible empirically administrate antibiotic confirm suspect febrile non urinary bacterial infection urologic renal complication anti thrombin baseline imaging abscess obstruction favourable early response antibiotic treatment hour first dose antibiotic effective causative uropathogen define improvement resolution sign symptom urinary tract infection present anti thrombin diagnosis written inform consent",
    "EXCLUSION CRITERIA": "patients following condition severe complicate condition rapidly progressing disease immediately life threaten illness include limited septic shock current impede respiratory failure acute heart liver failure admission stay intensive care unit anti thrombin baseline obstruction urinary tract renal perinephric prostatic abscess prior inclusion study current participation another interventional study dual antibiotic therapy prophylactic antibiotic cotrimoxazole allow dose aminoside allow randomization first month post transplantation current indwell catheter include bladder catheter ureteral stent percutaneous nephrostomy tube neurogenic bladder enterocystoplasty immunodeficiency immunosuppressive therapy relate kidney transplantation include hematologic favourable early response antibiotic treatment malignancy cancer asplenia neutropenia neutrophils cubic millimeter pregnancy breastfeed hypersensitivity previous severe adverse drug reaction antibiotic therapy unable unwilling judgment investigator comply protocol life expectancy month patient legal guardianship without healthcare coverage homeless patient women childbearing potential use adequate contraception",
    "TREATMENT": "standard day antibiotic duration swab bacterial resistance rectal carriage study followup consultation add standard procedure",
    "STATISTICAL": "sample size group achieve power detect noninferiority margin difference group proportion reference group proportion treatment group proportion assume null hypothesis inferiority power compute case actual treatment group proportion test statistic use onesided test unpooled significance level test"
  },
  "CAMOVID": {
    "TITLE": "camovid multicenter randomize trial evaluate efficacy safety camostat mesylate treatment severe acute respiratory infection ambulatory adult patient",
    "JUSTIFICATION": "since december novel coronavirus call severe acute respiratory severe acute respiratory syndrome coronavirus cause international outbreak respiratory illness describe march confirm case include death report world health organization march severe case france include death spectrum symptomatic infection range mild critical infection severe infected patient require hospitalization require intensive care unit admission diagnosis severe acute respiratory infection relies clinical symptom microbiological testing test severe acute respiratory infection test center use reverse transcription polymerase chain reaction rtpcr nasal swab patient productive cough number investigational agent explore antiviral treatment however date control data support use specific treatment antiviral drug immunomodulatory drug efficacy unknown severe acute respiratory infects human cell binding spike protein membranous aminopeptidase call angiotensin convert enzyme angiotensin converting enzyme among tissue angiotensin convert enzyme expression mainly find pneumocytes enterocytes renal tubular cell podocytes cellular entry severe acute respiratory require protein priming cellular serine protease cellular serine protease entail protein cleavage allow fusion viral cellular membrane murine model severe acute respiratory syndromecoronavirus pneumonia iwatayoshikawa others show cellular serine proteaseko mouse weaken inflammatory cytokine response reduced lung injury control mouse hoffmann others find cellular serine protease inhibitor camostat mesylate block viral entry reduce infection human primary pneumocytes lung cell line severe acute respiratory also show serum convalescent severe acute respiratory syndrome patient crossneutralized severe acute respiratory driven entry another study perform bojkova others show camostat mesylate reduce cytopathogenic effect due severe acute respiratory human colonic cell line camostat mesylate serine protease inhibitor commonly use japan dose milligrams day successfully safely use treat pancreatitisassociated pain postoperative reflux oesophagitis side effect report rare anti thrombin dos nausea diarrhea hypersensitivity case cytopenia less hyperkaliemia abnormal hepatic function less hypothesize camostat mesylate initiate early severe acute respiratory infection reduce viral infection viral cytopathogenic effect block severe acute respiratory entry cell therefore prevent deterioration toward severe form",
    "OBJECTIVE": "objective evaluate efficacy camostat mesylate treatment severe acute respiratory infection highrisk adult patient confirmed require initial hospitalization term hospitalization need day randomization primary endpoint proportion patient hospitalize deterioration world health organization die without hospitalization day day indicative basis criterion hospitalization presence following respiratory rate min anti thrombin rest room air blood pressure mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly hcsp acute lymphoblastic leukemia reason require hospitalization leave anti thrombin discretion physician secondary objective adult patient diagnose laboratory confirm covid require initial hospitalization evaluate impact camostat mesylate compare placebo safety day efficacy term need hospitalization management independent blinded committee review overall clinical improvement anti thrombin day clinical efficacy term intensive care need day clinical efficacy term time hospitalization day clinical efficacy respiratory function day overall survival anti thrombin day randomization patientreported outcome initial symptom day virological serological immunological efficacy day include surrogacy assessment candidate marker day renal complication day liver complication day transmission within household secondary endpoint adverse event aes number aes number serious aes saes investigational medication discontinuation reason day independent endpoint adjudication committeereviewed proportion patient hospitalize day day deterioration independent eac review patient file blind randomize group determine whether hospitalization criterion relate world health organization clinical improvement ordinal scale anti thrombin day oms descriptor score progression scale uninfected clinical virological evidence infection ambulatory limitation activity limitation activity hospitalized hospitalized oxygen therapy mild disease hospitalized oxygen mask nasal prong hospitalized hospitalized oxygen non invasive ventilation severe high flow disease intubation mechanical ventilation mechanical ventilation additional organ support pressor renal replacement therapy extra corporeal membrane oxygenation dead dead admission intensive care unit within day inclusion number day alive without hospitalization day initiation invasive mechanical ventilation severe within day inclusion initiation oxygentherapy within day inclusion overall survival day number day alive without symptom day severe acute respiratory virological assessment anti thrombin day day day day nasal swab droplet quantification severe acute respiratory syndrome rnaemia severe acute respiratory serological assessment anti thrombin day day day day plasma tnfa level anti thrombin day peripheral blood lymphocyte phenotyping telomere length measurement anti thrombin day day day acute kidney failure define anti thrombin least serum creatinine increase deciliter time baseline oliguria kilograms scale within day serum electrolyte estimate glomerular filtration rate anti thrombin day liver transaminase gamma glutamyl transpeptidase alkaline phosphatase anti thrombin day percentage affected individual share household anti thrombin day",
    "DESIGN": "multicenter singleblinded placebocontrolled twoarm parallel randomized phase iii trial additional risk camostat mesylate known side effect digestive nausea vomit diarrhea hypersensitivity cytopenias liver abnormal function hyperkaliemia risk level study patients screen consults participate primary care general practitioner gps emergency department saint louis hospital bichat hospital mondor hospital argenteuil hospital hospital outpatientcovid screening center bichat hospital mondor hospital outpatient consult internal medicine anti thrombin saint louis hospital sickle cell disease inherit red blood cell genetic disorder coordinate referral center anti thrombin henri mondor hospital anti thrombin initial consult patient screen eligibility standard care sample severe acute respiratory rtpcr nasal saliva antigen test upon positive laboratory confirmation information eligible patient world health organization consent participate trial randomly assign one following treatment arm camostat mesylate arm placebo tablets patients blind treatment arm inclusion visit followup visit perform anti thrombin day followup visit include medical interview either person teleconsultation paramedical assessment registered nurse vital sign measurement biological sampling acute lymphoblastic leukemia include patient benefit standard care ambulatory monitoring biological monitoring blood sample serum electrolyte creatinine liver enzyme virological monitoring rt pcr nasal swab day perform locally follow standard practice primary care data collect via webbased standardized electronic case report form case hospitalization hospital report use source data collection general practitioner randomization perform centrally via webbased system ensure allocation concealment use pre specified randomization list base permutation block",
    "INCLUSION CRITERIA": "ambulatory adult highrisk patient laboratory confirm require initial hospitalization patients year old patients increase risk severe belonging one following group age year body mass index kilograms month diabetes hypertension chronic renal failure egfr ml min chronic heart disease asthma chronic obstructive pumonary disease cystic fibrosis chronic liver disease chronic neurological disease solid organ transplant bone marrow transplant sickle cell anemia major thalassemia active currently treat year diagnose cancer active currently treat year diagnose malignant blood disease immunosuppressive treatment observe month laboratory confirm severe acute respiratory infection mild fulfil acute lymphoblastic leukemia following criterion positive severe acute respiratory rtpcr nasal saliva swab sample positive severe acute respiratory antigen test perform within inclusion visit clinical symptom sign consistent severe acute respiratory infection include limited fever upper respiratory tract infection sign digestive sign muscle pain anosmia dysgueusia informed consent participate trial patients must able willing comply study visit procedure",
    "EXCLUSION CRITERIA": "initial need hospitalization management define following severity criterion respiratory rate min anti thrombin rest room air blood pressure mmhg lethargy unconsciousness brutal overall deterioration lethargy elderly recommendation hcsp acute lymphoblastic leukemia reason require immediate hospitalization leave anti thrombin discretion physician pregnancy breastfeed participation another interventional drug trial subject protect law guardianship curatorship absence health insurance known hypersensitivity camostat mesylate known person share household already include study participation another ambulatory interventional study patients complete full severe acute respiratory vaccine immunization procedure less week prior diagnosis last vaccine injection perform less week prior diagnosis",
    "TREATMENT": "camostat mesylate oral administration day every hour day day day placebo tablet follow schedule investigational drug oral medication camostat mesylate placebo",
    "STATISTICAL": "descriptive analysis use either frequency percentage categorical variable median interquartile range quantitative variable number miss value report primary endpoint probability hospitalization within day compare group use twosided test secondary endpoint compare across group use fisher exact test compare probability group wilcoxon rank sum test compare quantitative endpoint acute lymphoblastic leukemia analysis perform intentiontotreat principle twosided significancelevel use comparison secondary endpoint"
  },
  "GREEN": {
    "TITLE": "randomized doubleblind multicenter placebocontrolled efficacy safety study glenzocimab used addon therapy top mechanical thrombectomy acute ischemic stroke glenzocimab reperfusion setting endovascular therapy brain infarction",
    "JUSTIFICATION": "emergent reperfusion main goal acute ischemic stroke therapy ais endovascular therapy evt recommend within hr stroke onset hr follow perfusion image criterion despite major benefit associate mechanical thrombectomy patient remain disabled anti thrombin month reperfusion rate mechanical thrombectomy critical determine functional outcome however complete reperfusion obtain patient due anti thrombin least part erratic embolus noreflow process thrombus composition analysis show platelet rich clot resistant alteplase suggest platelet inhibition represent relevant target improve reperfusion nevertheless currently available molecule recommended anti thrombin acute phase due associate sich risk therefrom still need safe efficient antithrombotic agent administrable anti thrombin acute phase without induce bleeding risk order reduce size clot favour cerebral reperfusion result obtain escalate dose phase actimis study show promising safety data completion five cohort dose progression carry study data safety monitor board member recommend use high dose milligram consolidation phase acute ischemic stroke patient recruit treat high dose experience symptomatic ichs low rate asymptomatic intracranial hemorrhage similar incidence saes susars comparison patient treat low dose milligram placebo consolidation phase conduct additional acute ischemic stroke patient parallelgroup design glenzocimab milligram versus placebo addon reperfusion standard care global safety result combine phase concern incidence symptomatic ichs observe acute lymphoblastic leukemia dose event patient milligram event patient glenzocimab group low one show placebo group events patient incidence nonsymptomatic ichs observe acute lymphoblastic leukemiadose events patient milligram events patient glenzocimab group low compare placebo group events patient kaplanmeier curve show reduced mortality acute lymphoblastic leukemia dose milligram glenzocimab group compare placebo group value respectively twenty death occur phase ib phase strokerelated outcome glenzocimab milligram show favorable safety profile term hemorrhagic event well generally include patient age year population despite concomitant medical condition though power showing efficacy study glenzocimab milligram show real benefit term death rate show decrease proportion patient severe level handicap encouraging result confirm ongoing future study platelet glycoprotein vi gpvi belong immunoglobulin superfamily expression restrict megakaryocyte platelet lineage gpvi key receptor collagen play major role platelet activation platelet recruitment thrombus growth studies also demonstrate gpvi platelet receptor polymerized fibrin interaction contribute thrombus growth reformation furthermore inhibition gpvi impair hemostasis subject genetic acquire gpvi deficiency prone excessively bleed gpvi therefore major target growth stabilization thrombus offer new therapeutic approach high safety profile study aim evaluate efficacy gpvi inhibitor glenzocimab addition endovascular therapy current protocol allow standard care use thrombolysis depend routine practice study site particular simpler mode administration tenecteplase single bolus injection lead many site adopt tenecteplase alternative alteplase acute lymphoblastic leukemia acute ischemic stroke patient",
    "OBJECTIVE": "primary objective evaluate efficacy glenzocimab addition endovascular therapy compare endovascular therapy plus placebo whether associate intravenous thrombolysis functional outcome anti thrombin day secondary objectives evaluate impact glenzocimab addition endovascular therapy compare endovascular therapy whether associate intravenous thrombolysis plus placebo overall survival anti thrombin day year evaluate impact glenzocimab addition endovascular therapy compare endovascular therapy whether associate intravenous thrombolysis plus placebo reperfusion anti thrombin end endovascular therapy early clinical improvement anti thrombin hr symptomatic intracranial haemorrhage anti thrombin hr overall intracranial haemorrhage anti thrombin hr serious adverse event saes suspect unexpected serious adverse reaction susars anti thrombin hr anti thrombin day bleedingrelated event bres anti thrombin hr anti thrombin day quality life anti thrombin day year evaluate cost effectiveness glenzocimab addition endovascular therapy compare endovascular therapy plus placebo primary efficacy endpoint primary efficacy endpoint functional outcome anti thrombin day assess modified mrs anti thrombin day day secondary endpoints efficacy favourable functional outcome define mrs score anti thrombin day proportion patient severe handicap mrs anti thrombin day overall survival anti thrombin year early reperfusion outcome stroke volume brain imaging anti thrombin hr reperfusion anti thrombin end mechanical thrombectomy procedure assess etici score early neurological improvement nihss anti thrombin hr euroqol anti thrombin day year safety incidence symptomatic nonsymptomatic intracranial hemorrhages ich anti thrombin hr incidence symptomatic intracranial hemorrhages ich anti thrombin hr incidence nonsymptomatic intracranial hemorrhages ich anti thrombin hr incidence nature severity adverse events saes susars bleedingrelated events bres treatmentemergent adverse events teaes anti thrombin hr anti thrombin day discharge day day incidence bleedingrelated event anti thrombin day antiglenzocimab antibody ada anti thrombin baseline predose anti thrombin month anti thrombin least patient cost effectiveness cost per qualityadjusted life year quality adjust life year gain use glenzocimab addition endovascular therapy cost per patient mrs score gain use glenzocimab addition endovascular therapy",
    "DESIGN": "national multicenter prospective randomize ratio parallel group doubleblinded placebo control phase ii iii study category predefined risk burden due administration study treatment highlight one year followup phone call schedule endovascular therapy standard care patient endovascular therapy add research nevertheless risk adverse event link endovascular therapy monitor glenzocimab give association endovascular therapy thromboembolic event bleeding infection risk relate endovascular therapy thromboembolic event bleeding hemorrhagic transformation infection mechanical complication like arterial perforation risk relate femoral arterial puncture anaesthesia include respectively groin hematoma without arterial hypotension first femoral arterial puncture second anaesthesia arterial hypotension anaphylactic shock aesthetic drug glenzocimab administration start prior endovascular therapy start",
    "INCLUSION CRITERIA": "patients clinical diagnosis acute ischemic stroke large cerebral vessel occlusion lvo hr symptom onset patient see last time well eligible endovascular therapy base perfusion imaging time window hour age year old year significant prestroke disability prestroke mrs must equal indication endovascular therapy within timewindow hr participant treat without intravenous thrombolysis present clinico radiological mismatch define aspect score occlusion cervical intracranial internal carotid artery ica proximal middle cerebral artery mca month month magnetic resonance angiography mra possible ct angiography cta informed consent sign patient inform consent sign family members trustworthy person condition allow express consent write per situation urgently absence family members trustworthy person patient enrol consent participate research request soon condition patient allow consent postmenopausal woman define menses month without alternative medical cause wocbp highly effective birth control method place achieve failure rate less per year last anti thrombin least month investigational medicinal product administration birth control method may consider highly effective wocbp include combine estrogen progestogen containing hormonal contraception associate inhibition ovulation intravaginal transdermal progestogenonly hormonal contraception associate inhibition ovulation injectable implantable intrauterine device iud intrauterine hormonereleasing system ius bilateral tubal occlusion vasectomized partner birth control method may consider highly effective men last month investigational medicinal product administration include vasectomy use condom combine highly effective birth control method wocb partner please note hormonal contraception risk factor thromboembolic event attention call reconsider intrathecal injection pass acute stroke phase women childbearing potential wocbp must negative serum urine pregnancy test anti thrombin baseline women childbearing potential fertile define woman follow menarche become post menopausal unless permanently sterile undergone hysterectomy bilateral salpingectomy bilateral oophorectomy affiliation social security health insurance",
    "EXCLUSION CRITERIA": "contraindications endovascular therapy contraindication contrast agent preexisting neurologic psychiatric disease mrs unknown symptom onset last seem well hour patients need immediate dual antiplatelet therapy administration significant mass effect midline shift confirm ct magnetic resonance imaging gastrointestinal urinary tract hemorrhage previous day patient intracranial haemorrhage known platelet count cubic millimeter pregnant breastfeed woman known hypersensitivity glenzocimab excipients known severe renal insufficiency grades glomerular filtration rate min participation another interventional clinical trial within day prior inclusion persons deprive liberty judicial administrative decision person subject psychiatric care section et person admit health social institution purpose research adults subject legal protection measure patient family patient unable give opinion express inability return protocol visit patient receive anticoagulant heparin within hour elevated aptt greater upper limit normal laboratory current use oral anticoagulant ex warfarin inr current use direct thrombin inhibitor direct factor xa inhibitor already mention nonauthorized concomitant treatment patient world health organization already receive another humanized fragment monoclonal antibody suspicion hypersensitivity withdrawal consent patient wish withdraw trial persons deprive liberty judicial administrative decision person subject psychiatric care section person admit health social institution purpose research",
    "TREATMENT": "nonauthorized concomitant treatments patients receive experimental therapy day study participation addition aforementioned exclusion criterion patient receive dual antiplatelet therapy dapt require intra extracranial stent thrombolysis tenecteplase glenzocimab infusion authorized concomitant treatments acute lymphoblastic leukemia symptomatic treatment use routinely disease relate symptom allow acute lymphoblastic leukemia patient involve trial specific treatment adverse event also permit thrombolysis alteplase antiplatelet monotherapy allow glenzocimab start soon possible addition alteplase details acute lymphoblastic leukemia treatment procedure must record electronic case report form glenzocimab acticor biotech formulate intravenous infusion administration sterile product millimeter sodium citrate millimeter sodium chloride buffer anti thrombin hydrogen ion concentration intrathecal injection supply clinical trial use vial contain ml drug product anti thrombin concentration milligrams ml vial contain milligram glenzocimab two vial mg glenzocimab administer concomitantly eligible patient total daily dose placebo glenzocimab nacl acticor biotech intravenous infusion administration intrathecal injection supply clinical trial use vial ml two vial placebo glenzocimab administer concomitantly eligible patient endovascular therapy glenzocimab placebo glenzocimab",
    "STATISTICAL": "interim analysis perform patient enrolment achieve patient control group consider distribution mrs calculate sample patient would yield power detect treatment effect associate consider twosided value plan interim analysis anti thrombin patient brien fleming scheme increase sample size first interim analysis consider statistically significant value final analysis consider statistically significant value interim analysis also allow stop futility futility bound calculate use brien fleming type beta spending inclusion patient statistic wald test value associate favour placebo group trial terminate futility"
  },
  "TEOREM": {
    "TITLE": "multicenter randomize doubleblind clinical trial assess benefit adherent invasive coli eradication adult ileal ileocolonic crohn disease",
    "JUSTIFICATION": "current medical treatment crohn disease cd consist immunosuppressive drug therapy corticosteroid azathioprine methotrexate antitnf monoclonal antibody agent control symptom crohn disease patient withdrawal lead disease relapse also associate serious side effect infection lymphoma cancer liver toxicity antitnf monoclonal antibody efficient cost prohibitive moreover year roughly responder antitnf become refractory treatment often become tolerized drug future crohn disease drug small molecule biologics antagonize proinflammatory cytokine gut homing lymphocyte yet similar safety issue immunosuppressive agent currently use current therapeutic algorithm crohn disease take account site inflammation composition intestinal microbiota moreover dysregulated intestinal immunity overproduction proinflammatory cytokine component crohn disease pathophysiology intestinal microbiota abnormal play important role pathogenesis crohn disease coli specie adhesive invasive property adherentinvasive coli aiec describe ileal mucosa patient crohn disease adherent invasive escherichia coli find patient ileal crohn disease control role adherent invasive escherichia coli crohn disease thoroughly investigate several laboratory around world show adherent invasive escherichia coli proinflammatory could play important role intestinal inflammation associate crohn disease intrathecal injection may important therapeutic target randomized trial propose novel approach treatment crohn disease intrathecal injection individualize patient colonize adherent invasive escherichia coli world health organization prescribe fdaapproved antibiotic show active bacteria vitro treatment discontinue week hope obtain clinical endoscopic remission patient world health organization randomize experimental arm trial successful intrathecal injection first kind facilitate new era clinical research patient crohn disease concomitant infection adherent invasive escherichia coli",
    "OBJECTIVE": "primary objective trial assess whether treatment ciprofloxacin rifaximin superior placebo obtain endoscopic remission adherent invasive escherichia colicolonized patient ileal crohn disease without involvement caecum right colon primary endpoint overall response anti thrombin week use centralize anonymous blind reading ileocolonoscopies overall response define segmental response anti thrombin least one segment crohn disease endoscopic index severity anti thrombin baseline increase crohn disease endoscopic index severity segment crohn disease endoscopic index severity segment segmental response segment crohn disease endoscopic index severity anti thrombin baseline define case isolated aphtoid ileitis colitis decrease lesion otherwise either decrease surface ulceration either deep superficial loss deep ulceration present anti thrombin inclusion increase superficial ulcerated surface secondary objective cid test correlation endoscopic remission adherent invasive escherichia coli eradication anti thrombin week cid assess evolution endoscopic lesion anti thrombin week cid assess rate clinical remission without steroid antitnf surgery anti thrombin week patient whose adherent invasive escherichia coli eradicate patient world health organization reach primary endpoint cid assess rate biological remission study cid assess side effect experimental placebo group secondary endpoint endoscopic remission anti thrombin week assess centralized reading ileocolonoscopies define crohn disease endoscopic index severity acute lymphoblastic leukemia segment cid mean variation segmental crohn disease endoscopic index severity anti thrombin week centralized reading ileocolonoscopies cid complete endoscopic remission anti thrombin week centralized reading ileocolonoscopies define crohn disease endoscopic index severity acute lymphoblastic leukemia segment cid ulceration anti thrombin week cid clinical remission define cdai without steroid antitnf resection surgery crohn disease anti thrombin week cid biological remission defined reactive protein serum level milligrams fecal calprotectin anti thrombin week cid side effect",
    "DESIGN": "phase ii clinical trial intrathecal injection multicentre prospective randomize doubleblind placebocontrolled adaptive clinical trial two parallel arm cid experimental arm oral ciprofloxacin milligram twice day oral rifaximin milligram twice day week cid control arm placebo ciprofloxacin twice day placebo rifaximin twice day week cid ciprofloxacin rifaximin placebo cid additional biopsy include biopsy ileum right colon adherent invasive escherichia coli search biological collection biopsy rectum adherent invasive escherichia coli search ileocolonoscopy cid ileocolonoscopy anti thrombin week include additional biopsy cid study fecal microbiota use pcr cid screening fecal adherent invasive escherichia coli lpf+ risk patient crohn disease screen realize biopsy check infection adherent invasive escherichia coli bacteria evaluable patient anticipate patient infect bacterium respond eligibility criterion study include study randomize experimental arm rifaximin+ciprofloxacin control double placebo arm ileocolonoscopy biopsy make anti thrombin week research adherent invasive escherichia coli infection thereby assess eradication bacteria take study drug placebo bacterial infection also seek stool sample",
    "INCLUSION CRITERIA": "crohn disease adult patient infect adherent invasive escherichia coli cid age year cid crohn disease ileum without involvement caecum right colon cid severe lesion confine within ileum right colon define segmental crohn disease endoscopic index severity ileum right colon segmental crohn disease endoscopic index severity segment transverse leave colon rectum cid informed consent participate study cid crohn disease either clinically inactive active severe cdai cid patient clinically active disease cdai prescription steroid treatment budesonide prednisone prednisolone independently entry study note patient without previous surgery crohn disease without crohn disease anal lesion without drain fistula seton enrol cid patients clinically active disease cdai world health organization respond budesonide initial dose milligrams prednisone prednisolone initial dose milligrams point decrease cdai pre inclusion inclusion visit patient clinically inactive disease cdai cid patients colonize adherent invasive escherichia coli initial ileal biopsy",
    "EXCLUSION CRITERIA": "cid ileal stenosis cross endoscope cid infliximab treatment receive less week preinclusion study cid methotrexate azathioprine start less three month preinclusion cid adalimumab treatment receive less week preinclusion study cid vedolizumab treatment receive less week preinclusion study cid hypersensitivity ciprofloxacin quinolones excipients cellulose microcrystalline crospovidone maize starch magnesium stearate silica colloidal anhydrous hypromellose titanium dioxide macrogol cid treatment tizanidine probenecid theophylline xanthine derivatives phenytoin oral anticoagulant ropinirole cid hypersensitivity rifaximin excipients sodium starch glycolate type glycerol distearate colloidal anhydrous silica talc microcrystalline cellulose hypromellose titanium dioxide disodium edentate propylene glycol red iron oxide cid previous extensive ileal surgery meter measure pathology surgical report cid short bowel syndrome cid need intestinal resection fistula abscess intestinal obstruction cid renal failure creatinine clearance ml min cid liver failure factor cid past history epilepsy cid health insurance cid pregnant lactate woman cid refusal double effective contraception ie hormonal barrier method intrauterine device barrier method double barrier method highly effective method contraception hormonal contraceptive combine oral contraceptive patch vaginal ring injectables implant intrauterine device iud intrauterine system ius vasectomy tubal ligation effective method barrier method contraception male condom female condom cervical cap diaphragm contraceptive sponge cid patients already include biomedical research observational study registry cohort",
    "TREATMENT": "association two antibiotic cid oral ciprofloxacin tablet milligram every hour week cid oral rifaximin tablet mg milligram every hour week association two placebo placebo correspond antibiotic manufacture tablet appearance intrathecal injection administrate every hour week",
    "STATISTICAL": "data analyze intenttotreat basis trial base upon adaptive scheme allow reestimation required number included patient sample size reestimation ssr design take account uncertainty endoscopic remission rate anti thrombin week placebo arm thus one interim unblind statistical analysis perform one half patient successively enrol primary endpoint analysis concern comparison main end point ie percentage endoscopic remission group compare use chisquare test unless validity violate fisher exact use secondary endpoint analyze whole sample size reach"
  },
  "SALMA": {
    "TITLE": "phase ii clinical trial assessing combination sulfasalazine standard care induction therapy newly diagnosed acute myeloid leukemias aml patients year old salma study",
    "JUSTIFICATION": "nonfavorable acute myeloid leukemia old patient unmet medical need acute myeloid leukemia aml heterogeneous clonal myeloid neoplasm abnormal proliferation impaired differentiation hematopoietic stem myeloid progenitor cell impede normal hematopoiesis despite significant progress make understand acute myeloid leukemia oncogenesis past decade disease remain devastate new case every year europe fiveyear overall survival median age anti thrombin diagnosis acute myeloid leukemia year cure rate patient old improve recent decades standard care soc newly diagnose acute myeloid leukemia include cytarabine anthracyclin combination follow repeated course high dose cytarabine without allogeneic hematopoietic stem cell transplantation hsct recent advance soc approach include addition multikinase inhibitor midostaurine induction consolidation patient gene mutations maintenance oral azacitidine completion induction without consolidation patient ineligible transplantation use liposomal formulation cytarabinedaunorubicin combination instead conventional patient highrisk features patient old adequate performance status comorbidities deem fit intensive chemotherapy induction course combine day idarubicin ida continuous cytarabine arac infusion induce complete remission cr complete remission incomplete platelet recovery case nonfavorable cytogenetics recent advance supportive care patient notably progress antifungal armementarium lower toxicity induction course early date ed rate within range however despite high complete remission low ed rate median eventfree survival efs remain month patient year old nonfavorable cytogenetics owe frequent relapses improving antileukemic efficacy induction course contribute good long term prognosis patients however modification induction course must rely additional toxicity limit risk ed jeopardize postremission therapy repositioning drug excellent safety profile appear promising approach regard nonfavorable risk acute myeloid leukemia old patient represent unmet medical need novel option improve efficacy induction course thus necessary end induction measurable residual disease predict longterm outcome old acute myeloid leukemia patient treat intensively standardization molecular technique development multiparameter flow cytometry mfc assay make intrathecal injection possible assess measurable residual disease mrd anti thrombin different time point course acute myeloid leukemia therapy virtually acute lymphoblastic leukemia patients old patient treat match related donor measure anti thrombin end induction course eoi time point base transcript patient mfc assay leukemia aberrant immunophenotypes laip leukemic stem cell lsc method predict longterm outcome patient young role eoi match related donor assess relative transcript level also well established although data scarcer old patients altogether eoi match related donor appear relevant surrogate endpoint estimate efficacy alternative induction regimen old acute myeloid leukemia patient non favorable cytogenetics cystine import targetable vulnerability acute myeloid leukemia metabolic rewiring leukemic cell increasingly recognize targetable vulnerability acute myeloid leukemia leukemic stem cells lscs endow increased quiescence chemoresistance specific metabolic profile may instance underpin remarkable efficacy azacitidinevenetoclax combination patient ineligible lscs notably rely high level cysteine amino acid fuel glutathione synthesis maintain low level reactive oxygen species ros chemical depletion intracellular pool cysteine precursor cystine preclinical antileukemic activity vitro query transcriptional profile multiple acute myeloid leukemia patient cohort identify close correlation expression stemness program active cysteine metabolism pathway querying crispr screen conduct cancer cell line reveal specific dependence acute myeloid leukemia cell line cysteine metabolism among gene belong pathway high expression identify bear poor prognostic relevance acute myeloid leukemia cohort genetic silencing reduce viability colony formation acute myeloid leukemia cell line cysteine dependent fashion encode xct neutral amino acid antiporter import cystine glutamate xct antiport broadly express acute myeloid leukemia cell line three chemical inhibitor xct different chemical backbone include erastin carboxyphenylglycine cpg sulfasalazine ssz highly concordant cystinedependent anti leukemic activity panel acute myeloid leukemia cell line data suggest cystine import could represent targetable vulnerability acute myeloid leukemia sulfasalazine repurposed inhibit cystine import acute myeloid leukemia sulfasalazine ssz broadly available well tolerate antiinflammatory medicine approve treatment ulcerative colitis rheumatoid arthritis intact ssz metabolite acid sulfapyridine competitively inhibit xct ssz thus ideal candidate drug repurposing acute myeloid leukemia vitro ssz inhibit viability primary acute myeloid leukemia specimen increase sensitivity compare hematopoietic stem progenitor cell heathly donor ssz half maximal inhibitory concentration acute myeloid leukemia versus healthy cell ssz concentration range peak plasma concentration ssz healthy individuals also significantly reduce vitro longterm culture initiate potential primary acute myeloid leukemia sample finally twicedaily intraperitoneal administration single agent ssz significantly reduce leukemic burden two distinct acute myeloid leukemia patientderived xenograft pdx model finally compassionate administration oral ssz anti thrombin period patient advanced refractory acute myeloid leukemia result transient clinically meaningful cytoreduction mechanistic study find ssz induce global metabolic rewiring cysteine onecarbon pathway result glutathione depletion rosdependent cell death partly correspond ferroptosis total protein expression correlate ssz activity thus ssz repurposed inhibit cystine import impair leukemic viability acute myeloid leukemia sulfasalazine improve efficacy anthracycline cytarabine combination chemotherapy preclinical acute myeloid leukemia model two distinct acute myeloid leukemia cell line anthracycline daunorubicin dnr identify among panel acute myeloid leukemia drug one top synergism combine ssz observation may underpin rosinducing potential anthracyclins cohort primary acute myeloid leukemia sample addition ssz anti thrombin low concentration mimic trough concentration healthy donors significantly increase antileukemic activity combination daunorubicine arac total leukemic bulk lscs nichelike ex vivo drug screen platform combine stromal coculture hypoxia plasmalike medium finally addition ssz regimen combine day anthracycline adriamycin day cytarabine maximally tolerate regimen immunocompromised nogexl mouse far decrease leukemic burden pdx model significantly prolong survival adriamycincytarabine chemotherapy alone pardieu et al manuscript preparation data present anti thrombin annual meeting european hematology association data support clinical evaluation addition ssz acute myeloid leukemia addition sulfasalazine standard care chemotherapy manageable repurposing ssz inhibit xct investigate alone standard care chemotherapy solid tumors first study conduct singleagent ssz highly debilitated patient high grade progress glioblastoma terminate prematurely base lack efficacy trial toxicity ssz anti thrombin low dos mostly neurological suggestive tumorspecific poor tolerability possibly cause drug related peritumoral edema conversely another doseescalation study single agent ssz day patient advanced gastric cancer identify mtd grade anorexia dlt grade aes include elevated aspartate amino transferase bilirubin fatigue nausea vomit hyponatremia grade hematological grade non hematological adverse event trial median number ssz cycle range mean relative dose intensity dose level anti thrombin mtd finally phase study combine ssz thrice daily day cisplatin pemetrexed day ssz cycle conduct patient advanced nonsmallcell lung cancer mtd gram per day recommended phase dose gram per day dlts include grade elevation aspartate amino transferase alanine amino transferase aminotransferase level hypotension pneumonitis anorexia overall combination appear manageable promise activity note term overall response rate progressionfree survival compare historical controls antitumor activity ssz continue explore solid tumor nct overall addition ssz chemotherapy appear feasible carefully design dose escalation phase trial collectively preclinical finding provide strong rationale clinical evaluation addition sulfasalazine standard care induction regimen nonfavorable acute myeloid leukemia patient old year purpose phase study evaluate safety feasibility strategy provide preliminary signal efficacy identify potential biomarkers",
    "OBJECTIVE": "primary objective phase assess safety characterize doselimiting toxicity dlts identify maximal tolerate dose mtd anticipate recommended phase ii dose combination sulfasalazine ssz idarubicin ida cytarabine arac patient newly diagnose nonfavorable acute myeloid leukemia probability dlt exceed anti thrombin end induction cycle eoi idaarac ssz treatment day phase ii assess preliminarily antileukemia efficacy combination idaarac ssz mainly phase ii newly diagnose nonfavorable acute myeloid leukemia reference historical data complete remission rate define eln guideline match related donor centralize flow cytometry primary endpoint phase documentation dose escalation dose limit toxicity dlt identification maximal tolerate dose mtd anticipate recommended phase ii dose dose limiting toxicity dlt dlt define safety observation period correspond induction cycle idaarac ssz day events occur onset second treatment cycle salvage consolidation consider dlts following event consider dlt unless event attribute investigator clearly identifiable cause underlying illness disease progression concurrent illness concomitant medication prolonged myelosuppression define grade neutropenia thrombocytopenia day start therapy later without evidence leukemia assess bone marrow aspiration biopsy grade hemorrhage day grade non hematological toxicity day exception grade infection grade fever neutropenia nb grade infection grade fever neutropenia consider dlts grade nausea vomit diarrhea manage grade within hour symptomatic treatment grade asymptomatic liver enzymes elevation improve grade within hour onset grade tumor lysis syndrome resolve within hour onset medical treatment maximal tolerated dose mtd mtd define target dlt rate assess dose escalation phase continual reassessment method recommended phase ii dose anticipate mtd however intrathecal injection could equal one dose level low mtd intrathecal injection determine interaction data safety monitor board insofar dose level validate pharmacokinetic pharmacodynamic study efficacy preliminary data phase ii match related donornegative complete response anti thrombin eoi day per eln criteria complete response define complete remission complete remission cri cr incomplete hematologic recovery mean complete remission platelet count absolute neutrophil count crh cr partial hematologic recovery mean complete remission fulfil complete remission cri peripheral blood count criterion platelet count absolute neutrophil count match related donornegativity define bone marrow fcm match related donor anti thrombin eoi note base match related donor bone marrow pb carry exploratory endpoint patient secondary objective characterize pharmacokinetics pk pharmacodynamics pd ssz ida arac administer combination dose escalation phase confirm intrathecal injection phase trial describe phase trial response leukemia treatment survival patient month end induction eoi visit document far phase ii trial safety profile confirm ida arac ssz combination secondary endpoint assessment safety safety outcome measure assess continuously study monitoring ecgs clinical laboratory value integral safety assessment adverse event ae treatment emergent adverse event teae treatmentrelated teaes evaluate accord national cancer institute common terminology criterion adverse event version serious adverse event define per protocol accord european medicine agency international conference harmonization criterion causality relationship experimental treatment assess investigator frequency duration maximal severity teae treatmentrelated teaes teaes lead treatment discontinuation serious adverse event saes death document phase ii trial patients follow acute lymphoblastic leukemia treatment relate teaes return grade baseline deem irreversible investigator pharmacokinetics assess ssz metabolite ida metabolite arac allow determine pharmacokinetic model ssz anti thrombin early late time point confirm lack interaction ssz ida arac pharmacokinetic plan detail section pharmacokinetic pk study conduct patient recruit phase part trial assess pharmacokinetics sulfasalazine main metabolite asa mesalazine sulfapyridine mostly involve adverse event pharmacokinetic perform anti thrombin day pharmacokinetic profiling cytarabine idarubicine idarubicinol anti thrombin day confirm lack drugdrug interaction following pharmacokinetic parameter determine use non compartmental analysis winnonlin pharsight corporation maximum plasma concentration cmax maximum plasma concentration time tmax area plasma concentration time curve auc clearance cl mean residence time mrt distribution volume vd pharmacokinetic analysis dose ssz administer orally together ml water patient fast overnight meal permit blood sample anti thrombin drug give blood sample obtain day predose anti thrombin first ssz dose day predose anti thrombin start ida injection day predose anti thrombin first ssz dose blood sample collect heparinized tube immediately collection tube invert several time keep anti thrombin approximately centrifugation tube centrifuge min anti thrombin anti thrombin within min collection separate plasma plasma separate aliquot polypropylene screwcap tube place anti thrombin analysis acute lymphoblastic leukemia sample label patient identification study identification sample number actual date time anti thrombin sample collect plasma concentration ssz metabolite determine validated ultraperformance liquid chromatography tandem mass spectrometry method pharmacodynamics pharmacodynamic assay aim anti thrombin demonstrate ros induction upon ssz exposure relative pretreatment level peripheral blood repeat bone marrow aspiration shorttime period unethical blood sample pharmacodynamic day effect ssz alone day combined effect ssz ida arac pharmacodynamic assay include plasma level malondialdehyde mda glutathione reduced oxidized two robust biomarkers oxidative stress biomarkers previously involve ferroptosis ssz mode action preclinical result assess acute lymphoblastic leukemia patient anti thrombin acute lymphoblastic leukemia time point regardless white blood cell count percentage circulate leukemic cell patient circulate leukemic cell ros level peripheral blood mononuclear cell flow cytometry antileukemia activity response anti thrombin eoi assessment day per eln criteria morphologic leukemiafree state mlfs blastic criterion response bone marrow aspirate absence extramedullary disease requirement hematologic recovery partial response pr absence circulate blast absence extramedullary disease decrease bone marrow blast percentage decrease pretreatment bone marrow blast percentage anti thrombin least overall response rate orr define complete remission cri crh mlfs professor rate primary refractory disease define patient lack criterion define response cr cri crh mlfs pr anti thrombin eoi assessment exclude patient death aplasia death due indeterminate cause define per eln criterion death aplasia death due indeterminate cause define per eln criterion survival assessment anti thrombin month eventfree survival efs event define non achievement hematologic response include complete remission cri crh hematologic relapse progressive disease initiation subsequent antileukemic therapy exclude hydroxyurea deaths prior one event mention reasons subsequent therapy initiation include intolerance resistance hematologic relapse unsatisfactory match related donor evolution type intensive lessintensive best supportive care frame clinical trial offlabel compassionate use prospectively record duration response dor relapse free survival rfs overall survival os incidence subsequent allogeneic hematopoietic stem cell transplantation overall respond patient specifically apart specific mention acute lymphoblastic leukemia hematological endpoint define accord late recommendation european leukemia network eln currently eln recommendation",
    "DESIGN": "phase iii open label multicenter clinical trial subsequent phase phase doseescalation design use survival continual reassessment method identify maximal tolerate dose mtd recommend phase ii dose phase ii extension anti thrombin choose data safety monitoring board dsmb confirm safety preliminarily document clinical efficacy",
    "INCLUSION CRITERIA": "patients year recently diagnose non favorable acute myeloid leukemia eligible intensive chemotherapy patients age year old newly diagnose acute myeloid leukemia short course treatment hydroxyurea steroid acceptable patients acute myeloid leukemia secondary antecedent myelodysplastic syndrome mds myeloproliferative neoplasm mpn eligible therapyrelated acute myeloid leukemia eligible intensive chemotherapy accord investigator opinion multiparameter flow cytometry anti thrombin screen compatible mfcbased matched relate donor monitoring accord eln criterion phase ii eastern cooperative oncology group performance status aspartate amino transferase alanine amino transferase upper limit normal uln total direct serum bilirubin upper limit normal unless consider due leukemia estimated glomerular filtration rate gfr ml min accord mdrd equation written inform consent obtain prior screening procedure eligible national health insurance france",
    "EXCLUSION CRITERIA": "myeloid sarcoma bone marrow blast patient world health organization receive vaccine injection live attenuated virus last three week proven central nervous system leukemic involvement favorable risk cytogenetics inv pmlrara cbfb fusion transcript presence tkd mandate treatment midostaurin concurrent therapy cytotoxic drug within week first study dose hydroxyurea control blood count permit patients plan receive myelodysplasiarelated change therapyrelated acute myeloid leukemia previous treatment sulfasalazine last year ongoing treatment sulfasalazine aminosalicylic acid ulcerative colitis inflammatory rheumatism history allergic reaction sulfonylarylamines sulfonamide salicylate sulfasalazine excipients history allergic reaction idarubicin idarubicin excipients history allergic reaction cytarabine cytarabine excipients known glucose dehydrogenase deficiency known acute intermittent porphyria porphyria variegata uncontrolled systemic fungal bacterial viral infection define ongoing signs symptoms relate infection without improvement despite appropriate treatment uncontrolled active malignant disease within prior month exclude myelodysplastic syndrome cutaneous basal cell carcinoma insitu carcinoma cervix breast local malignancy excise known human immunodeficiency virus hiv infection human immunodeficiency virusrelated malignancy clinically active hepatitis hepatitis infection inability swallow known malabsorption syndrome condition may significantly impair absorption oral study medication participation another therapeutic interventional clinical study within day enrolment administration therapy consider investigational use nonapproved indication context research investigation within drug halflives whichever longer prior first dose study drug previous treatment anthracyclines contraindication use anthracyclines include uncontrolled coronary disease severe renal failure severe hepatic failure recent myocardial infarction symptomatic congestive heart failure severe cardiomyopathy significant arrhythmia estimate investigator lvef assess echocardiography muga anterior treatment idarubicin anthracyclines anthracenediones beyond maximum cumulative dose contraindication use cytarabine include degenerative toxic encephalopathy condition require treatment digoxin concurrent severe uncontrolled medical condition could compromise participation study females world health organization pregnant breastfeeding man whose sexual partner woman childbearing potential unwillingness inability man woman use highly effective contraceptive method entire treatment period anti thrombin least month completion protocol treatment highly effective contraception method include combine estrogen progestogen containing hormonal method associate inhibition ovulation intrauterine device surgical sterilization include bilateral tubal occlusion partner vasectomy sexual abstinence preferred usual lifestyle patient male patient must freeze donate sperm start anti thrombin screening throughout treatment period month administration final dose study medication heterosexually active woman childbearing potential unwillingness inability use highly effective contraceptive method describe entire treatment period anti thrombin least month administration final dose study medication women regard childbearing potential postmenopausal least year without menses surgically sterile least month enrollment female patient must donate retrieve use ovum time screening throughout treatment period week administration final dose study medication female patient must agree breastfeed time screening throughout protocol period life day administration final dose study medication adults subject legal protection order unable give consent persons deprive freedom judicial administrative decision person hospitalize without consent virtue article world health organization subject provision article",
    "TREATMENT": "investigational medicinal product sulfasalazine approve market year treatment inflammatory disease tablets dose anti thrombin milligram oral route water anti thrombin follow dose level dl test phase twice day hence day tid hence day tid hence day tid hence day tid hence day tid hence day four time per day hence day anti thrombin acute lymphoblastic leukemia dose level patient receive standard care idaarac backbone consider auxiliary medicinal product clinical trial consist drug dose administration days time idarubicin intravenous infusion day milligrams month day cytarabine continuousintravenous day milligrams month day two drug body area cap month dose escalation conduct accord survival continual reassessment method number patient assessed anti thrombin dose level depend safety observation patients hospitalize induction course anti thrombin least day achievement neutrophil count thereafter discharge accord judgment investigator medical condition allow intrathecal injection acute lymphoblastic leukemia nonhematological treatmentemergent aes resolve grade patients adequate intravenous infusion hydration ssz exposure following eoi visit patient continue follow treatment relate teaes day follow end ssz exposure postinduction therapy relapse survival month eoi visit treatments beyond eoi leave clinician choice may include consolidation chemotherapy oral maintenance allogeneic stem cell transplantation alfa guideline postremission therapy acute myeloid leukemia patient year old treat intensively provide protocol appendices minimal followup transplantation relapse death additional year study exit undertaken none interventions add study limit following procedure systematic assessment troponin serum anti thrombin day day day eoi additional electrocardiogram anti thrombin day day eoi pharmacokinetic pharmacodynamic exam peripheral blood sample plasma serum cell centralized match related donor peripheral blood bone marrow aspirate fcm",
    "STATISTICAL": "phase bayesian adaptive dose escalation design use trial objective intrathecal injection allow sequential monitoring data trial use acute lymphoblastic leukemia current evidence straightforward inference safety efficacy decision making select evaluate optimal dose design rely bayesian continual reassessment method crm phase cohort size maximum sample size patients target dlt rate definition mtd within eoi observation window timetoevent extension crm survcrm design use depend anticipated accrual rate compare dlt observation window allow accounting rightcensored toxicity observation sequential mtd estimation dose assignment process phase ii phase complete provide estimate mtd determine base data safety monitor board recommendation accord safety data efficacy signal phase inclusion criterion phase addition additional inclusion criterion laip detect anti thrombin baseline fcm assessment relate primary endpoint complete response negative match related donor based historical data rate match related donornegative complete response study population estimate anti thrombin british data spanish pethema data british data freeman pers comm simon minimax twostage design use phase simon optimal twostage designs phase ii clinical trials controlled clinical trials phase ii assessment require maximum total subject decide whether proportion responding less equal great equal anti thrombin first stage among first included patient number response low equal phase ii stop early futility otherwise enrollment continue maximum patient overall number response become hypothesis reject target type error rate total number response less hypothesis reject target type ii error rate note phase patient treat anti thrombin choice include analysis assessable fcm match related donor presence laip"
  },
  "ERYTHROSIM": {
    "TITLE": "randomized prospective trial evaluate efficacy monoclonal antibody isatuximab treatment pcra major abo mismatch allogeneic hematopoietic stem cell transplantation",
    "JUSTIFICATION": "quarter allogeneic hematopoietic stem cell transplantation perform situation major abo mismatch expose patient risk immunological pure red cell aplasia prca transplant pcra transplant define anemia low reticulocyte count day despite good leucocyte platelet engraftment full donor chimerism associate persistence recipient hemagglutinins antia antib antibody bone marrow evaluation perform show erythroid hypoplasia red blood cell transfusion necessary every two week remission lead impaired quality life anemia repeat hospitalization iron overload need iron chelation therapy treatments currently use inefficient anti monoclonal antibody epo steroid plasma exchange proteasome inhibitor anti thrombin risk severe acute graft versus host disease donor lymphocytes infusion pure red cell aplasia demonstrate associate persistence recipient plasma cell monoclonal antibody target plasma cell secrete hemagglutinins responsible pcra promising treatment case report literature support rapid sustain efficacy chapuy nejm bathini amjhematol rautenberg bmt salas others eur haematol preethi others blood cell mol dis yates others transfusion prospective randomized evaluation efficacy safety context necessary",
    "OBJECTIVE": "main objective efficacy treatment pure red cell aplasia isatuximab allogeneic hematopoietic stem cell transplant compare supportive care control group reduction pure red cell aplasia resolution time day primary endpoint time obtention transfusion independence patient pure red cell aplasia time interval randomization correspond month posttransplant resolution pure red cell aplasia date resolution reticulocytopenia treat anticrohn disease monoclonal antibody isatuximab secondary objective evaluate two arm term clinical biological outcome reduction red blood cell transfusion need isatuximab evolution iron overload adverse event relate isatuximab context allogeneic stem cell transplantation ctcadverse event grade group month posttransplant quality life functional repercussion chronic anemia iterative transfusion iron overload anti thrombin day month randomization overall survival without relapse anti thrombin month month month month posttransplant identify prognostic factor spontaneous resolution pure red cell aplasia major abo mismatch day month type donor cell stem cell condition regimen occurrence acute chronic graft versus host disease discontinuation immunosuppression evaluate interest followup group hemagglutinins compare arm term ofcost effectiveness cost isatuximab treatment hospitalization transfusion support chelation treatment secondary endpoints number red blood cell transfusion randomization ferritin level anti thrombin month month month posttransplant adverse event ctcadverse event grade randomization quality life questionnaire eortc anti thrombin day day month month month month posttransplant factors associate spontaneous resolution pure red cell aplasia day month posttransplant antibody level anti anti titer anti thrombin day day month posttransplant anti thrombin visit day day day month month month post randomization number day hospitalization transfusion support chelation treatment",
    "DESIGN": "randomized prospective phase ii clinical trial assess efficacy safety antibody isatuximab patient persistent pure red cell aplasia anti thrombin month allogeneic hematopoietic stem cell transplantation including patient anti thrombin day transplant help define factor associate unresolved pure red cell aplasia month thus identify patient could benefit isatuximab treatment earlier future interim analysis perform observation event primary endpoint trial major risk add clinical trial experimental treatment adverse event expect occurrence reaction infusion fever chill asthenia nausea desaturation bronchospasm grade diarrhea grade occurrence pneumonia hypogammaglobulinemia",
    "INCLUSION CRITERIA": "allogeneic stem cell transplant recipient year age old pure red cell aplasia patients aged year old receive allogeneic hematopoietic stem cell transplantation condition major abo mismatch pcra define persistent red blood cell transfusion dependence anti thrombin day posttransplant reticulocyte count giga liter despite full donor chimerism good leucocyte platelet recovery relapse progression underlie disease contraception method must prescribe acute lymphoblastic leukemia duration clinical trial use effective contraceptive method treatment woman childbearing age continue abstinence heterosexual intercourse accept man study treatment period anti thrombin least month last dose study treatment refrain donate sperm period health insurance coverage sign write informed consent parent patient age less",
    "EXCLUSION CRITERIA": "patients aged year relapse underlie disease leucocyte chimerism pure red cell aplasia relate parvovirus infection positive blood pcr known human immunodeficiency virus+ hepatitis active infection active tuberculosis pregnancy hcg positive breastfeeding patient receive recombinant human erythropoietin patient receive proteasome inhibitor bortezomib example patient receive thrombopoietin receptor agonist artpo patient receive plasma plasmapheresis exchange transplant planned receive investigational drug within day halflives investigational drug whichever long clinically significant uncontrolled medical condition investigator opinion would expose excessive risk patient may interfere compliance interpretation study result hypersensitivity active substance history intolerance steroid mannitol pregelatinized starch sodium stearyl fumarate histidine base hydrochloride salt arginine hydrochloride poloxamer sucrose component study therapy amenable premedication steroid blocker would prohibit treatment agent world health organization debilitating medical psychiatric illness tutorship curatorship world health organization understand informed consent optimal treatment followup",
    "TREATMENT": "isatuximab treatment anti thrombin dose milligrams kilograms intravenous route first injection isatuximab perform anti thrombin randomization month day second injection may perform anti thrombin day reticulocyte third anti thrombin day reticulocyte patients assess day day day day month month month month randomization treatment supportive care allow premedication infusion isatuximab followup hemagglutinin antibody titer anti anti titer kinetic immunologic reconstitution pcr hbv donor recipient history hbv infection",
    "STATISTICAL": "bilateral logrank test consider sample size randomized patient experimental group median transfusion independence month control group median transfusion independence month achieve power alpha risk considering patient include anti thrombin day randomize anti thrombin month patient include interim analysis perform observation event primary endpoint trial"
  },
  "EQUAALL01": {
    "TITLE": "evaluation longterm health status quality life adult survivor philadelphianegative acute lymphoblastic leukemia lymphoma treat intensive pediatric pediatricinspiredinspired protocol",
    "JUSTIFICATION": "overall survival adult patient philadelphia negative acute lymphoblastic leukemia lymphoma dramatically improve use full pediatric pediatric inspired protocol aim reduce risk relapse adopt intensive chemotherapeutical schedule approach lead global improvement overall survival survival whatever patient age responsible excess treatmentrelated mortality patient old year patient pediatric longitudinal study point long term leukemia survivor increase risk develop specific adverse event like dysmetabolic syndrome obesity decrease fertility organ dysfunction osseous event impaired cognitive function study aim evaluate impact term longterm event quality life adult patient receive intensified therapeutic approach recently implement adult cooperative group",
    "OBJECTIVE": "evaluate prevalence late effect adult patient treat year ago acute lymphoblastic leukemia intensified pediatric inspire protocol expose patient increase cumulative dos chemotherapy central nervous system irradiation allogeneic transplant total body irradiationbased regimen boost irradiation central nevous system primary endpoint thus define prevalence adverse event include metabolic trouble dysmetabolic syndrome dyslipidemia diabetes osseous event osteoporosis cardiac vascular trouble neurologic trouble lung dysfunction endocrinal trouble ophthalmological trouble fertility disorder secondary neoplasia evaluate quality life patient correlate prevalence late effect quality life status previous social situation previous medical condition acute lymphoblastic leukemia treatment scheme include administration protocol phase delayed intensification maintenance centralnervous system irradiation allogeneic stem cell transplantation graftversus host disease occurrence elaborate riskadapted recommendation longterm followup adult patient treat acute lymphoblastic leukemia reinforced therapeutic strategy secondary endpoint thus prevalence metabolic trouble dysmetabolic syndrome dyslipidemia diabetes prevalence osseous event osteoporosis prevalence cardiac vascular trouble prevalence neurologic trouble prevalence lung dysfunction prevalence endocrinal trouble quality life prevalence ophthalmological trouble prevalence fertility disorder prevalence secondary neoplasia",
    "DESIGN": "multicenter crosssectional interventional minimal risk constraint human research study hormons test antral follicle count us questionnaire none",
    "INCLUSION CRITERIA": "adult patient age anti thrombin diagnosis treat ten year ago acute lymphoblastic leukemia lymphoma patient philadelphianegative acute lymphoblastic leukemia treat accord pediatriclike pediatricinspired protocol graall fralle without allogeneic transplant patients old year old less year old anti thrombin diagnosis patient followup first complete remission year patient world health organization give inform signed consent baseline examination",
    "EXCLUSION CRITERIA": "patient world health organization experience acute lymphoblastic leukemia relapse within past year philadelphia positive acute lymphoblastic leukemia patient",
    "TREATMENT": "none",
    "STATISTICAL": "analysis handle left data truncation give patient world health organization survive able include study approximately patient include among august considering patient alive anti thrombin last followup opportunity include patient treated accord protocol inclusion success approximately patient recruit allow assess prevalence trouble ci width anti thrombin assume prevalence assume prevalence detection anti thrombin respectively also allow reach statistical power anti thrombin least detect anti thrombin"
  },
  "EFRAIM-II": {
    "TITLE": "empirical steroid antifungal immunocompromised patient acute respiratory failure undetermined etiology multicenter doubleblind randomize control trial",
    "JUSTIFICATION": "acute respiratory failure arf lead reason intensive care unit admission immunocompromised patient failure identify arf etiology associate increased mechanical ventilation mortality rate confirm large efraim study publish undetermined arf etiology affect patient anti thrombin day patient anti thrombin day patient overall associate case fatality vs patient lung biopsy autopsy finding patient invasive fungal infection steroid sensitive affection organize pneumonia non infectious interstitial involvement drugrelated pulmonary toxicity lung infiltration underlying disease lymphoma carcinomatous lymphangitis systemic vasculitis connective tissue disease etc lead etiology study evaluate survival benefit empirical steroid antifungal immunocompromised patient arf undetermined etiology",
    "OBJECTIVE": "main objective reduce mortality immunocompromised patient arf undetermined etiology anti thrombin intervention would evaluate impact steroid isavuconazole day intensive care unit discharge primary endpoint mortality anti thrombin day secondary study objective evaluate early empirical therapy affect intensive care unit hospital mortality whether steroid increase proportion patient intensive care unit acquire microbiologically document bacterial infection within month follow randomization proportion patient invasive fungal infection within month follow randomization proportion patient hsv vzv cmv reactivation within month follow randomization whether steroid complicate severe hypokalemia meq newly acquire decompensated diabetes severe newly acquire hypertension whether isavuconazole favor emergence infection aspergillus mucorale specie decreased sensitivity isavuconazole occurrence candida infection steroid affect psychiatric symptom posttraumatic stress disorder anxiety depression anti thrombin month early intervention improve quality life anti thrombin month secondary end point intensive care unit mortality hospital mortality day mortality proportion patient intensive care unit acquire microbiologically document bacterial infection proportion patient invasive fungal infection within month follow randomization proportion patient hsv vzv cmv reactivation within month follow randomization occurrence severe hypokalemia meq decompensated diabetes severe newly acquire hypertension emergence aspergillus specie decreased sensitivity isavuconazole incidence candida infection incidence posttraumatic stress disorder iesr anxiety depression anti thrombin month hads quality life anti thrombin month",
    "DESIGN": "multicenter doubleblind randomize controlled trial base factorial design risk",
    "INCLUSION CRITERIA": "immunecompromised patient acute respiratory failure arf undetermined etiology either intervention steroids antifungal associate improved survival acute respiratory failure arf lead reason intensive care unit admission immunocompromised patient admission age year year immunosuppressive drug solid organ transplant solid tumor hematological malignancy primary immune deficiency intensive care unit admission acute respiratory failure define respiratory distress tachypnea respiratory rate min cyanosis labour breathing need standard oxygen maintain peripheral oxygen saturation pulse oxymeter high flow oxygen noninvasive invasive mechanical ventilation establish arf etiology hour hospital admission patient admit anti thrombin least hour anti thrombin hospital informed consent sign patient informed consent sign family members trustworthy person condition allow express consent write per situation urgently absence family members trustworthy person patient enrol consent participate research request soon condition patient allow consent note patient pneumocystis pneumonia include give treatment require use neither antifungal drug corticosteroid",
    "EXCLUSION CRITERIA": "patient world health organization improve enough discharge intensive care unit inclusion documented invasive fungal infection require antifungal therapy patient needing receive prophylactic empirical antifungal treatment clinical care patient receive corticoid therapy palliative care comfort measure intubate dni resuscitate dnr patient include pregnant breastfeeding social security coverage known hypersensitivity isavuconazole excipients cresemba specialty treatment ketoconazole ritonavir inductor short qt syndrome patient family history short qt syndrome liver insufficiency stage moribund patient participation another interventional research acute respiratory failure person deprive liberty person subject psychiatric care patient enforced hospitalization adults legal protection unable give consent isolated hi",
    "TREATMENT": "methylprednisolone give day anti thrombin dose milligrams kilograms day three day recommend fibrosing pneumonitis deeply hypoxemic patient day daily dose taper milligrams kilograms day day follow milligrams kilograms day day day isavuconazole give anti thrombin dose milligram every hour day administration daily day intensive care unit discharge event occur first patients one arm receive isavuconazole methylprednisolone whith establish interaction investigator must check smpc acute lymphoblastic leukemia need information available placebo methylprednisolone placebo isavuconazole none",
    "STATISTICAL": "interim analysis perform recruitment patient death whichever occur first"
  },
  "RECORDS": {
    "TITLE": "rapid recognition corticosteroid resistant sensitive sepsis",
    "JUSTIFICATION": "world health organization estimate yearly million people develop sepsis die aprocchs phase placebocontrolled trial demonstrate absolute reduction sepsis mortality hydrocortisone+fludrocortisone number factor may positively negatively impact corticosteroid cs benefit sepsis",
    "OBJECTIVE": "compare effect hydrocortisone plus fludrocortisone vs placebo composite death persistent organ dysfunction define continued dependency mechanical ventilation new renal replacement therapy vasopressor assess anti thrombin day intensive care unit icu adult different biological profile immune response corticosteroid bioactivity primary endpoint death persistent organ dysfunction define continued dependency mechanical ventilation renal replacement therapy vasopressor score sequential organ failure assessment score score day mortality healthrelated quality life anti thrombin month daily organ function sofa score day daily secondary infection day daily blood urinary level glucose sodium potassium day daily gastroduodenal bleeding day daily cognitive function muscle strength day day",
    "DESIGN": "multiarms parallel blind randomize control trial precede runin observational period observational phase runin period interventional phase webbased randomization system available eligible patient randomize ratio corticoseroids match placebo use permuted block undisclosed variable size stratify randomization site biomarkers enroll total anti thrombin patient adaptative trial sites expect enroll anti thrombin least patient per month enrol evaluable patient per arm study power detect absolute risk reduction correspond relative risk reduction",
    "INCLUSION CRITERIA": "interventional phase patients year old admitted intensive care unit proven suspected infection main diagnosis community acquire pneumonia relate sepsis vasopressor dependency norepinephrine epinephrine vasopressin dopamine phenylephrine septic shock singer vasopressor maintain mean blood pressure anti thrombin least mmhg lactate level mmol acute respiratory distress syndrome ards ranieri acute onset within one week apparent clinical insult progression respiratory syndrome bilateral opacity chest image explain pulmonary pathology pleural effusion atelectasis nodule etc evidence heart failure volume overload millimeter hg peep cm patient world health organization sign informed write consent whevener able consent ascent representant whenever present anti thrombin time screen inclusion patients world health organization test one records specific biomarkers circi endocan gilz dualspecificity phosphatase monocyte distribution width lymphopenia transcriptomic endotype pcr pcr influenza pcr respiratory virus cutaneous vasoconstrictor response glucocorticoids affiliation social security system universal health coverage couverture maladie universelle cmu patients guardianship curatorship include patients case simple emergency legal definition include patients manage covid biological sample available",
    "EXCLUSION CRITERIA": "interventional phase pregnancy expected death withdrawal lifesustaining treatment within hour previously enrol study formal indication corticosteroid accord recent international guideline vaccination live virus within past month hypersensitivity hydrocortisone fludrocortisone microsined betamethasone dipropionate excipients spc women childbearing potential use contraception nursing woman patient include stratum applicable apply cream infect ulcerated area",
    "TREATMENT": "",
    "STATISTICAL": ""
  },
  "KAPKEY": {
    "TITLE": "phase ii multicentric study pembrolizumab classic endemic kaposi sarcoma",
    "JUSTIFICATION": "classic endemic kaposi sarcoma ks lymphangioproliferations associate human herpes virus treatment poorly codify chemotherapies give anti thrombin best transient response interferon response frequent drug often poorly tolerate elderly patient therefore new therapy need classic ks represent ideal model evaluate new drug since patient receive concomitant immunosuppressive regimen antiviral therapy pembrolizumab monoclonal antibody recently show improve survival several solid tumor ks data available role axis significant expression pleural effusion lymphoma ks sample recently report experience classical endemic ks support role pathway expression subpopulation cell also nk cell peripheral blood cell patient expression tumor cell ks lesion study evaluate benefit safety profile pembrolizumab classic endemic ks",
    "OBJECTIVE": "simon optimal design main objective assess whether pembrolizumab clinically inactive partial+complete response probability truly active partial+complete response probability classic endemic kaposi sarcoma ks use simon stage optimal design primary endpoint best overall response rate borr define occurrence complete response partial response follow actg criterion record start treatment month beginning specific systemic therapy ks intrathecal injection occur month extension phase event truly active conclusion simon optimal design extension phase would perform evaluate element extension phase would perform far evaluate efficacy pembrolizumab setting additional patient include obtain accurate estimate treatment effect month primary endpoint extension phase best overall response rate accord actg criterion record start treatment month start ksspecific systemic therapy intrathecal injection occur month secondary objective simon stage optimal design extension stage assess safety profile pembrolizumab classic endemic kaposi sarcoma characterize efficacy pembrolizumab relate pharmacodynamics assessment secondary endpoint efficacy endpoint different aspect clinical response evaluate best overall response rate accord pga criterion month beginning specific systemic therapy ks intrathecal injection occur month response rate anti thrombin month month month month month month accord actg pga criterion response rate number lesion anti thrombin month month month month month anti thrombin best response define follow pga response rate size target lesion anti thrombin month month month month month atbest response define follow pga response rate tumor infiltration target lesion anti thrombin month month month month andmonth anti thrombin best response define follow pga response rate lymphedema circumference scale absence painful ooze anti thrombin month month month month anti thrombin best response define follow pga time response define time first response record start treatment time progression define time start treatment progression acute lymphoblastic leukemia patient response rate accord actg pga criterion anti thrombin month month month month extension stage duration response define time start response progression patient achieve partial complete response quality life follow dlqi kaposi anti thrombin baseline cycle cycle cycle every month eot early study termination anti thrombin month safety endpoint safety assess term drug toxicity evaluate clinic laboratory parameter score accord common terminology criteria adverse events ctcae version acute lymphoblastic leukemia study",
    "DESIGN": "uncontrolled openlabel multicentric phase ii study pharmacodynamic evaluation base tumor tissue collection cutaneous biopsy correlative blood sample quality life assessment dlqi kaposi risk simon optimal design acute lymphoblastic leukemia patient receive pembrolizumab milligram intraveinously every week assess drug safety efficacy patients continue treatment month unless experience disease progression unacceptable adverse event treatment period extend month case study delay due adverse event resolve extension stage acute lymphoblastic leukemia patient include extension stage receive pembrolizumab milligram intraveinously every week assess drug safety efficacy patients continue treatment month unless experience disease progression unacceptable adverse event confirm complete response occur month treatment lasting anti thrombin least cycle pembolizumab",
    "INCLUSION CRITERIA": "adult classic endemic kaposi sarcoma patient meet following criterion may include study simon optimal design extension stage classic endemic histologically confirm ks progressive disease ks lesion involve one limb segment involvement body surface ks anti thrombin least lesion ks anti thrombin least cutaneous tumor available repeated pharmacodynamics evaluation willing provide tissue cutaneous biopsy tumor lesion anti thrombin least week washout acute lymphoblastic leukemia ks specific therapy include chemotherapy immunotherapy provide write informed consent prior performance study specific procedure year age day sign informed consent performance status eastern cooperative oncology group performance scale demonstrate adequate organ function hematological absolute neutrophil count anc cubic millimeter platelets cubic millimeter hemoglobin deciliter renal calculated creatinine clearance min use mdrd formula hepatic aspartate amino transferase sgot alanine amino transferase sgpt serum total bilirubin direct bilirubin upper limit normal participant total bilirubin level female subject childbearing potential negative serum pregnancy within hour prior receive first dose study medication health insurance",
    "EXCLUSION CRITERIA": "patient meet following criterion must include study simon optimal design extension stage know history organ transplantation receive systemic steroid therapy form immunosuppressive therapy within day prior first dose trial treatment ks symptomatic visceral involvement unless therapeutic option available previously receive treatment antipharmacodynamic antibody antibody drug specifically target tcell costimulation immune checkpoint pathway uncontrolled infection human immunodeficiency virus hbv hcv infection diagnosis immunodeficiency relate result chronic infection patients known hepatitis hepbsag+ world health organization control infection serum hepatitis virus dna pcr limit detection receive antiviral therapy hepatitis permit patients controlled infection must undergo periodic monitoring hbv dna per local standard must remain antiviral therapy anti thrombin least month beyond last dose investigational study drug patients world health organization know hcv ab+ world health organization control infection undetectable hcv rna pcr either spontaneously response successful prior course antihcv therapy permit active infection require systemic therapy hypersensitivity pembrolizumab keytruda excipients prior anticancer monoclonal antibody mab within last week world health organization recover grade anti thrombin selection adverse event due agent administer week earlier prior chemotherapy target small molecule therapy radiation therapy within week half life prior study day world health organization recover grade anti thrombin selection adverse event due previously administer agent note participant grade neuropathy exception criterion may qualify study note subject receive major surgery must recover adequately toxicity complication intervention prior start therapy know additional malignancy progress require active treatment exceptions include basal cell carcinoma skin squamous cell carcinoma skin undergo potentially curative therapy situ cervical cancer active autoimmune disease require systemic treatment past year use disease modify agent corticosteroid immunosuppressive drug replacement therapy eg thyroxine insulin physiologic corticosteroid replacement therapy adrenal pituitary insufficiency etc consider form systemic treatment patients vitiligo type diabetes mellitus hypothyroidism psoriasis non require systemic treatment permit enroll active noninfectious pneumonitis know history noninfectious pneumonitis require steroid severe pulmonary disease hypoxia know psychiatric substance abuse disorder would interfere cooperation requirement trial pregnant breastfeeding expect conceive father child within projected duration trial willing use adequate contraceptive method study visit throughout study period day last dose study therapy receive live vaccine within day prior first dose trial treatment participate trial currently participate participate study investigational agent within week first dose treatment history current evidence condition therapy laboratory abnormality might confound result trial interfere subject participation full duration trial best interest subject participate opinion treating investigator patient guardianship curatorship",
    "TREATMENT": "simon optimal design phase development phase ii treatment pembrolizumab route intraveinous infusion dose regimen milligram per infusion every week duration treatment month cycle extension stage phase development phase ii treatment pembrolizumab route intraveinous infusion dose regimen milligram per infusion every week duration treatment month cycle confirmed complete response define simon stage optimal design intrathecal injection occur month month pembrolizumab treatment cycle last cycle complete response observe confirm anti thrombin least month pembrolizumab stop na",
    "STATISTICAL": "simon optimal design multicenter uncontrolled phase ii study base stage phase ii simon optimal design sample size computation base statistical hypothesis regard treatment effect main endpoint best overall response rate type error statistical power sample size compute assess whether drug inactive partial+complete response probability truly active partial+complete response probability based hypothesis intrathecal injection compute patient would accrue stage necessary inclusion stop month inclusion wait primary endpoint trial stop conclusion inactivity response observe stage otherwise additional patient recruit total sample size patient anti thrombin least response indicate drug effective enough case observe response end stage stage directly begin withouit stop extension stage patient include extension stage consider main analysis expected complete best overall response rate complete response partial response anti thrombin month would obtain ci interval complete response rate equal secondary analysis perform patient include extension stage plus patient include simon stage optimal design expect best overall response rate anti thrombin month analysis reach ci interval complete response rate equal"
  },
  "UPFRONT-MUD": {
    "TITLE": "upfront matched unrelated donor transplantation pediatric patients idiopathic aplastic anemia phase ii feasibility study",
    "JUSTIFICATION": "pediatric patient idiopathic aplastic anemia aa respond well adult immunosuppressive therapy ist longterm risk relapse ciclosporine dependence clonal evolution high uk investigator report estimate failurefree survival ffs ist contrast successive child world health organization receive match unrelated donor mud hematopoietic stem cell transplantation hsct excellent estimate ffs forty child previously fail ist excellent result upfront fully match unrelated donor mud hematopoietic stem cell transplantation hsct become attractive firstline option uk cohort child idiopathic aplastic anemia thus receive matched unrelated donor hscts firstline therapy receive ist prior hsct results excellent low graft versus host disease rate death idiopathic pneumonia cohort compare historical matched control transplant outcomes upfront unrelated cohort hematopoietic stem cell transplantation similar matched related donor hematopoietic stem cell transplantation superior ist unrelated hematopoietic stem cell transplantation postist failure since many investigator offer front match unrelated donor hematopoietic stem cell transplantation pediatric patient worldwide however result treat extreme caution design retrospective excellent front match unrelated donor hematopoietic stem cell transplantation may arise use alemtuzumab conditioning regimen alemtuzumab easily available worldwide formal quality oflife assessment moreover strategy highly dependent donor identification caucasian patient high likelihood mud donor availability thus know many patient eventually receive hematopoietic stem cell transplantation risk infections complications cause unexpected donor delay cancellation prospective trial thus urgently need address feasibility procedure term timing delay offer matched unrelated donor hsct condition regimen nothing know use regimen non alemtuzumabbased setting",
    "OBJECTIVE": "main objective realize upfront hematopoietic stem cell transplantation within month match unrelated donor identify primary endpoint upfront match unrelated donor hematopoietic stem cell transplantation effectively perform within month day identification match unrelated donor secondary objective clinical biological outcome graft failure graft versus host disease gvhd progression free survival relapse nonrelapse mortality overall survival quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment anti thrombin day first day consecutive day neutrophils giga liter first day consecutive day platelet absolute number neutrophil platelet anti thrombin month month month month month day last platelet red blood cell transfusion acute graft versus host disease incidence anti thrombin month month date maximum grading first line treatment response steroid treatment course case steroid refractory gvhd chronic graft versus host disease incidence date grade anti thrombin month relapse incidence anti thrombin month month progression free survival anti thrombin month month incidence cmv ebv infection anti thrombin month severe infection ctae grade month month month month nonrelapse mortality month overall survival anti thrombin month quality life questionnaire pedqql anti thrombin inclusion post transplantation month month month month chimerism anti thrombin month month month month immune reconstitution analyze nk regulatory cell level peripheral blood anti thrombin month month month month posttransplantation ferritin level anti thrombin month month month month",
    "DESIGN": "phase ii multicenter national prospective cohort study major risk donor cancellation thus prolong period aplasia anti thrombin risk infection hemorrhage decide include interim analysis indication upfront matched unrelated donor hematopoietic stem cell transplantation context idiopathic aplastic anemia pediatric patient",
    "INCLUSION CRITERIA": "pediatric patient age less year idiopathic aplastic anemia indication treatment severe aplastic anemia moderate aplastic anemia require transfusion patients age old pediatric patient age less year idiopathi aplastic anemia indication treatment severe aplastic anemia moderate aplastic anemia require transfusion good probability human leukocyte match unrelated donor available patient need anti thrombin least match unrelated donor identify within book bmdw bone marrow donors worldwide use easy match software include usual criterion allostem cell transplantation lansky year karnofsky year severe uncontrolled infection adequate organ function aspartate amino transferase alanineaminotransferase total bilirubin creatinine clearance high normal value age health insurance coverage beneficiaire ou ayant droit contraception method young girl men childbearing age must prescribe acute lymphoblastic leukemia duration research parents read understand information note sign write informed consent patient agreement depend age seek typical presentation aplastic anemia posthepatitis nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius man absence permanent sterilization condom",
    "EXCLUSION CRITERIA": "patients match related donor available uncontrolled infection seropositivity human immunodeficiency virus active hepatitis define positive pcr hbv hcv associate hepatic cytolysis renal failure creatinine clearance high normal value age pregnant hcg positive breastfeeding heart failure accord new york heart association ii preexisting acute hemorrhagic cystitis urinary tract obstruction yellow fever vaccine within month transplantation world health organization debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup depend age understanding contraindication treatment use research",
    "TREATMENT": "conditioning regimen patient age less year fludarabine month day day day cyclophosphamide milligrams kilograms day day day antithymocyte globulin milligrams kilograms day day day patient age fludarabine month day day day cyclophosphamide milligrams kilograms day day day anti thymocyte globulin milligrams kilograms day day day total body irradiation gray day however intrathecal injection allow realize total body irradiation fludarabine local planning reason total body irradiation day antithymocyte globulin day et day fludarabine day day total body irradiation day fludarabine day day cyclophosphamide day stem cell source bone marrow minimal target dose nucleated cells kilograms recipient ideal body weight graft less rich minimum target dose intrathecal injection administer anti thrombin discretion physician graft versus host disease prophylaxis graft versus host disease prophylaxis consist association cyclosporine plus methotrexate mtx intravenous infusion cyclosporine milligrams kilograms anti thrombin day year post hematopoietic stem cell transplantation plus methotrexate mtx intravenous infusion month give subsequently anti thrombin milligrams month day prevention ebv reactivation rituximab month intravenous infusion anti thrombin post hematopoietic stem cell transplantation infusion rituximab precede administration anti pyretic antihistaminic paracetamol diphenhydramine additional test specific examination",
    "STATISTICAL": "justification sample size use simon minimax twostage phase design demonstrate success primary outcome patient consider treatment valuable option less consider unacceptable interim analysis interim analysis perform inclusion trial terminate receive upfront match unrelated donor hematopoietic stem cell transplantation study end conclusion inefficacy otherwise inclusion pursue total patient conclude treatment efficacy anti thrombin least success identify among patient"
  },
  "HAPLORESCUE": {
    "TITLE": "haploidentical allogeneic hematopoietic stem cell transplantation posttransplant cyclophosphamide rescue patient graft failure phase ii study",
    "JUSTIFICATION": "prognosis patient graft failure dismal transplantation sole option longterm survival currently consensus concern therapeutic option patient primary secondary within day posttransplantation graft failure find new donor within acceptable delay challenge literature poor subject overall survival patient anti thrombin year situation thus represent today challenging unmet medical need recently haploidentical haplo relate donor stem cell transplantation haplosct improve dramatically outcomes use tcell replete graft administration posttransplantation cyclophosphamide ptcy target alloreactive cell generate early human leukocyte antigen mismatch transplant spar regulatory cell leave unaffected nondividing hematopoietic stem cell standard posttransplant immune suppression calcineurin inhibitor cni mycophenolate mofetil group retransplanted patient world health organization experience two consecutive graft failure successfully manage third haplostem cell transplantation son use ptcy retrospectively collect analyze data primary graft failure patient transplant center behalf french society stem cell transplantation cell therapy sfgmtc study population consist mainly patient primary secondary within day posttransplantation graft failure world health organization underwent haplostem cell transplantation receive ptcy graft versushostdisease prophylaxis overall survival suggest approach might valid option particular poor clinical situation need validation phase ii multicenter national prospective cohort study",
    "OBJECTIVE": "main objective rescue patient graft failure first allogeneic stem cell transplantation allosct use haplostem cell transplantation ptcy primary endpoint overall survival rate compare historical control anti thrombin year secondary objective graft failure graft versus host disease progression free survival relapse nonrelapse mortality interval first allostem cell transplantation rescue haplostem cell transplantation quality life chimerism immune reconstitution secondary endpoints graft failure incidence neutrophils platelet engraftment anti thrombin day consecutive day neutrophile giga liter consecutive day platelet absolute number neutrophil platelet anti thrombin month month month month month day last platelet red blood cell transfusion use growth factor poor hematopoietic reconstitution acute graft versus host disease incidence anti thrombin month month date maximum grading first line treatment response steroid treatment course case steroid refractory graft versus host disease chronic graft versus host disease incidence date grade anti thrombin month relapse incidence anti thrombin month month progression free survival anti thrombin month month incidence cmv ebv infection anti thrombin month severe infection ctae grade month month month month nonrelapse mortality month month month month incidence cardiac toxicity anti thrombin month overall survival anti thrombin month interval first allostem cell transplantation rescue haplostem cell transplantation quality life questionnaire eortc anti thrombin inclusion posttransplantation month month month chimerism anti thrombin month month immune reconstitution analyze nk regulatory cell level peripheral blood anti thrombin month month month month month posttransplantation",
    "DESIGN": "phase ii multicenter national prospective cohort study risks relate stem cell transplantation haplo donor arm cardiac toxicity hemorrhagic cystitis particularly monitor",
    "INCLUSION CRITERIA": "patients year old acute lymphoblastic leukemia hematological disease suffer primary secondary within day posttransplantation graft failure allogeneic hematopoietic stem cell transplantation allosct patients aged year old acute lymphoblastic leukemia hematological disease suffering primary secondary within day posttransplantation graft failure allostem cell transplantation usual criterion allostem cell transplantation eastern cooperative oncology group severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanineaminotransferase total bilirubin creatinine clearance min identification haploidentical donor brother sister parent adult child cousin absence donor specific antibody dsa detect patient mfi antibody direct towards distinct haplotype donor recipient health insurance coverage beneficiaire ou ayant droit understand informed consent optimal treatment followup contraception method must prescribe acute lymphoblastic leukemia duration research women men childbearing age must use contraceptive method within month month last dose cyclophosphamide respectively sign write informed consent parent patient age less",
    "EXCLUSION CRITERIA": "patients aged year old uncontrolled infection seropositivity human immunodeficiency virus active hepatitis define positive pcr hbv hcv associate hepatic cytolysis yellow fever vaccine within month transplantation cancer last year except basal cell carcinoma skin situ carcinoma cervix uncontrolled coronary insufficiency recent myocardial infarction month current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction heart failure accord new york heart association ii preexisting acute hemorrhagic cystitis renal failure creatinine clearance min urinary tract obstruction pregnant hcg positive breastfeeding world health organization debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup tutorship curatorship contraindications treatment use research",
    "TREATMENT": "conditioning regimen fludarabine month day day day cyclophosphamide milligrams kilograms day anti thrombin day day except patient world health organization receive total dose cyclophosphamide kilograms first bone marrow transplantation total body irradiation gray day source stem cell source peripheral blood stem cell minimal target dose cells kilograms recipient graft versus host disease prophylaxis cyclophosphamide milligrams kilograms day anti thrombin ciclosporine residual mycophenolate mofetyl anti thrombin kilograms day prevention ebv reactivation rituximab month anti thrombin post haplostem cell transplantation",
    "STATISTICAL": "overall survival estimate use kaplan maier estimator confidences intervals comparaison historical control anti thrombin year perform use onesample logrank test propose standardization uveitis nomenclature others terminal analysis perform followup last included patient"
  },
  "FIRST": {
    "TITLE": "upfront related donor transplantation patients myelodysplastic syndrome phase trial",
    "JUSTIFICATION": "three recent prospective transplant transplant study conclude advantage overall survival transplantation patient high international prognostic scoring system risk significant kroger study prospective randomize trial assess pretransplant therapy mds patient yet information extract recent study french study patient donor receive hematopoietic stem cell transplantation previously treat hypomethylating agent hma trend good survival patient achieve complete remission pre graft therapy hr high risk death unresponsiveness patient transform acute myeloid leukemia hr nakamura study patient donor transplant previously treat hma multivariable cox model overall survival os leukemiafree survival show excess risk patient treat hma moreover responder still high risk mortality compare patient world health organization receive pregraft therapy hr german study aim initiate azacytidine anti thrombin inclusion transplant patient cycle donor among register patient initiated lose pregraft therapy allocation donor nodonor arm different reason include death cycle patient donor arm transplant multivariable analysis show remission status influence overall survival previous clinical trial thus suggest substantial number patient plan transplantation transplant nowadays evidence hma benefit hematopoietic stem cell transplantation clearly identify phase study aim assess feasibility upfront hematopoietic stem cell transplantation patient high risk mds order increase probability transplant achieve subsequent remission good survival",
    "OBJECTIVE": "primary objective demonstrate improved diseasefree survival dfs patient undergo upfront transplantation related donor compare historical prospective cohort primary endpoint diseasefree survival year transplantation secondary objectives clinical biological outcome overall survival os incidence transplantation donor identification incidence transformation acute myeloid leukemia relapse progression engraftment acute late rejection nonrelapse mortality nrm acute graft versus host disease chronic graft versus host disease severe infection ctae grade cardiac event grade ctae secondary endpoints overall survival anti thrombin month inclusion transplantation non relapse relate mortality anti thrombin month transplantation cumulative incidence transformation acute myeloid leukemia inclusion anti thrombin month acute graft versus host disease grade anti thrombin day post hematopoietic stem cell transplantation chronic graft versus host disease grade anti thrombin year post hematopoietic stem cell transplantation engraftment anti thrombin month hematological recovery donor chimerism graft failure acute late rejection non engraftment anti thrombin year post hematopoietic stem cell transplantation severe infection ctae grade anti thrombin month month month month cardiac event grade ctae anti thrombin month month",
    "DESIGN": "study use uncontrolled phase openlabel design increase level incidence external comparison secondly perform demethylating agent use individual patient data prospective cohort robin ii use aggregate data publish randomized clinical trial kroger excess risk burden add study compare human leukocyte antigen match sibling haploidentical routine transplantation standard care transplantation risk level study",
    "INCLUSION CRITERIA": "adults year old patient mds diagnosis transplantation indicate related donor identify inclusion criterion age year human leukocyte antigen match sibling donor familial haploidentical donor identify disease fulfill anti thrombin least one following criterion high risk accord classical international prognostic scoring system risk marrow fibrosis grade poor risk cytogenetics accord international prognostic scoring system classify high high risk accord international prognostic scoring system mds therapyrelated neoplasm usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group severe uncontrolled infection cardiac function compatible high dose cyclophosphamide lvf adequate organ function aspartate amino transferase alanineaminotransferase total bilirubin creatinine clearance ml min accord cockroft formula case transplantation haploidentical donor absence donor specific antibody dsa detect patient mfi antibody direct towards distinct haplotype donor recipient recommend ebmt guideline contraception method must prescribe woman childbearing age acute lymphoblastic leukemia study cyclophosphamide use effective contraceptive method men acute lymphoblastic leukemia participation study health insurance coverage write informed consent sign nb authorized contraceptive method woman childbearing age absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable implantable progestogenonly hormonal contraception intrauterine device iud intrauterine hormonal releasing system ius bilateral tubal occlusion vasectomised partner sexual abstinence preferred usual lifestyle participant man absence permanent sterilization sexual abstinence condom",
    "EXCLUSION CRITERIA": "exclusion criterion marrow blast anti thrombin time inclusion mds excess blast mutation recurrent genetic abnormality relate acute myeloid leukemia chemotherapy aml like intensive chemotherapy demethylating agent treat mds anti thrombin current stage disponibility unrelated donor mud absence genoidentical donor patient uncontrolled infection cancer last year except basal cell carcinoma skin situ carcinoma cervix renal failure creatinine clearance min accord cockroft formula contraindication treatment use research uncontrolled coronary insufficiency recent myocardial infarction month current manifestation heart failure uncontrolled cardiac rhythm disorder ventricular ejection fraction heart failure accord new york heart association ii patient seropositivity human immunodeficiency virus active hepatitis define positive pcr hbv hcvyellow fever vaccine alive vaccine within month transplantation pregnancy hcg positive breastfeeding world health organization debilitating medical psychiatric illness would preclude give well understand inform consent optimal treatment followup protection law tutorship curatorship",
    "TREATMENT": "procedures study indication transplant confirm donor identify related donor case haplo identical donor choose probability identify human leukocyte antigen unrelated donor nul low potential unrelated donor file donor well human leukocyte antigen type informed consent sign eligible patient hematopoietic stem cell transplantation plan soon possible transplantation schedule day inclusion new disease assessment perform transplantation check disease transform acute myeloid leukemia yes patient undergo upfront transplantation modalities transplant conditionning regimen tbf ric fludarabine day milligrams month total busulfan day milligrams kg thiotepa kg tec ric thiotepa milligrams kilograms day cyclophosphamide milligrams month day de day day etoposide milligrams month day fludarabine milligrams month day busulfan milligrams kilograms day case body mass index bmi chemotherapy busulfan thiotepa cyclophosphamide adapt annexe fludarabine cap anti thrombin month type stem cell source stem cell source priority peripheral blood stem cell pbsc collection pbsc carry accord prac tice centre minimal target dose cells kilograms bone marrow possible collected accord practice centre target yield nucleated cells kilograms recipient ideal body weight exceed donor volume kilograms graft versus host disease prophylaxis consist case human leukocyte antigen match sibling donor thymoglobulin day milligrams kilograms total dose cyclosporine intravenous infusion milligrams kilograms day per overall survival milligrams kilograms day day absence gvhd mycophenolate mofetil mmf milligrams kilograms day day case human leukocyte antigen haploidentical related donor cyclophosphamide day milligrams kg day day adapt overweight follow cyclosporine milligrams day day day mycophenolate mofetil milligrams kilograms day day day additional sample collect routine blood sample hematopoietic stem cell transplantation day blood sample send lille chru laboratory exam procedure add study standard care procedure",
    "STATISTICAL": "twosided onesample logrank test calculate sample subject achieve power anti thrombin significance level detect proportion surviving new group proportion survive historic control group historical proportion estimate previous french cohort study publish leukemia diseasefree survival rate observe patient donor world health organization transplant upfront contrast ebmt study report diseasefree survival patient mds expect survive proportion period month subjects accrue period month followup continue period month last subject add probability subject experience event study expected number event study intrathecal injection assume survival time distribution group approximate reasonably well weibull distribution shape parameter increase level evidence external indirect comparison secondly perform demethylating agent use individual patient data prospective cohort robin ii use aggregate data publish randomized clinical trial kroger"
  },
  "APARR": {
    "TITLE": "evaluation optimized allogeneic hematopoietic stem cell transplantation protocol posttransplant cyclophosphamide patient age year old acquire aplastic anemia refractory relapse immunosuppression",
    "JUSTIFICATION": "hematopoietic stem cell transplantation hsct major therapeutic option patient acquire aplastic anemia aa improved survival achieve patient young year old thanks good donor selection condition regimen graft versus host disease prophylaxis together improved supportive care however never case patient age overall survival hematopoietic stem cell transplantation never exceed anti thrombin year use available sibling unrelated donor ref thus standard immunosuppressive therapy ist associate cisclosporine horse antithymocyte globuline together addition eltrombopag epag consider standard care adult patient old year aplastic anemia ref indeed outcome patient world health organization refractory firstline ist remain poor lack nontransplant treatment poor result transplantation anti thrombin age ref past decade significant decrease infectionrelated mortality population initial ist risk hemorrhage longterm fatigue still present moreover clonal evolution include paroxysmal nocturnal hemoglobinuria pnh myelodysplastic syndrome mds acute myeloid leukemia aml still occur longterm grim prognosis mds acute myeloid leukemia ref overall survival adult patient acquire aplastic anemia refractory relapse ist outside hematopoietic stem cell transplantation thus anti thrombin year ref recently new strategy prevent acute chronic graft versus host disease include tcell replete graft administration posttransplantation cyclophosphamide ptcy revolutionize field change extend option hematopoietic stem cell transplantation primary patient refractory relapse aplastic anemia world health organization lack human leukocyte antigen match donor ref recently optimize baltimore protocol use ptcy strategy also appear improve engraftment reduce graft versus host disease gvhd classical setting sibling match unrelated hematopoietic stem cell transplantation outside aa ref one first cause death hematopoietic stem cell transplantation patient old year age refractory relapse aplastic anemia graft versus host disease use optimize baltimore protocol acute lymphoblastic leukemia type donor haplo also sibling match unrelated transplantation within field aplastic anemia rapidly appear promising ref using optimized hematopoietic stem cell transplantation procedure marrow source stem cell ptcy strategy haploidentical donor setting also case available matched sibling unrelated donor might prevent drastically graft versus host disease eventually practice change evaluating new transplant protocol new strategy main objective aparr",
    "OBJECTIVE": "main objective demonstrate benefit term year grfs graft versus host disease graft versus host disease primary secondary graft failurefree survival historical rate patient refractory relapse aplastic anemia undergo hematopoietic stem cell transplantation ref use optimized hematopoietic stem cell transplantation procedure marrow source stem cell ptcy strategy patient year old haploidentical donor setting primary endpoint grfs follow hcst primary composite endpoint measure time hematopoietic stem cell transplantation first following event primary secondary graft failure grade acute graft versus host disease severe chronic graft versus host disease death secondary objective demonstrate benefit term clinical biological outcome primary secondary graft failure mortality overall survival quality life treatment relate morbidity notably severe infection cardiac toxicity chimerism immune reconstitution secondary endpoint engraftment consecutive day neutrophile giga liter consecutive day platelet donor chimerism total blood absolute number neutrophil platelet anti thrombin month month month month month day last platelet red blood cell transfusion acute graft versus host disease incidence grade anti thrombin month chronic graft versus host disease incidence anti thrombin month severe chronic graft versus host disease anti thrombin month secondary graft failure anti thrombin month month severe infection ctcae grade anti thrombin month month month month month incidence cardiac toxicity anti thrombin month incidence cmv ebv infection anti thrombin month mortality anti thrombin month month overall survival anti thrombin month month quality life questionnaire anti thrombin pretransplant month month month chimerism anti thrombin month month month month month immune reconstitution anti thrombin month month month month month lymphocytes nk lymphocytes gammaglobulines",
    "DESIGN": "phase ii multicenter national prospective singlearm trial rituximab injection risk level study indication hematopoietic stem cell transplantation patient refractory relapse aplastic anemia age year world health organization refractory relapse first line ist",
    "INCLUSION CRITERIA": "patients age year refractory relapse aplastic anemia ist eligible hematopoietic stem cell transplantation patients aged year old suffering acquire refractory severe idiopathic aplastic anemia anti thrombin least month treatment antithymocyte globulin cyclosporine eltrombopag relapse allograft validate national multidisciplinary expertise meeting french reference centre aplastic anemia available genoidentical donor match donor haploidentical donor absence donor specific antibody detect patient mfi antibody distinct haplotype donor recipient usual criterion hematopoietic stem cell transplantation eastern cooperative oncology group severe uncontrolled infection cardiac function compatible high dose cyclophosphamide adequate organ function aspartate amino transferase alanineaminotransferase conjugate bilirubin total bilirubin available clearance creatinine min health insurance coverage women childbearing potential men must use contraceptive method participation research month month last dose cyclophosphamide respectively sign write informed consent nb authorized contraceptive method woman childbearing potential absence permanent sterilization oral intravaginal transdermal combine hormonal contraception oral injectable transdermal progestogenonly hormonal contraception intrauterine hormonalreleasing system ius sexual abstinence need evaluate relation duration clinical trial preferred usual lifestyle participant men absence permanent sterilization sexual abstinence condom individuals must meet acute lymphoblastic leukemia inclusion criterion verified anti thrombin screening inclusion visit eligible participate anti thrombin study",
    "EXCLUSION CRITERIA": "patients morphologic evidence clonal evolution patient isolated bone marrow cytogenetic abnormality also eligible except chromosome abnormality complex karyotype seropositivity human immunodeficiency virus active hepatitis associate hepatic cytolysis cancer last year except basal cell carcinoma skin situ carcinoma cervix pregnant hcg positive breastfeeding yellow fever vaccine acute lymphoblastic leukemia others live virus vaccine within month transplantation research uncontrolled coronary insufficiency recent myocardial infarction current manifestation heart failure accord new york heart association ii ventricular ejection fraction renal failure creatinine clearance min contraindication mention smpc investigator brochure acute lymphoblastic leukemia medicinal product plan use trial include condition regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis known allergy intolerance acute lymphoblastic leukemia medicinal product excipients plan use trial include condition regimen graft versus host disease prophylaxis prevention ebv reactivation infection prophylaxis accord investigator brochure smpc world health organization debilitating medical psychiatric illness preclude understand inform consent well optimal treatment followup legal protection tutorship curatorship state medical aid participation another interventional trial medicinal product cell therapy individuals meeting exclusion criterion verify anti thrombin screening inclusion visit ineligible participate anti thrombin study",
    "TREATMENT": "conditioning regimen thymoglobulin milligrams kilograms day milligram kilograms anti thrombin day milligrams kilograms day fludarabine month day day day pre transplant cyclophosphamide milligrams kilograms day day day total body irradiation gray day stem cell source bone marrow target nucleated cells kilograms recipient body weight granulocyte colony stimulate factor give subcutaneously start day anti thrombin milligrams kilograms day absolute neutrophil count great day graft versus host disease prophylaxis cyclophosphamide milligrams kilograms day anti thrombin tacrolimus milligrams kilograms day per overall survival divide dos milligrams kilograms ivse mycophenolate mmf begin absence graft versus host disease mycophenolate mofetil stop day day tacrolimus anti thrombin day prevention ebv reactivation rituximab month intravenously anti thrombin post hematopoietic stem cell transplantation except patient donor ebv serology ebv pcr negative infusion rituximab precede administration antipyretic antihistaminic paracetamol diphenhydramine nb however intrathecal injection permissible delay administration rituximab hour occur sunday great safety anti thrombin discretion investigator additional test specific examination except quality oflife questionnaire rituximab consider add research provide sponsor",
    "STATISTICAL": "sample size calculation twosided onesample logrank test calculate sample subject achieve power anti thrombin significance level detect grfs new group year grfs historic control group acute lymphoblastic leukemia patient follow year analysis primary endpoint several interim analysis primary outcome measure plan every month unless less enrolled patient base bayesian approach anti thrombin end trial accrual+followup grfs estimate use kaplan meier method correspond confidence interval compare historical rate use one sample twosided logrank test additional terminal analysis use external patient observational cohort propensity score weighting ensure unbiased comparison enhance level evidence treatment effect"
  }
}